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1. Summary 
Prediction and modulation of pharmacokinetics and the effects of drugs is a major concern in drug 
discovery, drug safety, and clinical practice. The projects in this thesis span the entire range of levels upon 
which these issues can be explored, ranging from in silico to in vivo evaluations and molecular, cellular, 
organ, and systemic phenomena. Drug discovery has come a long way, from a mostly serendipitous 
endeavor to the highly focused process in today’s global pharmaceutical companies, where large numbers 
of candidate substances are routinely weeded out to arrive at a few promising drug leads. 
 
Effective wet lab screening tools (such as high-throughput screening (HTS)) exist to evaluate compounds 
that exist physically. Increasingly, however, chemical libraries are designed using combinatorial chemistry 
– by applying a pre-defined set of permissible reactions to a few scaffold structures, by creating databases 
of compounds with a certain degree of similarity to members of a successful drug class, or any other such 
method. These virtual libraries require virtual screening tools. The first set of projects in this thesis 
presents such tools. They assess pharmacokinetic and toxicological profiles using machine learning 
methods. The second set of projects deals with the clinical implications of individual pharmacogenetic 
differences and ways of predicting or circumventing them. 
 
The first study outlines the development of decision tree induction (DTI) models to evaluate interactions 
with P-glycoprotein (P-gp, MDR1, ABCB1). This efflux pump protein is a major factor in the elimination of 
xenobiotics from cells. Substrate, inhibitor, and inducer properties are predicted by these models with an 
accuracy of 77.7 % (substrates), 86.9 % (inhibitors), and 90.3 % (inducers). Furthermore, the study shows 
the superiority of the DTI algorithms CHAID and CART over the more widely used work-horse algorithm 
C4.5, and the utility of lipophilic distribution coefficients that take into account differing states of ionization 
depending on the pH of the environment. 
 
In the second study, interactions with the Cytochrome P450 (CYP) family of enzymes are predicted. These 
enzymes are involved in phase I metabolism of most drugs, during which compounds are not only 
detoxified and prepared for elimination but also active metabolites are formed. Because of the promiscuity 
and cross-selectivity of the different CYP isoforms, they are heavily involved in complications arising from 
co-administration of multiple drugs or seemingly innocuous natural substances (e.g. St. John’s wort, 
grapefruit juice). Models were built for substrate, inhibitor, and inducer activities for CYP 1A2, CYP 2D6, 
and CYP 3A4 using DTI, the k-nearest neighbor algorithm, random forests, artificial neural networks, and 
support vector machines. Predictive accuracies were very high (81.7 to 91.9 % for CYP 1A2, 89.2 to 92.9 
% for CYP 2D6, and 87.4 to 89.9 % for CYP3A4). The commonly held hypothesis that P-gp substrates are 
CYP 3A4 substrates was evaluated using data from the first study. Both datasets overlap for only 84 
compounds and agreement was moderate at 45%. 
 
The third study takes a more global approach and discusses the development of models for broad classes 
of adverse drug reactions (in the central nervous system, liver, kidney, and allergic potential). Here, the 
adverse drug reactions of over 500 drugs were determined from the drug register of Switzerland and 
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classified according to the categories mentioned above. The resulting models perform very well (88.0 to 
89.7 % for the CNS, 87.1 to 90.2 % for the liver, 84.7 to 88.6 % for the kidney, and 78.4 to 78.9 % for 
allergic potential) and can serve as valuable tools not only in early drug discovery but also in 
pharmacovigilance. A comparison with the data on P-gp obtained in the first study of this thesis indicates 
that compounds extruded by P-gp do not cause less CNS related adverse drug reactions. 
 
The fourth project deals with the potential consequences of dysfunction in the efflux pumps P-gp and 
breast cancer resistance protein (BCRP, ABCG2). Several genetic polymorphisms are known for these 
proteins, some of which alter phenotypes. Because both proteins are expressed at crucial barriers such as 
the luminal wall of the intestine or the blood brain barrier, decrease in activities is thought to influence 
disease susceptibility and severity in inflammatory bowel disease (IBD, i.e. Crohn’s disease and ulcerative 
colitis). Furthermore, they influence success of pharmacotherapy because many drugs used in the 
treatment of IBD are transported by or alter activity of these pumps. Genetic constitution also influences 
activity and knowledge the individual pharmacogenomic profile could help predict response to 
pharmacotherapy. In this study, the prevalence of two single nucleotide polymorphisms (SNPs) of P-gp 
(C3435T, G2677T) and one SNP of BCRP (C421A) were assessed in peripheral blood in healthy 
volunteers and patients newly diagnosed with IBD, both from the Swiss population. All three SNPs are 
known to result in a decrease in activity. The rationale behind this study was therefore that such 
constitutional changes in efflux pump activities may predict disease susceptibility for IBD. While no 
statistically significant results could be obtained, there are discernible trends towards BCRP 421A (p < 
0.18), MDR1 2677T (p < 0.27), and the wild type allele MDR1 C3435 (p < 0.46) in patients with ulcerative 
colitis. Also in these patients, the haplotypes MDR1 3435CC / BCRP 421CC (Χ2: 1.0142, p < 0.30) and 
MDR1 2677G / BCRP 421A (Χ2: 1.5615, p < 0.22) were more prevalent, although, again, with no statistical 
significance. IBDs are complex multifactorial diseases and any single SNP is unlikely to serve in reliably 
predicting susceptibility. However, the study showed the promise of these SNPs and haplotypes derived 
from them, and a repeat in a larger sample from the Swiss population may reveal stronger associations. 
Also, because the genotype analysis was performed in peripheral blood (obtained by venipuncture instead 
of more costly and complex intestinal biopsies), such a study may yield an easily applicable tool for 
predicting response to pharmacotherapy with P-gp and BCRP substrates. 
 
The fifth study deals with a rare genetic variation in the phase II metabolizing enzyme uridine 5'-
diphospho-glucuronosyltransferase 1A1 (UGT 1A1) and the ensuing Crigler-Najjar syndrome type II (CN II) 
in a Caucasian patient. The patient was suffering from the consequences of hyperbilirubinaemia, which are 
essentially cosmetic in nature. CN II patients still have residual UGT 1A1 activity (compared to CN I, 
which, prior to the availability of phototherapy often resulted in neonatal death due to kernicterus). 
Currently, patients are treated with phenobarbital which binds to the phenobarbital-responsive enhancer 
module of UGT 1A1. Phenobarbital is a barbiturate with a small therapeutic window and many adverse 
effects such as drowsiness, impaired motor function, sexual dysfunction, and dependency. Less toxic 
alternatives are therefore desirable. The residual activity in CN II could be enhanced in a variety of other 
ways, for example by translational activation via the pregnane X receptor (PXR), the glucocorticoid 
receptor (GR), or the aryl hydrocarbon receptor (AhR). It is therefore possible to predict that since some 
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degree of UGT 1A1 activity is present in the patient, translational activation can increase UGT-1A1-
mediated metabolism. This study tested this prediction for the PXR activator hyperforin (one of the 
constituents of St. John’s Wort (SJW)). SJW is available in standardized extracts, generally well tolerated 
(photo-toxicity, fatigue, and gastrointestinal discomfort are the most common adverse reactions), and cost-
efficient. The study showed a significant decrease in plasma bilirubin levels in the patient and suggests 
that SJW is an interesting therapeutic alternative. 
 
The sixth project is a proof-of-principle study showing the feasibility of transdermal pulsatile administration 
of nicotine in heavy male smokers. Nicotine substitution is an important therapeutic tool in weaning 
patients from tobacco and it is predicted that mimicking the pharmacokinetic profile of cigarette smoking 
(short bursts of nicotine exposure resulting in acute peaks in plasma and fast elimination) may give better 
outcomes (abstinence from tobacco) than conventional modes of administration (e.g. reservoirs in 
transdermal patches which give long-lasting nicotine plasma levels or nicotine gum which, while giving the 
patient more control over release than patches, still continuously releases fractions of its content). For the 
study, volunteers were subjected to three increasing doses of nicotine from a prototype computer 
controlled device and showed statistically significant peaks in nicotine plasma levels for the highest dose. 
Adverse events, esp. on the skin, were minimal and receded shortly after the device was removed. The 
device is a promising way of nicotine substitution and could also be applied to other settings where 
transdermal patient-controlled delivery is desirable (e.g. opioids in pain control). 
 
In an isolated seventh project, a fully automated system was established for a general unknown screening 
for toxic substances in serum and urine using liquid chromatography / mass spectrometry technology. A 
library of over 350 compounds along with spectra is presented as well as a computer program which uses 
this library to identify substances on-line. 
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2. Aim of thesis 
The main aim of this thesis is the exploration of different techniques to predict or modify transport, 
pharmacokinetics, and the effect of drugs. Much emphasis lies upon machine learning methods for the 
study of metabolic pathways, toxicological aspects, and ultimately drug discovery and safety. The role of 
pharmacogenetics in the pathogenesis of inflammatory bowel disease and Crigler-Najjar syndrome type II 
and in drug metabolism is also discussed. 
 
The first part of this thesis presents numerical models for the prediction of interactions with P-glycoprotein 
and the cytochrome P450 system of enzymes. Also presented are predictive models for general classes 
(central nervous toxicity, hepatotoxicity, nephrotoxicity, and allergic potential) of adverse drug reactions. 
The second part features projects on the pathology of drug metabolism in inflammatory bowel disease 
(concerning the relevance of single nucleotide polymorphisms and related haplotypes in P-glycoprotein 
and breast cancer resistance protein) and Crigler-Najjar syndrome type II. Strategies for modulating 
metabolism in the latter are discussed. An alternative way of transdermal drug delivery is presented in a 
study of the effect of pulsatile nicotine release by a computer-controlled prototype mounted on the skin of 
male heavy smokers. In an isolated project, a fully automated system for the determination of 
toxicologically relevant compounds in liquid chromatography / mass spectrometry is described. 
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3. Introduction 
3.1. Computational intelligence in drug discovery 
3.1.1. Approaches to drug discovery 
Serendipity (or, less flatteringly put, accident) accounts for many advances and quantum leaps in 
pharmacology. The discovery of penicillin is attributed to Sir Alexander Fleming’s accidentally 
contaminated bacterial cultures [1], oral contraceptives were the accidental by-product of Carl Djerassi’s 
synthesis of progesterone [2] and the accidental discovery of the psychedelic effects of lysergic acid 
diethylamide (LSD) during a bicycle ride home [3] was commemorated by its inventor Albert Hofmann until 
his death with the celebration of the annual ‘Bicycle Day’. 
 
A more directed approach, that of bounded rationality, lies in the tapping of the wealth of pharmacological 
experience in traditional medicine and herbal remedies (the initial discovery of which is also attributable to 
serendipity) by isolating active ingredients. Willow tree bark, for example, has long been appreciated for its 
antipyretic and analgetic effects, first leading to medicines based on a bark extract in the 19th century, and 
culminating in the preparation of acetylsalicylic acid in the 1890s and subsequent marketing of the drug 
under the name ‘Aspirin’ by Bayer [4]. 
 
As understanding of the molecular pathology of disease and toxicology increases, so does the possibility 
to create models of specific sites of action and how ligands (i.e. drug candidates) interact with them. For 
these models to work, a lot of information on a lot of different structures and mechanisms has to come 
together, and although there is an ever growing body of structural and mechanistical information, there are 
still only a few cases where this paradigm has led to tangible results. 1 
 
In situations where targets of interest (such as receptors or transporters) have been identified, one could 
try and identify drug candidates with high-throughput screenings (HTS), i.e. by confronting them with a 
large set (104 to 105) of available compounds in an in-vitro assay. Continuous minimization of assay 
technology, e.g. the move from 96- over 384- to 3456-well micro-titer plates, reduction in variance of 
proven strategies such as radio-ligand binding, and automation through use of robotics allow ever higher 
numbers of substances to be screened within a day’s time. 
 
However, with a chemical universe (the set of potentially interesting compounds) estimated to number 1062 
or even higher [5], it remains questionable whether a brute-force strategy such as HTS is efficient to find 
the metaphorical needle in the haystack. Nevertheless, one can enhance the output of HTS (and even 
replace it in early stages) by testing only ‘promising’ subsets of compounds. 
                                                           
1 The anti-glaucoma agent dorzolamide (1995) and the tyrosine kinase inhibitor imatinib (2001) are 
examples of successful rational drug design. 
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This can be achieved through studies of quantitative structure activity relationships (QSAR) where a 
certain biological property is measured for a range of different structures in the hopes of establishing a 
relationship between structure and activity. Insights into structural requirements are then applied to a wider 
range of compounds of unknown activity, even compounds that only exist in a virtual chemical library 
whose entries have not been synthesized yet. In a way, this testing of more or less random compounds 
can be seen as taking a full circle back to the early days of drug discovery.  
3.1.2. Quantatitive Structure Activity Relationships (QSAR) 
The fundamental concept in Quantatitive Structure Activity Relationships (QSAR) studies is the Similar 
Property Principle, i.e. the assumption that similar structures have similar properties or activities [6]. The 
goal is to predict compound activities by analyzing their structures (in silico) instead of making explicit 
measurements in vitro or in vivo. Correlating pharmacodynamical or toxicological effects solely with 
structure while disregarding the molecular mechanisms at the target level may seem like an 
oversimplification at first. However, if a complex in question (e.g. a receptor or enzyme) is able to 
distinguish between active and inactive molecules, structure-based models should in theory be capable of 
doing the same [5]. 
3.1.2.1. Historical background 
Pioneering work by Hermann Kopp dates back to the mid-19th century [7-9], when he described changes in 
boiling points and atomic volumes in compounds that were largely part of a homologous series of alkanes. 
In fact, this may be seen as the first appearance of the additivity principle [10], stating that each of several 
structural features of a molecule makes a separate contribution to a given property. Kopp formulated these 
relationships in algebraic equations and matrices using physicochemical properties. 
 
Credited with first proposing a mathematical relationship between structures and their activity are Crum-
Brown and Fraser in a series of papers published in 1868 and 1869 [11]. Studying the curare-like 
properties of a series of quaternized strychnines, they came to note the importance of the quaternizing 
group. In their words, physiological function Φ (or activity) follows from a compounds constitution C (or 
structure):  
 
€ 
Φ = f (C)  
 
Changing the constitution (ΔC) will bring about a change in function (Δϕ). At the time, however, it was 
thought that chemical structures could not be subjected to mathematical analysis. This perception changed 
with a landmark of QSAR studies, the lipoid theory of anesthesia, put forward by Overton [12] (building on 
work by Meyer [13]), in which he showed that the potency of aqueous anesthetics in tadpoles correlates 
with their partitioning in water and lipophilic phases 2, P’: 
                                                           
2 Overton used olive oil. Today, lipophilic partitioning is usually assessed with an octanol phase (see below 
and in section 4.1.7.4). 
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P’ = (concentration in organic phase) / (concentration in water) 
 
It was later shown [14] that the effective anesthetic concentration C’ in tadpoles is fairly constant: 
 
C’ · P’ = const. ≈ 0.05 
 
Expressed in its logarithmic form, the equation is known as the Overton-Meyer relationship, the first QSAR 
ever reported: 
 
€ 
log 1C'
⎛ 
⎝ 
⎜ 
⎞ 
⎠ 
⎟ = log(P ') + const. 
 
Apart from formalizing empirical findings, this equation has other important applications. Firstly, one may 
deduce a structural requirement for anesthetic agents: high lipophilicity. 3 Secondly, it can be used to 
screen unknown compounds for their narcotic potential by determining their lipid solubility. 4 
3.1.2.2. Origins of modern QSAR: sigma and pi effects 
A further milestone occurred in 1937, when Hammett published the equation that bears his name [17]. 
Hammett correlated substituents of organic acids with their reactivity. In aromatic systems such as the 
benzene ring, electronic charges are distributed equally. Substituents introduced to the system can 
delocalize these charges. 
 
                                                           
3 It has been shown that this parameter cannot be extended ad libidum, i.e. analgetic potency cannot be 
increased infinitely to achieve ever higher effects. This is nicely summarized in the phrase ‘methyl, ethyl, 
butyl, futile’ [15].  
4 Meyer and Overton deduced from this that anesthetic effects occur when an agent reaches a critical 
concentration in a lipid phase of the body. This theory, however, fails to explain receptor-based analgesia 
(NMDA, opioid, and GABAA receptors) or effects on Na+ and K+ channels. While lipophilicity today is 
recognized as an important molecular feature, it is seen as insufficient to provide the global theory of 
anesthesia it was hoped to [16]. 
   
 Introduction 
 
 
 – 8 – 
   
 
Figure 1 – Changes in the dissociation constant K in a series of organic compounds. K is 
influenced by the type and position of substituents. 
Consider the series presented in Figure 1, where the first reaction shows the dissociation of benzoic acid 
with a dissociation constant K of 6.27 · 10-5. A nitro group introduced in the meta position increases the 
degree of dissociation (by withdrawing charge from the carboxyl group and stabilizing the negative charge 
in the product molecule), an effect even more pronounced when the group is moved to the para position. 
An ethyl group in the same position, however, decreases dissociation through its electron-donating quality. 
 
Hammett came to realize that similar modifications of other organic compounds produce similar effects. 
Let the dissociation constant of two distinct compounds be K0 and K0’, respectively, and K and K’ be the 
respective values for the same compounds substituted with the same functional group in the same 
position, then the following equation can be written: 
 
 
 
The reaction constant ρ depends solely on the reaction itself (in this case: acid-base dissociation). As the 
effects of a substituent in this context only depend on the functional group and not on the underlying 
molecule, the equation is usually written with a substituent constant σ (stating the relative strength) as: 
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With this, Hammett had introduced a concept known as the ‘sigma-effect’ to physical organic chemistry. 
His results were quickly applied to, amongst other things, ionization kinetics and biological equilibria. 
 
While working on plant growth regulators in the 1960s, Hansch and Muir sought to model auxin effects 
using Hammett-type equations [18], assuming that electron density at the ortho position in phenoxyacetic 
acids is responsible for their effects in plants. Surprised by the low predictive accuracy of their results, they 
surmised that, while their models were correct, the substances were not getting to the target in the first 
place. As concentrations within the plant cell directly depend on substances’ ability to cross several layers 
and membranes, Hansch and Muir looked for a suitable measure of permeability.  
 
They found it in a compound’s partition coefficient π between ‘water and a relatively non-polar solvent’ and 
chose 1-octanol as the lipid phase. 5 The equation for the ‘Hansch approach’ shows parallels to Hammett’s 
equation: 
 
€ 
log 1C = aπ + bπ
2 + ρσ + dEs + const. 
 
Here, C is the concentration required to produce the desired effect, the coefficients a, b, c, and d are 
determined with regression analysis for each study, σ and ρ characterize substituent and reaction-specific 
characteristics, and Es is a modification 6 of Hammett’s σ. Hansch and Muir’s contribution was two-fold. 
Firstly, they introduced a hydrophobic substituent constant, π, to account for rate-determining effects by 
distribution in biological systems. Secondly, they established partitioning in 1-octanol and water as a 
parameter. Their approach therefore uses hydrophobic, electronic, and steric attributes of molecules to 
predict effects. This is seen by many as the birth of modern QSAR studies [10, 20, 21]. 7 
 
A different route was proposed in 1964, when Free and Wilson provided a mathematical analysis of 
additivity schemes [22]. For the sake of their method, they assumed 8 that the biological effects in a series 
of homologous compounds are comprised of 
 
1.) a constant contribution of the scaffold structure, and 
                                                           
5 This was done, amongst other reasons, because 1-octanol has a relatively long aliphatic (non-polar) 
chain and hydrophilic head, much like the lipid monomers that make up biological membranes.  
6 The modification was proposed by Taft in 1956 [19] and is based on the rate of hydrolysis in esters of the 
type X-CH2COOR. 
7 To be precise, the efforts before this were QSPR studies, i.e. correlations were established between 
structures and properties. Hansch and Muir’s contribution was recognizing the importance of absorption to 
achieve biological effects. QSAR is currently the most widely used term for both. 
8 While the first assumptions are more or less easily accepted, the third assumption is clearly disproven by, 
amongst other things, Hammett’s sigma effect. 
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2.) a constant contribution (positive or negative) of substituents, and 
3.) that no interactions exist between substituents themselves or the scaffold. 
 
Free and Wilson took an observable biological response variable (LD50 in analgesic compounds) and 
noted the changes when substituents are added to a given atom. They then compared the change in the 
response variable to its average value and were thus able to numerically estimate substituent effects 
without the need for time-expensive physicochemical calculations. Unfortunately, models built with this 
method fail to predict activities for substituents and configurations not included in the original data. 9 
3.1.2.3. QSAR today 
Crum-Brown and Fraser [11] stated the following requirements for the creation of QSAR models: a 
reference set of compounds is needed, based on a selection criterion (an activity), and complemented with 
values describing the compounds so they can be analyzed mathematically. This still holds true today [23].  
 
 
 
Figure 2 – Possible target activities in QSAR studies range from molecular and receptor level 
kinetics to cellular toxicity and organ effects up to actions observable in the organism as a whole 
(adapted from [20]). 
The promise of predicting activities before spending time and money on expensive synthesis and assays 
has seen QSAR methodology being applied to a wide array of targets. Especially intriguing is the fact that 
one need not have an understanding of how compounds achieve their effect in order to create successful 
models (although it helps). All that is needed is an observable quality (receptor activity, cellular toxicity, 
systolic blood pressure, to name but a few examples) and a set of compounds to relate it to (Figure 2). 
 
Once a data set of compounds and activities has been collected, it is extended with values describing the 
compounds (so-called ‘descriptors’). The type of descriptors used can serve to roughly categorize the 
studies themselves, i.e. their dimensionality (Table 1). The historical approaches described in the 
preceding sections are 1D or 2D, and purely mathematical models will usually not go beyond the third 
dimension. An example of higher-dimensional studies is the generation of three-dimensional computer 
                                                           
9 Or: the training set (as will be seen below). 
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models of pharmacophores and the computer-aided fitting of ligands to binding sites (e.g. [24]). The need 
for the interaction by a human expert makes these approaches unsuitable for high-throughput screenings 
of virtual libraries. They do, however, provide mechanistical interpretations and models that statistical 
analysis will not always produce. 
 
Dimensionality Correlations 
1D Physicochemical properties (weight, lipophilicity, etc.) 
2D Structural motifs, functional groups  
3D Actual three-dimensional structure 
4D As 3D, but including conformational changes 
5D and beyond As 4D, but including induced fit models, solvation models, etc. 
Table 1 –  Definition of QSAR dimensionalities and what they correlate with (adapted from [25]) 
After descriptors are available, a variety of methods can be used to create a model. The procedure 
generally follows the scheme given in Figure 3: the available data is split into a training set to create the 
model and test set to estimate performance on unseen compounds. If the predictive accuracy meets 
expectations, the model can be applied to compounds with unknown activity. 
 
Before performing a virtual screening on a large database, it may be wise to filter it for cost-efficient 
compounds and other factors such as drug-likeness. For the latter, rules of thumb have been proposed. 
The best known might be the ‘rule of five’, put forth by Lipinski 10 et al. in an analysis [26] of structurally 
diverse drugs, where they found that a great many of well-absorbed or well-permeating drugs have ≤ 10 
hydrogen bond acceptors, ≤ 5 hydrogen bond donors, a molecular weight ≤ 500, and a logP ≤ 5. Filtering 
based on functional groups may also be applied. 11 A similar set of rules was put forth by Veber et al. [27] 
in 2002 for oral bioavailability in rats, coming to similar conclusions as Lipinski et al. According to this work, 
determinants for good bioavailability are ≤ 10 rotatable bonds and 140 Å2 polar surface area (see 4.1.7.4) 
or ≤ 12 hydrogen bonds. 
 
                                                           
10 Lipinski, notably, is an employee of a large pharmaceutical firm, and therefore prone to streamlining of 
drug discovery processes. 
11 Substances that fail the ‘rule of five’ (mostly antibiotics, antifungals, and vitamins) are thought by the 
authors to achieve drug-likeness by their special functional groups. Amending screening parameters can 
therefore lead to refined results.  
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Figure 3 – Development of QSAR models (example). A set of compounds with known activity of 
interest is split into a training and a validation / test set. The training set is analyzed using a 
statistical or learning method to produce a model which is applied to the validation compounds. If 
the model is satisfactory, it can be used to predict activity of unseen compounds. 
Compounds selected from a chemical database using QSAR models are called ‘hits’. These may be 
examined further in in-vitro assays to produce ‘validated hits’ or complemented with similarity searches 
(see below) of the database. Eventually, what is left are lead candidates. Such compounds receive further 
expert evaluation and may proceed into clinical trials. [28] 
3.1.3. Computational Intelligence 
The field of computational intelligence is hard to pin down, with definitions ever changing until first efforts 
were made to define it at the Dartmouth conference in 1956 as ‘artificial intelligence’ (AI). 12 A discipline of 
computer science, it is now widely regarded as the study and design of intelligent agents [29]. Its major 
goal, the reproduction of general intelligence (or ‘strong AI’) in machines, seems to still lie far in the future, 
and its feasibility is not only debated in the scientific community but also philosophically. Always looming 
over the field is the infamous test formulated by British mathematician Alan Turing in 1950 in the 
philosophical journal ‘Mind’ [30]. Turing stated that a machine should be considered intelligent if a human 
volunteer in a conversation over a typewriter terminal is unable to tell whether the conversation is with 
another human being or with a machine. To date, no system is considered to have passed this test. 
 
                                                           
12 The term was coined by John McCarthy when he proposed that intelligence can be described so 
accurately that a machine can reproduce it. 
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Research in the quest for this goal, however, has led to a wide variety of tools that are mostly statistical in 
nature (an overview is given in Section 4.2). Pattern recognition is an especially intriguing subfield of AI 
when it comes to drug discovery. The discipline deals with the classification of objects based on a priori 
knowledge or statistical evaluations. Classifications can then be passed to pattern matching systems and 
be applied to unseen objects [31]. Obvious applications are computer vision (i.e. the automated 
interpretation of scenes and visuals) and optical character recognition to extract text from printed 
materials.  
 
In drug discovery, pattern recognition can uncover patterns in chemical libraries and associate them to 
chemical or biological activities. Pattern matching based on classification systems is easily applied to 
chemical databases in high-throughput screenings (HTS, see below). 
 
3.2. Drug Metabolism 
Drug metabolism is the set of changes xenobiotics can undergo after they have been absorbed. Usually, 
lipophilic compounds are converted to hydrophilic compounds which are more readily excreted by the 
kidney and less easily re-absorbed in the renal tubuli. Metabolism commonly limits or terminates drug 
action, although in some instances, metabolites are the active principle. This is desired when, for example, 
the bioavailability of the parent compound is superior or its toxicity is lower (and the metabolite forms only 
at the site of action). Many pro-drugs have been discovered serendipitously (e.g. molsidomine, which is 
metabolized to the unstable active SIN-, which, in turn, releases NO upon decay, or heroin, which is de-
acetylated to form active morphine derivatives) [32]. 
3.2.1. Functions of metabolism  
Conventionally, drug metabolism is divided into two phases, which do not necessarily occur in sequence. 
Chemical alteration such as hydroxylation, oxidation, or reduction are part of phase I metabolism, for 
example procaine, which is hydrolyzed by pseudocholinesterase to para-aminobenzoic acid (PABA) and 
diethylamino-ethanol (Figure 4a). 13 An overview of phase I enzymes is given in Table 2. A great number 
of phase I reactions are carried out by Cytochrome P450 (CYP) mono-oxygenase superfamily of enzymes. 
In humans, these are located on the endoplasmic reticulum or on the inner membranes of mitochondria, 
and are subdivided into different families. The most important ones in drug therapy are CYP1A2, CYP2C9, 
CYP2C19, CYP2D6, and CYP3A [32]. 
 
In general, phase I reactions introduce (e.g. R-H  R-OH) or unmask (e.g. R-CO2CH3  R-COOH + 
CH3OH) polar groups, or convert existing groups (e.g. R=O  RH-OH). These transformations increase 
solubility in water or prepare compounds for phase II of metabolism. 
 
                                                           
13 Deficiency in this enzyme is a recognized disease that usually only becomes apparent when undergoing 
anesthesia. 
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Reaction Enzymes (examples) 
Oxidation 
 
CYP-P450, monoamine oxidase (MAO), alcohol dehydrogenase, peroxidases, 
flavin-containing mono-oxygenase (FMO) 
Reduction NADPH-cytochrome P450 reductase 
Hydrolysis Esterases (acetylcholine esterase, pseudocholinesterase) 
Table 2 – Examples of enzymes involved in phase I metabolism 
Phase II reactions are conjugations that further increase hydrophilicity, typically with conjugates such as 
sulfate, methyl groups, acetate groups, glutathione, amino acids, or glucuronic acid. Conjugations are 
performed on parent compounds or their phase I metabolites, i.e. the two phases are complimentary and 
not mutually exclusive. An example showcasing the different fates of a single molecule is given for 
acetaminophen (Figure 4b). 
 
A final barrier before compounds reach their site of action are transport systems such as multidrug 
resistance proteins (MRPs), organic anion transporters (OATs), and P-glycoprotein (P-gp), all of which 
have been described above. They constitute phase III of metabolism [33]. 
 
 
Figure 4 – Metabolism of procaine (a) and acetaminophen (b). Procaine is subject to hydrolysis by 
pseudocholinesterase whereas acetaminophen is either sulfatized (20-40%), glucuronidized (40%), 
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or metabolized by CYP enzymes to the toxic N-acetyl-p-benzo-quinone imine (NAPQi) which, in 
turn, is deactivated by a phase II reaction (conjugation with glutathione-SH (GSH)). 
3.2.2. Pathology of Drug Metabolism 
3.2.2.1. Genetic constitution 
Genetic variations of drug metabolizing enzymes (DMEs) are a source for many pharmacological 
interactions and adverse events. A metabolizing enzyme family that is receiving increasing attention is that 
of UDP glucuronosyltransferases (UGT). They act on small lipophilic compounds (e.g. bile acids, steroids, 
bilirubin, and hormones) and conjugate them with UDP-glucuronic acid (UDPGlcUA). UGTs have been 
identified in virtually all vertebrates and show a broad specificity [34]. Enzyme deficiency has been well 
documented for the subtype UGT1A1, which has been implicated in hereditary disorders with decreased 
bilirubin conjugation (e.g. Gilbert’s syndrome [35], and Crigler-Najjar syndrome [36]). Even though many 
genetic polymorphisms have been identified, their effect on pharmacokinetics remains poorly understood 
[37]. 
 
Of even greater relevance is the CYP superfamily. CYP2C9, for example, metabolizes almost 20% of 
drugs in clinical use [38], CYP2D6 metabolizes about 15% [39], while CYP3A4/5/7 accounts for a 
staggering 45-60 % [40]. CYP4 to CYP51 are involved in endogenous pathways and do not play a role in 
xenobiotics metabolism [39]. Much effort has focused on single nucleotide polymorphisms (SNPs), DNA 
sequence variations of a single base with a frequency of > 1% in a given population. Most of the studied 
SNPs are biallelic, although it is apparent that up to three mutant alleles may exist. SNPs have been 
extensively studied in CYPs and are of importance to the concept of personalized medicine, where not 
only macroscopic features such as size, weight, or sex are considered, but also genetic constitution. 
Clinically relevant (functional) SNPs have been reported mostly for CYP2D6 and CYP2C9 whereas the 
broadly specific CYP3A is largely unaffected by them [38, 41]. 
3.2.2.2. Interactions 
PHASE I 
CYP activity is not only influenced by genetic constitution but also by dietary and hormonal factors and 
exposure to xenobiotics and drugs as has been recognized long ago, for example, in phenobarbital, 
pesticides, and carcinogenic polycyclic aromatic hydrocarbons [42]. Tobacco (CYP 1A2, CYP 2B1) and 
alcohol abuse (CYP2E1) [43] are common inducers of CYP activity and frequently interfere with 
pharmacotherapy and clinical trials. 
 
Most CYPs are induced via receptor-mediated mechanisms, commonly by aryl hydrocarbon receptor 
(AhR), the constitutive androstane receptor (CAR), the pregnane X receptor (PXR), and the peroxisome 
proliferator-activated receptor α (PPARα). AhR binds to inducing agents and then forms heterodimers with 
the aryl hydrocarbon receptor nuclear translocator (Arnt) which induce DNA expression. PXR, CAR, and 
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PPARα also bind inducers but then form heterodimers with the retinoid X receptor (RXR) to induce 
expression [44]. 
 
Inhibition of CYP activity is conferred by an equally broad spectrum of factors and inhibitors are often part 
of a healthy diet. A well explored example is grapefruit juice, whose ingredients include psoralens, a 
known inhibitor of CYP 3A4 [45]. While inhibition may have negative effects on drug therapy (by 
decreasing plasma concentrations of active metabolites or elimination of parent drugs, resulting in higher 
AUCs and increased toxicity), it also has benefits: less oxidation implies less toxic metabolites and free 
radicals. 14 
 
Clear lines cannot be drawn between substrates, inhibitors, and inducers for CYPs, e.g. substrates of a 
specific enzyme can induce their own metabolism (auto-induction). In principle, three mechanisms of CYP 
activity modification are recognized: reversible inhibition, mechanism-based inhibition, and induction on the 
level of gene expression [47]. Reversible inhibition is analogous to competitive agonism in general enzyme 
kinetics and arises from the competition of two compounds for the active site. More severe are 
mechanism-based inhibitions, where an intermediate metabolite binds irreversibly to the CYP enzyme, 
inactivates it, and only de novo protein synthesis can restore earlier levels of activity. This is influenced by 
many factors, including the availability of alternative pathways and the presence of other substrates, both 
of which potentially decrease inhibition (allosterically).  
 
As a consequence of all of this, CYP interaction potential is not easily predicted and even proper pre-
clinical ADMET assessment cannot rule out all toxicities. 15  In fact, in recent years there have been high-
profile withdrawals from market stemming from (idiosyncratic) CYP interactions, as was the case with the 
antihypertensive agent mibefradril in 1988 [48]. These interactions have therefore become a major 
concern in clinical therapy and for pharmaceutical companies who routinely assess the interaction 
potential of their products [49]. 
PHASE II 
Interactions in phase II enzymes are not as well understood. This is especially unfortunate in the case of 
the UGT superfamily of enzymes, as they are thought to be involved in the metabolism of 35 % of drugs 
undergoing phase II reactions [50]. Immunosuppressants (e.g. tacrolimus and ciclosporine A), non-
steroidal anti-inflammatory drugs (NSAIDs), benzodiazepines, and tricyclic antidepressants appear to be 
strong inhibitors. Induction of UGT has been demonstrated for several of isoforms and inducing agents 
include rifampin, phenobarbital, and phenytoin [51]. It should be noted that there is strong cross-selectivity 
                                                           
14 Somewhat ironically, the positive antioxidant effects of catechins such as epigallocatechin gallate in 
green tea [46] are sometimes counteracted by the presence of pesticides on green tea leaves which may 
induce CYP activity and the generation of radicals. 
15 Several cases are known in which in vitro assays show CYP 3A4 inhibition but in vivo data show 
induction. Imidazoles (e.g. clotrimazole) and chlorpromazine are two examples. [47]  
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with members of the CYP superfamily. This seems reasonable as both systems often act in concert and is 
supported by recent findings that show homology in transcription factors regulating both families [52]. 
Cross-selectivity within UGT enzymes and other families makes it difficult to assign specific isoforms to a 
given agent. Such redundancy allows for functional compensation when one system fails. 
 
3.3. Drug Transport and Metabolism in the Central Nervous System 
3.3.1. Blood-brain barrier (BBB) 
The blood-brain barrier (BBB) is a functional and physical barrier between peripheral circulation and brain 
tissue. Its co-evolution with the central nervous system (CNS) is seen not only in humans but also in other 
vertebrates and even insects [53, 54]. The concept of the BBB was developed well over a century ago, 
starting with Paul Ehrlich’s 16 observation in 1885 that aqueous dyes introduced into peripheral circulation 
do not stain the brain [55]. Edwin Goldmann, one of his students, repeated the experiments, but injected 
dye into the subarachnoid compartment of the brain, thereby staining only the brain [56]. The special role 
of the vascular endothelium was first recognized in 1934 [57] and three decades later, electron microscopy 
revealed tight junctions as the morphological correlate of the barrier function [58, 59]. The necessity of 
active transport was proposed in the 1940s [60] on the basis that, given the existence of a virtually 
impermeable barrier, special transport mechanisms must also exist to supply the brain with nutrients. 
Today, several membrane transporters are recognized (see below). In fact, catalyzed transport in the form 
of carriers and transporters and lipid-mediated transport of small lipophilic molecules are considered the 
only means of effectively passing the BBB [61]. 
3.3.1.1. Structure of the blood-brain barrier 
The overall surface spanned by the blood-brain barrier (20 m2) is enormous [62]. Cerebral capillaries have 
the smallest caliber in the entire vascular system (3-7 µm) and are densely packed, with inter-capillary 
distance as low as 40 µm [63]. The endothelium of capillaries is a tightly woven single-layer stratum resting 
upon a basal lamina with tight junctions at the lateral interfaces, thereby limiting paracellular passage 
(Figure 5) [64].  
 
Pericytes, undifferentiated mesenchymal cells capable of transforming into fibroblasts and smooth muscle 
as well as performing macrophage-like functions, line the capillaries, providing physical support and aiding 
in angiogenesis [66, 67]. Astrocytic glia cells also communicate with the capillary system. They give 
metabolic support to neurons and the endothelium, are involved in nervous system repair, and modulate 
neural transmitter uptake via their connections to synapses. Together with synaptic nerve endings, they 
make up the structural component of the BBB [68]. 
                                                           
16 This was not Ehrlich’s only contribution to medicine. He is credited with first describing mast cells and 
erythroblasts, formulating the side-chain theory in immunology, and founding the era of chemotherapeutics 
with his development of arsphenamine (Salvarsan), the first pharmacological therapy of syphilis. 
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Figure 5  – Structure of the blood brain barrier: cross section of a capillary, the surrounding tissue, 
and the most important transporters: P-gp (ABCB1), BCRP (ABCG2), multidrug resistance-
associated proteins (MRP1, MRP2, MRP4, MRP5), and several organic anion transporters (Oatp2, 
Oatp3, Oat3) [65]. 
3.3.1.2. Drug transport over the BBB 
Drug transport over the BBB can be grouped into three distinct mechanisms: carrier-mediated (vitamins, 
thyroid hormones), receptor-mediated (larger molecules such as insulin), and efflux transport (removal of 
xenobiotics and toxic compounds) [69]. Until today, the mRNA of about 15 transporters of several families 
has been located at the BBB or detected in BBB cell lines [70, 71]. Examples include P-glycoprotein (P-gp, 
ABCB1), breast cancer resistance protein (BCRP, ABCG2), multidrug resistance associated proteins 
(MRP1, MRP2, MRP4, MRP5), and several organic anion transporters (Oatp2, Oatp3, Oat3). Pardridge 
[61] estimates that these represent about half of the actual inventory. 
 
Efflux transporters are mostly located on apicoluminal surfaces. Some, e.g. Oatp2 or MRP4, are also 
found basolaterally. This is not well understood, leading to the hypothesis that basolateral efflux pumps 
pair their function over a gradient with apicoluminal counterparts to move anionic xenobiotics from the 
CNS to the bloodstream [72]. 
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3.3.1.3. P-glycoprotein (P-gp) 
P-glycoprotein (P-gp) is a well known mammalian efflux transporter that is expressed in many human 
organs with secretory or barrier function, including the liver, the placenta, and the brain [73]. It is encoded 
for by the MDR gene family, and two isoforms are known in humans: MDR1 (ABCB1, or P-gp) and MDR2 
[74], which is of importance for biliar phospholipid secretion in hepatocytes [75]. Other isoforms are found 
in rodents [76].  
 
MDR1 is located on chromosome 7q21.1, and spans over 100 kb. However, MDR1 mRNA has a size of 
4.7 kDa, implying that only a small percentage of the gene actually codes [77]. The product of MDR1 is a 
170 kDa transmembrane protein consisting of two homologous parts, both of which are followed by an 
ATP-binding domain (ABD) that resides in the cytoplasm (Figure 6) [78]. The symmetry of the secondary 
structure suggests evolution from a tandem repeat of a single gene [79]. Reconstructions based on 
homology studies with ABC-transporters in E. coli and X-ray structures of ABD proteins suggest a tertiary 
structure with radial symmetry [80]. 
 
P-gp is currently the best studied ABC transporter, and to date 50 single nucleotide polymorphisms (SNPs) 
have been identified, more than half of which reside in the coding region [81-83]. Most SNPs in the coding 
region of P-gp have a relatively low frequency (<8%) [83]. With a reported prevalence of 34.3 % in 
Caucasians and 16.9 % in Asians, the SNP C3435T (exon 26) is an exception [84], whose effect on P-gp 
activity has been shown in vitro [85] and in vivo [83]. Why this synonymous SNP affects P-gp activity 
remains unclear. It has been proposed that it is in linkage disequilibrium with non-synonymous SNPs in 
regulatory regions [83]. 
 
 
Figure 6 – The 6+6 helical secondary structure of P-gp as proposed by Jones [78]. The ATP-binding 
domains are labeled ABD1 and ABD2. 
The organ distribution and cellular location (apical on endothelia and luminal in the intestine) suggest that 
P-gp has detoxification function (xenobiotics and toxic compounds). It accepts a wide variety of substrates, 
ranging from small organic ions to amino acids and even macromolecules like polysaccharides [86, 87]. 
Other physiological functions are still subject of debate, but are thought to include regulation of apoptosis, 
stem-cell differentiation, cytokine modulation, and translocation of platelet-activating factor [88]. 
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CLINICAL RELEVANCE OF P-GP 
The contribution of P-gp to mucosal barrier function has led to it being implicated in the pathophysiology of 
several conditions such as Crohn’s disease and ulcerative colitis [89, 90]. Studies on polymorphisms of the 
MDR1 gene, which encodes P-gp, however, have produced conflicting results, and underline both the 
multifactorial nature of these diseases as well as the relatively low importance of genetic predisposition 
[77, 91-93]. What can be said is that expression is altered in inflamed gut tissue [92, 94] and that this has 
therapeutic consequences [92, 95, 96]. 
MODULATION OF P-GP ACTIVITY 
In recent years, attempts have been made at reducing P-gp activity with the goal of developing 
‘chemosensitizers’ that increase therapeutic benefit. Inhibition of P-gp is desirable to increase 
bioavailability, e.g. of anti-cancer agents, but carries the danger of corrupting the functional BBB by 
allowing otherwise innocuous compounds to penetrate the CNS and increasing dose-dependent adverse 
effects. 17 Three modes of interference have been proposed: direct interaction with P-gp, disturbance of 
ATP-binding and hydrolysis, and disturbance of lipid bilayers, which is thought to influence membrane 
environment and drug-ligand interaction [98]. 
 
 
Figure 7 – Structural diversity of P-gp inhibiting compounds: terfenadine (a), verapamil (b), and 
ciclosporine A (c). 
Tsuruo et al. observed that verapamil administration sensitized vincristine-resistant leukemia cells to 
vincristine and vinblastine [99]. It was quickly shown that not only verapamil [100] but also other 
structurally diverse compounds (Figure 7) such as ciclosporine A [101] and terfenadine [102] reverse P-gp 
mediated multidrug resistance. This 1st generation of inhibitors is made up of previously available 
compounds re-evaluated for their inhibitory effects, and derivatives based on them. These attempts, 
                                                           
17 Conversely, this may be desirable in order to increase drug concentrations in the CNS, e.g. in anti-
epileptic therapy [97]. 
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however, were thwarted mostly by unacceptable toxicity profiles (such as dose-limiting cardiotoxicity for 
verapamil).  
 
High-throughput screenings formed the basis for 2nd generation inhibitors such as PSC-833 and VX-710 
[103, 104]. Peripheral toxicity was lower than in the 1st generation, as was the ensuing dosage of anti-
cancer drugs necessary to reach therapeutic plasma levels. However, so was overall efficacy. This 
apparent paradox was shown to be due to an overlap of CYP3A and P-gp substrate affinity [105] and 
concomitant regulation of the two metabolizing systems [106]. 
 
The current 3rd generation is the product of combinatorial chemistry and characterized by their low mean 
inhibitory concentration (IC50) [80]. GF120918 (elacridar) [107], LY335979 (zosuquidar) [108], XR9576 
(tariquidar) [109], and OC144-093 (ontogen) [110] are notable examples. Although the pharmacophoric 
characteristics of P-gp are not well understood, basic rules of thumb exist. Wang et al., for example, 
reported in a QSAR analysis that effective inhibitors should have a logP value of ≥ 2.92, carry at least one 
tertiary basic nitrogen, have a molecular axis of ≥ 18 atoms, and a high energy of the highest occupied 
orbital (Ehomo) [111]. 
 
In general, all of these inhibitors have not held their promise in clinical trials. This is probably because of 
drug resistance inferred by other mechanisms [112] (other efflux transporters, enzymatic degradation, 
alternate metabolic pathways in cancer cells, decreased permeability, or insufficient concentrations at the 
target site, to name but a few). The search for specific P-gp inhibitors remains an attractive goal, although 
specificity might better be extended to other drug metabolizing enzymes so as to cover alternative 
pathways of degradation and elimination. The co-application of low-dose ritonavir as an inhibitor of both P-
gp and CYP3A to boost anti-retroviral treatment in HIV infection is an example in clinical practice [113]. 
CHARACTERIZATION OF P-GP SUBSTRATES 
Ideally, CNS drugs should not be P-gp substrates because higher peripheral doses would be required to 
reach effective concentrations in the CNS. This, in turn, narrows the therapeutic window  by increasing the 
potential for peripheral toxicity [65]. Defining the characteristics of P-gp substrates is therefore of great 
importance for drug development, especially in view of its role in multidrug resistance.  
 
Recent studies indicate at least four distinct drug binding sites (DBSs) which can switch to high or low 
affinity configurations for substrates and inhibitors. As the P-gp subunits are mobile within the membrane, 
so are the DBSs, and they can therefore serve as physically distinct sites or contribute to a larger binding 
pocket. This can account for P-gp’s broad substrate specificity [114] but also for the difficulties in singling 
out common structural features. 
 
In 1988, Zamora et al. described the structural properties of P-gp substrates roughly as lipid soluble at 
physiological pH, planar, and carrying a cationic charge [115]. These results have been confirmed and 
augmented with hydrogen bonding potential, presence of an amine or aromatic rings, and several less 
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specific features such as molecular mass, surface area, and dimensions [98, 111, 116, 117]. These rather 
unspecific determinants come as no surprise given P-gp’s promiscuity. 
3.3.1.4. Breast Cancer Resistance Protein (BCRP) 
Breast cancer resistance protein (BCRP, ABCP, MXR) is the product of the ABCG2 gene, located on 
chromosome 4q22 and spanning > 66 kb. With reference to other (two-dimer) members of the ABC family 
of transporters, which consist of twelve transmembrane domains (TMD) and two ATP binding domains 
(ABD), BCRP has been characterized as a half-transporter, as it only has six TMDs and one ABD [118]. 
BCRP is expressed in the epithelium of the small intestine and small biliary ducts as well as in the breast 
and placenta [119]. Just as P-gp, it is considered to maintain functional barriers and a limiting factor in 
drug absorption and distribution, e.g. in topotecan, doxorubicin, and mitoxantrone [120, 121]. 
 
   
 Materials and methods 
 
 – 23 – 
   
4. Materials and methods 
4.1. Cheminformatics methods 
4.1.1. The chemical graph 
In chemical graph theory, the atomic structure of a compound is described as a mathematical graph  
whose set of vertices is a list of the compound’s atoms and whose set of edges corresponds to the 
bonds between the atoms (vertices) so that 
 
€ 
G = V ,E[ ]  
 
Applied to molecules, this yields a labeled, undirected multigraph which may or may not be disconnected. 
18 Usually, hydrogen-depleted graphs are used, i.e. graphs where vertices that represent implicit 19 
hydrogen atoms are omitted (Figure 8) unless they are part of a functional group (e.g. –OH or –NH2). 
 
 
Figure 8 – Isopentane structure with implicit hydrogen atoms (a), its structural formula (b) without 
implicit hydrogens, and the corresponding molecular graph (c) 
The chemical graph is a prime example of Eugene Wigner’s ‘unreasonable effectiveness of mathematics 
in the natural sciences’ 20, an observation further underlined by the co-evolution that the mathematical field 
                                                           
18 A graph is connected if a path exists between every pair of vertices. Disconnected graphs do not have 
this property and therefore consist of two or more components. As a chemical example, one might 
consider salts (which have a cationic and an anionic component). 
19 Implicit hydrogen atoms are those that fill up valencies in the carbon skeleton. 
20 In his 1960 paper [122], Wigner describes how mathematical models applied to problems within the 
natural sciences pave the way to a deeper understanding of the problem itself.  
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of graph theory and the chemical concept of graphs have undergone. 21 Graph theory provides the tools to 
assess identity between two molecular graphs (graph isomorphism), 22 measures of connectivity (see 
below), and properties of mathematical graphs have chemical interpretations. 
4.1.2. Simple Molecular Input Line Specification (SMILES) 
The Simple Molecular Input Line Specification (SMILES) is a language that can be used to unambiguously 
describe molecular structures as ASCII strings [125]. These are obtained by generating the chemical 
graph of a molecule (see above) and then printing out a depth-first traversal of the resulting tree [126]. 
Usually, hydrogen-depleted graphs are used to save computer memory and simplify the final string. 
 
Due to the unambiguousness of SMILES strings, one of their main applications is as a means of 
generating index keys in chemical databases (i.e. serving as the primary key). Furthermore, the format is 
used in cheminformatics systems for the calculation of molecular properties (descriptors). Also, because of 
efforts in the standardization of the notation, anyone who uses the canonical SMILES notation will come 
up with the same string for a given molecule, thereby easing the exchange of chemical information. 23 
Lastly, SMILES provides additional grammar for chemical reactions. 
 
While a given SMILES string corresponds to one and only one molecule (or compound), the reverse does 
not hold true. Ethanol (C2H5O), for example, can be encoded as OCC, [CH3][CH2][OH], C-C-O, and so 
on, whereas the canonical SMILES version is CCO. However, most current cheminformatics systems and 
structure editors will arrive at the same representation. 
 
Five general rules govern the generation of SMILES codes: 
ATOMS 
Atoms are specified by their atomic symbols and enclosed in square brackets ([ ]) unless they are part of 
the organic subset (C, N, O, P, B, S, F, Cl, Br, and I) or have valences other than the standard ones. 
Aromatic carbon atoms are given as ‘c’ (small C, Table 4). 
 
                                                           
21 In fact, when the term ‘graph’ was introduced into mathematics by the English mathematician James J. 
Sylvester in 1878, he had derived it from the chemical term ‘graphical notation’ for the depiction of a 
molecule [123]. Sylvester is also credited with coining the mathematical term ‘matrix’. 
22 Isomorphism is assessed by showing that a bijection 
€ 
f :V (G)↔V (H)exists for two compounds  
and  so that any two adjacent vertices  and  in the first graph are also adjacent in the second graph 
[124]. 
23 One of the most widely used repositories for chemical structures in SMILES and other formats is the 
National Center for Biotechnology Information’s (NCBI) PubChem Project. A script for retrieving structural 
information from PubChem is given in the appendix. 
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SMILES Common name Structure 
C Methane CH4 
O Water H2O 
S Hydrogen sulfide H2S 
[S] Elemental sulfur S 
[H+] Proton H+ 
Table 3 – Examples of atomic SMILES notation 
BONDS 
Adjacent atoms are considered to be connected either by a single or an aromatic bond, depending on 
context. Bonds may be explicitly stated as -, =, and # for single, double, and triple bonds, whereas 
aromatic bonds are denoted by a colon (“:”). 
 
SMILES Common name Structure 
CC Ethane CH3CH3 
C=C Ethane CH2=CH2 
C#N Hydrogen cyanide HCN 
CCO Ethanol CH3CH2OH 
c1ccccc1 Benzene Benzene ring 
Table 4 – Examples of SMILES bond notation 
BRANCHES 
The branching structure is enclosed in parentheses and assumed to be connected to the left. 
 SMILES Common name Structure 
CCCCCCCC n-octane 
 
CCCC(C)CCC 4-methylheptane 
 
C(CCC(C)(C)C)C 2,2-dimethylhexane 
 
Table 5 – Examples of SMILES branching notation 
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CYCLIC STRUCTURES 
Because the SMILES notation is non-cyclic, ring structures need to be split. This is done by designating an 
arbitrary break point in a connected structure and listing the atoms and bond connections as a non-cyclic 
structure. 
 
 
Figure 9 – Example of SMILES notation of a cyclic structure (cyclohexane) 
DISCONNECTED FRAGMENTS 
Compounds are not necessarily a single connected molecule. Some, for example, are formulated as salts 
or have counterions. In SMILES notation, this is expressed by joining fragments by a period (“.”). Common 
salt (NaCl), for example, translates to [Na+].[Cl-] in SMILES notation. 
 
4.1.3. Canonical and isomeric SMILES 
Isomerisms need not be explicitly specified to produce valid SMILES strings. This is arguably a flexibility 
feature of the standard, allowing for simpler handling of molecules where these aspects are either of no 
importance or unknown. Stereochemical information can, however, be added to canonical SMILES strings 
to produce isomeric SMILES whenever the canonical version does not yield the desired results. 
 
For example, the string [H]C(O)(Br)CC represents Molecule 1 in Figure 10. The molecule is structurally 
the same as Molecule 2, specified by the fully-featured isomeric version [H][C@@](O)(Br)CC, because it 
is implicitly assumed that attached substructures are listed in clock-wise order. Molecule 3 is an 
enantiomer of the first two and is described with [H][C@](O)(Br)CC. 
 
 
Figure 10 – Tetrahedral chirality in SMILES codes. The structures translate to [H]C(O)(Br)CC 
(Molecule 1), [H][C@@](O)(Br)CC  (Molecule 2), and [H][C@](O)(Br)CC (Molecule 3). 
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Various other forms of chirality are handled, including allene-like (E and Z symmetry), octahedral, square-
planar, and trigonal-pyramidal. Whenever available (and sensible), the isomeric form was used in the 
databases presented here. 
 
4.1.4. SMILES Arbitrary Target Specification (SMARTS) 
A common task in cheminformatics is substructure search. While one might assume this can be achieved 
by matching character patterns within a SMILES encoded molecule set, this is not the case because a 
single molecule can be represented by different SMILES strings (see above) and patterns that span 
branches are hard to retrieve with a character based approach. For instance, a character-based search for 
the benzene ring (c1ccccc1) of the amino acid tryptophan 
(N[C@@H](CC1=C[N](C2=C1C=CC=C2)[H])C(O)=O) is prone to fail. 
 
SMARTS Common name Target 
[CX3]=[OX1] Carbonyl group (low specificity, hits 
carboxylic acid, esters, ketones, and others)  
[CX3](=O)[OX2H1] Carboxylic acid 
 
[NX3][CX3](=[OX1]
)[#6] Amide 
 
Table 6 – Examples of SMARTS targets, their common names, and their structural representation 
SMARTS addresses this problem by providing a language built on the SMILES language. The similarity 
between the two is so high that almost all SMILES specifications are valid patterns (or rather ‘targets’) in 
SMARTS. The necessary flexibility of a pattern matching language is achieved by providing logical 
operators such as AND and OR, connectivity descriptors (CX4 hits carbon connected to four other atoms, 
CD4 hits quaternary carbon), and cyclicity descriptors. 24 It is also possibly to search with varying degrees 
of accuracy, e.g. when looking for carbonyl groups (C=O) one might specify a target that hits only 
carboxylic acid or one that will also find aldehydes, esters, ketones, etc. (see Table 6) 
 
The original development of SMARTS was done by Daylight Systems (who also established the SMILES 
standard) and their Daylight Theory Manual [127] provides thorough documentation of the standard.  
Modifications also exist, most notably by OpenEye Scientific Software. This work uses Daylight’s 
                                                           
24 Cyclicity is considered on the basis of the smallest subset of rings (SSSR). 
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standards. The versatility of the specification has resulted in a wide acceptance. SMARTS functionality can 
be added to common relational database software, thereby allowing high-throughput screenings of virtual 
libraries. 
4.1.5. Computational complexity of substructure searches 
While the notations discussed in the previous section provide a straightforward way to implement a 
compound library and search for targets, it is important to understand that substructure searches in 
general are computationally expensive [128]. Finding a substructure in a mathematical graph, which is 
essentially the same as searching for a target in the molecular graph, has been shown to be an NP-
complete (non-polynomial) 25 problem [129]. 
4.1.6. Chemical similarity 
The question of whether or not two structures are similar is not only encountered in QSAR models (Similar 
Property Principle, see above). It is also of relevance in queries of chemical databases (e.g., ‘find ten 
substances similar to this one’) and their characterization (e.g., ‘how heterogeneous is the compound 
library?’). 26 
4.1.6.1. Fingerprinting 
Fingerprints are an abstract representation of compounds used in chemical similarity studies and to 
enhance substructure searches. For a compound A, n attributes are recorded and stored in a vector VA of 
the form 
 
€ 
VA = {X1A ,X2A ,...,XnA} 
 
with length n [130]. Attributes may be numerical or binary (indicating absence (0 or OFF) or presence (1 or 
ON), e.g. of substructures, within the compound) and may be chosen as required by the underlying 
question (Figure 11). Binary fingerprints are of course preferable when only absence or presence of a 
feature is evaluated. Numerical descriptors such as molecular weight can be handled either by storing 
them directly in a field of the fingerprint or by binning 27 them. When examining, for example, the number of 
hydrogen bond donors, one might define multiple intervals such as 0, (0,2], (2, 4], and ≥ 4.  
  
                                                           
25 Solutions to these problems can be verified quickly. However, there is no known fast way to come up 
with a solution in the first place.  
26 A point worth noting, esp. when dealing with similarity measures (see below), is that perfect similarity 
does not imply identity. Similarity is an approximation and approaches identity as more and more features 
are taken into consideration.  
27 In binning, a continuous numerical range is separated into a small number of discrete segments (bins). 
These bins are assigned integer numbers in ascending range. In this way, continuous variables are 
discretized. 
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Figure 11 – Example of a binary fingerprint of lysine based on the elemental composition (a), 
interesting substructures (b), and spatial dimensions (c). The exact composition of fingerprints 
varies with compound libraries and purpose. 
 
Fingerprints are stored alongside the compound. Queries can then be designed to make use of these 
strings (e.g. if the desired target is an indole ring (2,3-benzopyrrole, C8H7N), the corresponding query 
could first check for the presence of nitrogen or for at least two ring systems). 
4.1.6.2. Assessment of chemical similarity 
While searches of substructures are probably the most common queries in chemical databases, similarity 
based queries are gaining in prevalence. They can refine a substructure search by specifying a context to 
filter potential hits (i.e. ‘look for phenol rings in structures like this.’). Also, given a molecule of interest 
(bait), queries can be formed that return similar compounds (i.e. ‘give me ten compounds like this.’). 
 
There is no accepted definition of what chemical similarity or diversity is, even though one generally 
recognizes it (or, more often, its absence). 28 Consequently, there is no agreed-upon way of ranking 
molecules by their similarity [131, 132]. This becomes clear when one looks at the different coefficients 
(Table 7) that are currently in use for measuring similarity or distance in the chemical space. 
 
                                                           
28 In fact, many chemical definitions are exclusive: carbocycles are defined as not containing heteroatoms, 
aromatics as lacking aliphatic components, and so on. 
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Coefficient Expression 
Tanimoto coefficient 
(Jaccard) 29 
  
Cosine coefficient 
(Ochiai coefficient) 
 
Hamming distance 
(Manhattan distance, city-block distance) 
€ 
a + b − 2c  
Euclidean distance 30  
Soergel distance 
€ 
1− c
a + b − c =
a + b − 2c
a + b − c  
Russel-Rao coefficient  
Forbes coefficient  
Table 7 – Similarity coefficients (synonymous names) for use in binary fingerprints, where a and b 
are the bits set to 1 in binary fingerprints of length m bits of two molecules A and B. c is the 
number of bits set in both a and b (logical AND; adapted from [130, 131]) 
 
All of these expressions are closely related and most may be interpreted geometrically as distances in a 
hyper-dimensional space spanned by the available attributes. Depending on the data set considered, e.g. 
the size distribution, some measures may fare better than others, esp. when it comes to judging a 
substitution series of smaller molecules. The Tanimoto coefficient is the most widespread [131] and also 
the one used in this work (an implementation is given in the appendix). The example in Figure 12 
illustrates one of the advantages of this measure 31 over the also quite popular Hamming distance. 
Identical substitutions (in this case –O-methyl for –Cl) tend to be overrated by measures that do not 
normalize like Tanimoto’s equation. 
 
                                                           
29 Tanimoto’s coefficient builds on Jaccard’s coefficient, a widely used similarity measure for binary data. 
The coefficient is therefore also known as ‘Extended Jaccard’, is applicable to real numbers, and, when 
applied to binary values, the same as Jaccard’s coefficient. 
30 For binary keys, this equals the square root of the Tanimoto index [133]. 
31 In the example, the complementary of Tanimoto’s coefficient, Soergel distance, is used. For similarity 
indices, the complementary (1 – measure) corresponds to distance. 
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Figure 12 – Soergel and Hamming distance for two pairs of molecules with identical substitutions 
(adapted from [134]) 
4.1.6.3. Applicability and interpretation of fingerprints 
An expert in the domain can quickly scan a chemical structure and extract important properties by noting 
absence or presence of certain functions or properties. Fingerprints seek to automate this by evaluating a 
given set of features for each compound. Feature selection may be general (in order to compare different 
heterogeneous databases) or more specific to a domain (in order to single out interesting leads). As a 
quality measure, chemical similarity is a valuable parameter that describes how diverse the investigated 
set is. Furthermore, it reflects the quality of the choice of descriptors.  
4.1.7. Descriptors 
The molecular structure is not easily accessible to numerical analysis and learning methods. It is, however, 
possible to derive parameters (descriptors) from molecules that describe their physicochemical properties, 
electronic features, and so on. For use in QSAR studies, they should be easy to interpret and calculate as 
well as sensitive to small variations in the properties they measure [135]. The following sections give an 
overview of the different classes of calculations commonly employed. 
4.1.7.1. Elemental analysis 
Calculations of this class are 1D QSAR descriptors as they are computed directly from the sum formula 
(i.e. C2H6O for ethanol). 
MASS CALCULATIONS 
One of the most straightforward ways of characterizing a compound is its mass. This can either be found 
by summing up the atomic weight of the constituents (mass, for ethanol: 46.0864) or the weights of the 
most common isotope found in nature (exact mass, for ethanol: 46.0419). 
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COMPOSITION COUNTS 
The total atom count and the count of heteroatoms (all elements except for carbon and hydrogen) are of 
biochemical relevance. Most cheminformatics systems also analyze isotope composition although its 
importance in biochemical models is very low because biological systems are generally insensitive to 
isotopes [136]. 32 
APPLICABILITY AND INTERPRETABILITY 
Molecular mass, of course, is an important feature of compounds, and appears in very simple but effective 
models [26]. Elemental analysis is also useful in identifying outliers and pre-screening of databases (e.g. 
removing heavy structures in a search for small drug-like compounds). 
4.1.7.2. Constitutional analysis 
Constitutional descriptors are slightly more abstract than their elemental counterparts and require the 
structural formula. Among the simplest ones are total counts of atoms and (single, double, aromatic, etc.) 
bonds. The number of general classes of substructures may also be counted (aliphatic, aromatic, and 
hetero rings) as well as specific motifs (e.g. phenol groups, amino acid residues). Special care must be 
taken in practice to precisely formulate such queries. For example, the explosive 2,4,6-trinitrotoluene 
(TNT) has strong radial symmetry. If the count of nitrobenzene groups has to be determined, a SMARTS 
query such as c1ccccc1-[#7+](=[#8])-[#8-] will return three hits (Figure 13). 
 
A less trivial constitutional descriptor is the cyclomatic number. It gives the number of independent cycles 
(rings) in a molecule and is equal to the minimum number of edges that need to be removed in order to 
transform it to an acyclic graph [138]. This must not be confused with the term cyclicity from graph theory, 
which states the total number of cycles (e.g. including cycles containing other cycles).  
 
 
Figure 13 – Substructure matching. In 2,4,6-trinitrotoluene (TNT, a), the substructure motif of 
nitrobenzene (b) can be found three times. 
                                                           
32 Radio-assays exploit this characteristic of enzyme kinetics by introducing radioactively marked 
substrates which are metabolized to the same degree as unmarked substances. Sometimes, however, a 
rate-determining step is the breaking or formation of hydrogen bonds, which is slowed down by replacing 
normal hydrogen (1H) by deuterium (2H), the bonds of which are harder to break [137]. 
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APPLICABILITY AND INTERPRETABILITY 
The descriptors outlined above disregard molecular geometry. They do not change with conformation, do 
not distinguish isomers, are among the most commonly used descriptors, and lend themselves to 
fingerprinting (see above). Interpretation is intuitive, e.g. presence of many aromatic bonds and features 
suggests lipophilicity, and so on. 
4.1.7.3. Electronic descriptors and charge analysis 
Electro-chemical properties are central to chemical reactions and biological activity, and charged protein 
domains and membranes greatly influence ADME behavior. The following survey of descriptors ranges 
from simple charge counts to rich properties encompassing molecular shape and size. 
ATOMIC CHARGE 
Maximum and total positive and negative charges, total absolute charges, and analysis of electrical dipole 
moments for atoms and molecules are among the most popular examples. 
HYDROGEN-BONDING DESCRIPTORS (HBA, HBD) 
Hydrogen bonds are weak bonds (5 – 30 kJ/mol) between an electronegative atom and a hydrogen atom 
connected to another electronegative atom. It is a dipole-dipole interaction and should not be confused 
with covalent bonds [139]. This type of bond is encountered both within and between molecules, and in 
organic (e.g. DNA) as well as in inorganic (e.g. water 33) compounds. 
 
 
Figure 14 – Hydrogen donor and acceptor sites in a hypothetical molecule. Donor count (HBD) is 2 
and acceptor count (HBA) is 4 with 4 donor sites and 5 acceptor sites. 
                                                           
33 This is where hydrogen bonds were first analyzed. For a molecule of low mass (~ 18 g/mol), water has 
unexpectedly high boiling and melting points, which can be explained by their tendency to form long, 
hydrogen-bond stabilized chains. 
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Functional groups can be hydrogen bond donors (HBD), acceptors (HBA) 34 or both (i.e. amphiprotic 
[140]), as illustrated in Figure 14. HBDs have electron-withdrawing substituents (e.g. –OH, –SH, –FH) 
while HBAs have electron-donating substituents (e.g. –O, –S, –F, –PO) [138]. Consequently, most 
computational methods of calculating these descriptors are based on group contribution (e.g. [141]). 
Hydrogen-bonding characteristics also depend on the environment, as the protonization of functional 
groups changes (Figure 15). 
 
 
Figure 15 – Hydrogen bond donor and acceptor sites (ordinate) with increasing pH (abscissa) for 
the hypothetical compound given in Figure 14. 
VAN DER WAALS SURFACE AND CHARGED PARTIAL SURFACE AREA DESCRIPTORS 
(CPSA) 
When compounds are immersed in a medium, e.g. drugs during oral absorption or in different 
compartments such as plasma or CSF, non-covalent interactions take place between the compound and 
its surroundings. The most simple of those is solution (or suspension) in water. For these situations, the 
                                                           
34 Count of the functional groups with said properties should not be confused with the number of HBD and 
HBA sites, where the number of donatable or acceptable hydrogens is counted. 
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van der Waals surface area (VDWSA) is of great utility. This views molecules as sets of overlapping hard 
spheres 35 with a size determined by the van der Waals radii of their atoms (Figure 16a). 
 
In 1990, Stanton and Jurs introduced a set of descriptors that link charge to shape [144] by building on 
work by Lee and Richards who refined the VDWSA [145]. Here, the same three-dimensional 
representation is traced with another sphere, this time representing a solvent molecule (e.g. water). The 
basis for calculations is a contact surface defined by the center point of the tracing sphere, which is 
complemented by attractive and repulsive forces over each point as defined by the electron distribution of 
the original molecule (Figure 16). This contact surface is what defines polar interactions. 
 
 
Figure 16 – Molecular representation used in charged partial surface area (CPSA) calculations. 
Atoms are represented as solid overlapping spheres with a radius corresponding to the van der 
Waals radius (solid black line) of each atom (a). For CPSA, this is traced with another sphere () 
representing a solvent (b). The traced surface (c) is shown as a dotted line (adapted from [134, 
144]). 
The most basic values give the partial positive and negative surface areas. Weighing the total positive and 
negative charges of the molecule against partial charges and individual atoms (and several other 
correlations) results in a total of 25 different descriptors. Stanton and Jurs successfully linked their 
descriptors to boiling points and surface tension. 
TOPOLOGICAL POLAR SURFACE AREA (TPSA) 
Polar surface area (PSA) descriptors such as CPSA quickly proved successful in predicting membrane 
transport and drug properties. Their calculation, however, is time consuming because a 3D-model has to 
be generated for every compound. In 2000, Ertl described a fragmentation-based scheme based on a 
study of over 30’000 substances [146]. He gives 41 fragments and their contribution to polar surface area. 
Using this approach, PSA can be estimated by summing up individual contributions. Of course, as 
                                                           
35 This is highly reminiscent of the ball-and-stick molecular model in John Dalton’s atomic theory. While 
this has been largely abandoned, the paradigm works well in certain areas of molecular modeling such as 
this. Of course, restrictions apply [142, 143], e.g. when conformational changes expose surfaces during 
ligand-receptor interactions. 
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molecules increase in size, polar groups that contribute to TPSA may become inaccessible. Therefore, this 
descriptor does not do well for macromolecules. 36 
 
Descriptor Meaning Equation 
PPSA-1 Partial Positive Surface Area Σ(+SAi) 
PPSA-2 Total Charge Weighted PPSA (Σ(+SAi)) Q+T 
PPSA-3 Atomic Charge Weighted PPSA (Σ(+SAi)) Q+i 
PNSA-1 Partial Negative Surface Area Σ(-SAi) 
PNSA-2 Total Charge Weighted PNSA (Σ(-SAi)) Q-T 
PNSA-3 Atomic Charge Weighted PNSA (Σ(-SAi)) Q-i 
DPSA-1, DPSA-2, 
DPSA-3 
Difference in Charged Partial 
Surface Areas 
(PPSA-1 – PNSA-1), (PPSA-2 – PNSA2), 
(PPSA-3 – PNSA-3) 
FPSA-1, FNSA-1, 
FPSA-2, FNSA-2, 
FPSA-3, FNSA-3 
Fractional Charged Partial 
Surface Areas 
 
CPSA / total molecular surface area 
 
WPSA-1, WNSA-1, 
WPSA-2, WNSA-2, 
WPSA-3, WNSA-3 
Surface Weighted Charged Partial 
Surface Areas 
 
(CPSA)(total molecular surface area) / 
1000 
 
RPCG Relative Positive Charge 
(charge of most positive atom) / (sum 
total positive charge) 
RNCG Relative Negative Charge 
(charge of most negative atom) / (sum 
total negative charge) 
RPCS 
 
Relative Positive Charged Surface 
Area 
(SAMPOS)(RPCG) 
RNCS 
 
Relative Negative Charged 
Surface Area 
(SAMNEG)(RNCG) 
Table 8 – Charged Partial Surface Area (CPSA) descriptors [144]. 
APPLICABILITY AND INTERPRETABILITY 
As was seen before, electronic charge influences intra- and inter-molecular attraction. Hydrogen bonding 
is of direct relevance to many physicochemical properties such as compressibility, boiling and melting 
points, and molar refractivity. Along with partition coefficients (see below), these descriptors are good 
                                                           
36 The original study was limited to molecular mass < 800 and > 100. 
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predictors of passive membrane permeability and absorption [147]. PSA descriptors deliver good results in 
these areas as well [148-151] and the special usefulness in combination with connectivity indices for 
biological studies has been shown [152]. 
 
Although polar interaction plays an important part in transport phenomena and the good explanatory power 
of such descriptors therefore does not come as a surprise, one should remember that some of the PSA 
descriptors were developed using drug databases (e.g. the World Drug Index for TPSA [146]). This 
preference for drug molecules should be kept in mind when interpreting polar surface contributions.  
4.1.7.4. Partitioning 
PARTITION COEFFICIENT (LOGP) 
The hydrophobic properties of compounds have been found to correlate well with their pharmacokinetic 
and pharmacodynamic behavior [18, 153]. As a measure of hydrophobicity, the partitioning of the 
unionized compound in a two-phase system with n-octanol (hydrophobic compartment) and water 
(hydrophilic compartment) may be determined experimentally 37 (see 3.1.2.2). The logarithm of the solute’s 
distribution ratio within these compartments gives logP: 
 
€ 
logPoct /wat = log
[solute]oct
[solute]wat
⎛ 
⎝ 
⎜ 
⎞ 
⎠ 
⎟  
 
Several computational approximations for this descriptor exist. First attempts were made in 1964 with 
substitution studies in aromatic rings by Fujita, Iwasa, and Hansch [154], who gave π values for over 60 
substituents. Extrapolation in other series eventually led to the development of CLOGP [155] which is still 
in use today. CLOGP splits molecules at isolating carbons, meaning C atoms without double or triple 
bonds to heteroatoms. These carbons and their connected hydrogen atoms are considered hydrophobic, 
and the remaining contribute to the molecules polarity. LogP values are computed by summing up these 
contributions with appropriate correction factors (Figure 17).  
 
 
Figure 17 – Example of a CLOGP calculation of benzyl bromide (adapted from [134]) 
                                                           
37 Experimental values may be difficult to obtain when dealing with very lipophilic or zwitterionic 
compounds [134].  
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Atom-centric approaches, such as ALOGP [156] and XLOGP [157], take into account not only the atom 
type but also its environment [158]38. Of course, it is not always clear how to properly fragment a (large) 
molecule, and for some fragments, these contributions are not known (although systems like CLOGP can 
provide estimates).  
DISTRIBUTION COEFFICIENT (LOGD) 
An adaptation of logP for ionizable compounds is the distribution coefficient (logD). The experimental 
setup is analogous to that of the partition coefficient [139] with the exception that the aqueous phase is 
buffered to a certain pH (so that it is not altered by introduction of the compound). Both the ionized as well 
as the neutral form of the solute are measured to give logD depending on pH 39  (Figure 18):  
 
€ 
logDoct /wat = log
[solute]oct
[solute]watneutral + [solute]wationized
⎛ 
⎝ 
⎜ 
⎞ 
⎠ 
⎟  
 
 
 
 
Figure 18 – logD of benzene (logP = 2.05, left) and phenylalanine (logP = 1.11, right) over the entire 
pH range (0 to 14) 
With this equation, distribution and hydrophobic character can be estimated for given environments such 
as the blood plasma (pH = 7.4), the stomach (acidic, with a fasted pH of about 1.4 – 2.1 and a fed pH of 
                                                           
38 CLOGP and ALOGP, both widespread, are at two ends of the spectrum of computational logP 
prediction. CLOGP uses longer fragments and heavy correction for intramolecular forces, whereas ALOGP 
uses atom-size fragments and does not perform these corrections [159]. 
39 It follows for un-ionizable compounds that logD = logP. For ionizable compounds, logP = logD(7.0). 
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3.0 - 7.0 [160]), and so on. State of ionization therefore has major implications for solubility, permeability, 
and, finally, absorption.  
APPLICABILITY AND INTERPRETABILITY 
As stated before, a compound’s hydrophobic character is of importance in pharmacological studies. 
Hydrophilic compounds tend to be found in hydrophilic compartments such as the blood plasma whereas 
lipophilic structures distribute to lipid bilayers and the like [147]. Even though logP plays a major role in 
many pharmacological models, its very definition rests on the distribution of an unionized solute. Most 
drugs, however, are ionizable, 40 and hence logD would seem more appropriate, especially when 
absorption needs to be considered. 
 
The number of different software systems for the prediction of logP values suggests that none is truly 
superior. In fact, some studies show poor correlation (R2 in unseen compounds for ALOGP of 0.75 and 
0.72 for CLOGP) of computed logP values with observations [28]. Choosing one for modeling depends on 
cost, hardware considerations, and simply how well it performs for the endpoint. 
4.1.7.5. Molecular connectivity indices 
In a series of isomers, physicochemical parameters, e.g. boiling points, vary with the shape or the degree 
of branching (Figure 19). The class of molecular connectivity indices formalizes the rather intuitive notion 
of how complex a structure actually is. In general, these descriptors are graph-theoretical invariants. 41 
 
 
 
Figure 19 – Structure of pentane isomers with boiling points 
                                                           
40 This important point is noted in many logP methodology studies where, for example, corrections for the 
zwitterion character of amino acids are accounted for explicitly by a correction factor. 
41 Invariants in mathematics are properties that remain constant after transformation of the underlying 
object. Applied to working with labeled multigraphs (such as the chemical graph), invariants yield the same 
result regardless of how the graph is displayed or in which order it is traversed. As was seen before, 
SMILES notation allows for countless representations of the same molecule (see Section 4.1.2). Invariants 
are therefore of special importance for consistent results. 
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WIENER, PLATT, AND RANDIC INDICES 
The oldest of these, the Wiener number ( ), is the sum of distances between all pairs of vertices [161]. 
To compute it, one takes the hydrogen-depleted graph, adds up the length of the shortest path between 
every pair of atoms, and then multiplies it by factor ½ because the chemical graph is undirected 42 and any 
path between two atoms will be traversed twice. In the Wiener index (W) equation, N is the number of non-
hydrogen atoms and dij is the shortest distance between two atoms i and j. 
 
 
 
The Mean Wiener Index ( ) averages these distances. For a graph with n vertices, one arrives at the 
following equation: 
 
 
 
Building on this and work by Platt [162] (who details a descriptor that takes neighboring features into 
account), Randic developed a connectivity index for alkane branching that separates bonds based on the 
valencies m and n of the two partners into different classes of (m, n)-edges (Figure 20). 
 
 
 
Figure 20 – Partial contributions to the Randic index in isopentane. The numbers near the atom 
centers denote the valencies and the contributions are given in parentheses along the edges. 
The contributive numerical values of the edge classes are added to give the Randic index [163]: 
 
€ 
Χ = (did j )∑
−
1
2  
 
                                                           
42 i.e. if nodes ni and nj are connected, then so are node nj and ni. In directed graphs, a node can have 
predecessors and ancestors, in which case a connection only goes one way. 
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The individual terms didj are called ‘edge connectivity’ and provide a measure of how accessible each 
bond within the structure is to intermolecular interaction, that is, the higher the edge connectivity, the lower 
the accessibility [164]. 
VALENCE CONNECTIVITY INDICES 
Kier and Hall refined Randic’s index by considering valences and also longer fragments than just one bond 
[165, 166] in a large set of topological descriptors. The basis for many of these calculations is the simple 
delta (δ) and the valence delta (δv) value for every non-hydrogen atom. Given the number of attached 
hydrogens (h), its sigma electrons (σ) and valence electrons (Zv), the delta values are defined as 43  
 
€ 
δ =σ − h ; δV = Zv − h  
 
For elements beyond fluorine, δv is modified as 
 
 
 
where Z is the atomic number of the element. The first set of indices proposed by Kier and Hall are the chi 
molecular connectivity indices (mΧ and mΧv), which are sums of δ and δv over a bond length m. For zero 
order paths (individual atoms only) in molecules with n atoms, this gives 
 
€ 
0X = (δ i)
−
1
2
i=1
n
∑ ; 0X v = (δ iv )
−
1
2
i=1
n
∑  
 
Of course, this does not encode any structural information. This can be achieved by summing over bonds, 
e.g. for bond length m = 1 with two adjacent atoms at position i and j: 
 
€ 
1X = (δ iδ j )
−
1
2
i=1, j≠ i
n
∑ ; 1X v = (δ ivδ jv )
−
1
2
i=1, j≠ i
n
∑  
 
The kappa shape indices [167] provide a further link to shape by comparing bond counts P of molecules to 
extreme shapes (i.e. those that yield maximal or minimal index values) as provided by graph theory.  
 
                                                           
43 Thus, while CH3 differs from –CH2– in its δ value, it does not differ from –NH3. Valence delta, however, 
is different. 
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Figure 21 – Extreme shapes in first and second order kappa connectivity indices for 4 – 6 atoms. 
Minimum values are achieved by linear chains (Pmin) and maximum values (1Pmax and 2Pmax) are 
produced by complete graphs (adapted from [134]). 
ELECTRO-TOPOLOGICAL STATE (E-STATE) 
Further work by Kier and Hall uses the intrinsic state of an atom and the electronic and topological 
contexts (or fields) within which it is embedded in a molecule (electro-topological state (E-state)). The first 
consideration [20, 168] is the count of sigma- and non-sigma-electrons (as was introduced above as 
simple and valence delta values δ and δv) that encodes an atom’s intrinsic value I: 
 
 
 
The electron configuration not only correlates with electronic properties such as electronegativity but also 
to its topology (the degree to which the atom is buried within the structure). The actual E-state (S) of an 
atom is defined as the sum of I and the effects ΔI of each of the other atoms j (rij being the distance 
between atoms i and j) on the current one: 
 
 
 
The E-state is affected not only by a change in chain length. Effects are also seen when branches and 
higher bonds are introduced, mirroring the altered accessibility as atoms are buried. Substitution of a 
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heteroatom not only changes valencies but electronegativity, too, again changing the E-state [168]. Values 
for an entire molecule are usually achieved by calculating the mean square value for every atom [134]. 
SMALLEST ASSOCIATED BINARY LABELS (SABL) 
The chemical graph is abstracted to such a degree that it allows the application of other tools from graph 
theory to molecules. For instance, connectivity might also be characterized by the length of the Smallest 
Associated Binary Labels (SABL), i.e. the shortest sequence of bits required to define the connections 
within a molecule as represented by the corresponding adjacency matrix (Figure 22). 44 For pentane 
(Figure 22b), the SABL is ”10, 101, 1010, 10100, 1000” (length = 18 bits), for isopentane (Figure 
22d) ”1, 1, 10, 101, 11010” (length = 12 bits), and ”1, 1, 1, 1, 11110” (length = 9 bits) for 
neopentane (Figure 22f). 
 
 
Figure 22 – Hydrogen-suppressed molecular graphs and adjacency matrices for pentane (a, b), 
isopentane (c, d), and neopentane (e, f). 
APPLICABILITY AND INTERPRETABILITY 
The distinct advantage of connectivity descriptors is that they can be calculated from the molecular graph 
itself, require no experimental verification, and correlate well with many physicochemical parameters [163, 
165]. However, even though their ease of interpretation suggest generality, very abstract descriptors such 
as the Wiener index or SABL work best in homogenous compound sets, e.g. in substitution schemes. 
Newer work addresses this problem and extends well known indices (for instance the Szeged Index [169, 
                                                           
44 An adjacency matrix has n x n dimensions where n is the number of nodes and whose elements ai,j are 
equal to the number of connections between node ni and nj (0 for non-adjacent nodes). 
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170] and Overall Wiener Index [171]). Still, for very heterogeneous sets, information-rich descriptors as 
detailed by Kier and Hall are preferable. 
 
A general interpretation for connectivity is notoriously hard to give. Edge connectivity as a measure of 
accessibility of individual bonds (e.g. in the Randic index) can be seen as contribution to interaction 
between two different molecular species. 
4.1.7.6. Structural and geometrical indicators 
MOLAR REFRACTIVITY 
Several descriptors exist to give numerical approximations of molecular dimensions and shape. The molar 
refractivity (MR) index is a very straight-forward way to do this. It links molecular weight (MW) to molecular 
density (d) and refractivity (n): 
 
 
 
Because refractivity changes only minimally between different molecular species, MR helps to gain an 
impression of the steric bulk and thereby complements connectivity indices such as the Wiener or Randic 
index (see 4.1.7.5). 
 
 
Figure 23 – Steric bulk and accessibility of the lone pair electrons of nitrogen (blue) in tri-tert-
butylamine (N,N-ditert-butyl-2-methylpropan-2-amine). 
MOMENTS OF INERTIA 
Moments of inertia are simple physical indicators of mass distribution and symmetry. They are calculated 
for each atom i of the n atoms in a molecule by summing up the product of the mass and the perpendicular 
distance to every other atom along any of the principal axes of a three-dimensional coordinate system as 
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or, explicitly, for the axes X, Y, and Z, given atomic coordinates as (x,y,z): 
 
 
 
Ratios defined from these values (MOMIXY, MOMIYZ, and MOMIXZ) are also frequently used. A closely 
related descriptor is the molecular radius of gyration about the center of gravity [172] 
 
 
 
where MW is molecular weight. These descriptors not only serve to characterize rotational dynamics but 
also hint at molecular symmetry. For example, in CCl4 the principle moments are all equal (MOMIX = 
MOMIY = MOMIZ), and the molecule can be said to have the symmetry of a spherical top. Similar 
relationships can be found for linear (e.g. C2H2), planar (e.g. C6H6), and other symmetries. 
GRAVITATIONAL INDICES 
Much like the moments of inertia and molecular refractivity, gravitational indices reflect mass distribution 
and bulk of a molecule by relating measures of mass to measures of intramolecular distance. In its 
simplest form, calculations are performed for pair of atoms i and j with mass mi and mj and distance rij:  
 
 
 
Similar calculations limit themselves only to bonded atom pairs or only heavy atoms. Square and cubic 
roots are also frequently employed [138]. 
APPLICABILITY AND INTERPRETABILITY 
The attractiveness of this class of descriptors lies not only in their low computational expense. They are 
also easily interpreted from a physical point of view. Moments of inertia are, in the end, common concepts 
in everyday life (consider, for example, how ice skaters reduce them along two axes (linear symmetry) to 
increase speed in pirouettes, or water divers along three axes (spherical top symmetry) during spins). 
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4.2. Machine learning methods 
4.2.1. Overview of machine learning methodology 
Machine learning (ML) is a discipline of artificial intelligence (AI) and deals with the learning and 
representation of knowledge. Some of its methods are taken from multivariate statistics (e.g. regression), 
others are distinctively AI (e.g. neural nets), although both fields borrow from each other. Data mining, the 
task of sifting through large data sets, pattern recognition, and data warehousing, the task of storing and 
archiving large data sets, are closely linked to ML. 
 
The simplest way of representing knowledge or experience is by listing all previously encountered 
instances and finding the instances to be predicted in this list. Of course, this would not be considered 
learning in common understanding, and new events could easily fail to be classified correctly if they do not 
exactly match entries in the list. The main goal in ML is therefore to derive concepts from existing data, 
generalize them, and successfully apply them to unseen instances (i.e. predict them). 45 
4.2.1.1. Supervised versus unsupervised learning 
Generally, learning can occur supervised or unsupervised. In supervised learning, the list of instances (the 
data set) as a vector of attributes is augmented by another dimension that denotes the class or outcome of 
this event (i.e. labeled data). For example, a data set on acute pancreatitis patients would likely contain 
reported symptoms, laboratory values, and examination results, plus a column ‘outcome’ that states 
whether or not the patient was actually diagnosed with the condition. A supervised learning method would 
take a random sample of this data (the training set), build a model based on this, check its validity based 
on the rest of the data (the test set), and repeat the process until the test set is predicted with good 
accuracy. Decision trees and Naïve Bayes learning are classical examples. 
 
In unsupervised learning, the method is left to come up with its own classes. These can be validated on 
other, previously unseen, data. The advantage of this is that a system may be revealed as more complex 
(or less) than previously thought. Notable methods that use this approach are clustering and Kohonen’s 
Self-Organizing Maps (SOM). 
                                                           
45 Memorization is an extreme form of what is known as ‘lazy learning’ in ML. Lazy learning methods do 
not derive rules or relationships during learning. Rather, they compare the instances to be predicted with 
the knowledge base only during runtime. Learning is therefore faster and new instances can be 
continuously added. Eager learning is the opposite case. Models are built during learning and are usually 
not modifiable afterwards without repeating the learning process.  
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4.2.1.2. Explanatory power 
Many criteria exist for judging the quality and applicability of ML models (model validation, see below). 
When discussing the explanatory power of models, two less formal concepts are often used: Occam’s 
razor and the Minimum Description Length (MDL) principle. 
OCCAM’S RAZOR 
In 1495, the Franciscan friar and logician William of Ockham 46 put forth the following maxim in his work 
‘Sentences of Peter Lombard’: 47 ‘numquam ponenda est pluralitas sine necessitate’ (‘never posit plurality 
without necessity’, or, more freely, ‘All things being equal, the simpler explanation is usually the best’). This 
reductionist piece of philosophy, known as ‘Occam’s Razor’, is a useful rule of thumb when it comes to 
choosing between two models that perform with the same accuracy on a data set. The one that is least 
complex, i.e. which depends on the least attributes, will be more general and perform better on unseen 
data. 
MINIMUM DESCRIPTION LENGTH (MDL) PRINCIPLE 
In information theory, Occam’s Razor is formalized to give the Minimum Description Length (MDL) 
principle [173]. Any given set of data can be represented as a string of symbols with length s. A description 
d(s) of such a string is of minimal length when it uses the least amount of symbols and this length is called 
Kolmogorov complexity [174] of s: 
 
€ 
K(s) = d(s)  
 
The MDL principle states that the best hypothesis of a data set also leads to the best compression of that 
data. For example, a string such as ‘AAAAAAAAAAAAAAAAAAAA’ (length: 20 characters) can be 
represented in English as ’20 times A’ (length: 10 characters), which is a compression ratio of 50%. 
 
Applied to machine learning, description of a data set is the model (or hypothesis) learned from the training 
set and the errors (or exceptions to the hypothesis) it makes on the entire set. During learning, the 
description complexity for training data decreases with the error rate (less exceptions need to be coded). 
Overfitted models, however, are punished because they perform much worse on test data (more 
exceptions need to be coded). Although the MDL principle is a sensible quality criterion, it does not allow 
one to find the best model. This is because the Kolmogorov complexity in a given language cannot be 
calculated [175]. 
                                                           
46 Nowadays, ‘Ockham’ is usually spelled ‘Occam’. 
47 Peter Lombard (c. 1100 – July 20th 1160) was a scholastic theologian and bishop. His ‘Four Books of 
Sentences’ was the standard textbook at medieval universities. 
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4.2.1.3. Linear separability 
Most methods classify instances by creating a space of n dimensions (where n is the number of available 
attributes) and defining planes that separate it into regions where a given class occurs as homogenously 
as possible. In the case of linearly inseparable data sets, this is impossible. The XOR problem [176] 
illustrates this in two dimensions. XOR is an operation on two binary variables that is only true when the 
two variables differ, i.e. contradict each other (Figure 24). A linear method (such as linear regression) 
would separate the two classes (0, 1) by trying to draw a straight line. All possible solutions (gray lines in 
Figure 24) fail. 
 
 
Figure 24 – XOR problem and linear separability. The XOR operation spans a problem space that 
cannot be separated by linear methods (decision lines, in gray). 
4.2.2. Validation methods 
During every modeling attempt, one is faced with two questions: is the model good enough and is there a 
method that performs better? In traditional statistical analysis, the quality of a model is only stated as the 
coefficient of determination (R2) and it is considered valid once it crosses a certain threshold. This 
procedure is only applicable when a common definition of R2 exists and its value is interpretable over 
different modeling techniques. This is certainly not the case in ML where numerical methods co-exist 
alongside classification methods. 
 
The basic principle behind all ML validation methods is using a larger part of the available data for learning 
(training set) and the other data to judge the performance on unseen data (test set) [177]. By modifying 
learning parameters and minimizing the error on training data, several models are generated and 
compared by their respective errors on the test set. 
 
When comparing different learning methods to each other, part of the unseen data can be held back as a 
validation set, which would then be used as a test set. The best models for each method are selected 
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(based on performance on this validation set) and then used to predict the test set. However, this is only 
feasible when large data sets are available. 
4.2.2.1. Skewed data and subset creation 
Frequently, real-world data sets are skewed, i.e. the members of one class greatly outnumber those of the 
other ones. This gives rise to two problems. Firstly, if the predictive power of a method is reported as 
number of correct hits over the number of instances in the training set, a method can show impressive 
results when it constantly assigns the most frequent class to any new instance it classifies. 48 This issue is 
easily addressed by calculating the corrected classification rate (CCR) 49 where the predictive power of a 
model with n classes is reported as 
 
 
 
where Ti is the number of correct predictions of class i and Ni the total number of class i compounds in the 
model. The strategy of assigning the majority class to all new instances will not perform better than a fair 
coin toss. 
 
The second problem lies in the representative selection of instances for either of the sets. If a class is 
grossly underrepresented, it might not occur in the training set. In that case, the class will be unseen 
during learning and therefore not be correctly predicted. Conversely, the performance on a test set with 
unseen classes will be lower than if the instances were properly distributed. The work-around for this 
would be the stratified sampling, where one aims to proportionally represent all classes in every set 
instead of selecting instances at random. 
4.2.2.2. Inter-rater agreement 
Kappa statistics are a measure of inter-rater agreement for categorical data and considered to be a more 
robust measure than simple percentage calculation. They are used to compare two different assessments 
of the same data, i.e. when two raters (judges) assign a value to an instance, kappa statistics evaluate 
how well these correlate. Various methods exist, and for situations with two raters, Cohen’s kappa [179] is 
widely used. Its value is calculated as  
 
 
                                                           
48 This effect is especially pronounced when the most frequent class has a probability of 50% or more. It is 
not unlikely for real data sets to have probability peaks of 80% or more. 
49 Or any other similar measure, such as the Matthews Correlation Coefficient [178] for binary 
classification. 
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where Pr(a) is the actual agreement and Pr(e) the agreement to be expected by chance. In other words, it 
compares the actual success rate of the predictor (numerator) with the performance of a perfect predictor 
(denominator). In this respect, kappa statistics are analogous to the corrected classification rate (CCR) 
discussed above. 
 
Cohen’s approach can be extended to incorporate multiple raters (Fleiss’ kappa [180]) by reformulating the 
equation to use the means of the raters’ agreement: 
 
 
 
To calculate Fleiss’ kappa for N instances indexed as i=1…N which have been assigned one of k 
categories indexed as j=1…k by n different raters, one first calculates the mean expected agreement per 
chance, Pr(e), from the proportion of all assignments to a given category j (pj): 
 
 
 
and 
 
 
The mean of actual agreement, Pr(a), is calculated from the extent of the agreement to which raters agree 
on a given instance i (Pi). 
 
€ 
Pi =
1
n(n −1) nij (nij −1)j=1
k
∑  
 
and 
 
 
 
Generally,  it can be said that the higher the κ value, the better is the agreement. Landis and Koch [181] 
give an interpretation of κ values which is valid for both Cohen’s and Fleiss’ kappa (Table 9). It is worth 
noting that this table is based on the personal opinion of the authors and therefore up for debate. 
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Furthermore, as the number of categories k decreases, κ can be shown to increase [182], showing the 
lack of robustness of this approach. Despite all this, both kappa statistics and Landis and Koch’s table are 
widely used instruments in inter-rater agreement analysis. 
 
Kappa value Interpretation 
κ ≤ 0 No agreement 
0 < κ ≤ 0.2 Slight agreement 
0.2 < κ ≤ 0.4 Fair agreement 
0.4 < κ ≤ 0.6 Moderate agreement 
0.6 < κ ≤ 0.8 Substantial agreement 
0.8 < κ ≤ 1.0 Almost perfect agreement 
Table 9 – Interpretation of kappa values according to Landis and Koch [181] 
4.2.2.3. Diversity of sets 
In analogy to assessing chemical diversity (see 4.1.6), one may assess the suitability of available data for 
modeling. One obvious way of doing so is to evaluate the variance of descriptors because it is pointless to 
look for patterns that show no variation for different classes. For some methods (e.g. decision trees, see 
4.2.4), this selection is built into the algorithms. For others (e.g. neural networks, see 4.2.6) it is not. 
 
Normalization of variables eliminates bias towards those which are on larger scales. Auto-scaling is an 
easily applied technique, producing descriptors scaled down to a mean  = 0 and σ’ = 1: 
 
 
 
In some cases, independent variables correlate with each other such as that plotting them together gives a 
scatter along a straight line (Figure 25).  
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Figure 25 – Correlation of example data. a) Negative correlation (Pearson’s r: -1.0), b) positive 
correlation (Pearson’s r: +1.0), c) random data with almost no correlation (Pearson’s r: -0.05) 
Pearson’s correlation coefficient r checks for negative or positive correlation (r approaches -1.0 or +1.0, 
respectively, and 0.0 for no correlation at all) between two variables x and y with means  and  for n 
instances: 
 
 
4.2.2.4. Cost sensitivity 
Not all classes are necessarily of equal interest and two models with the same predictive power may not 
be equal when it comes to applicability. For instance, a virtual mass screening of compounds for leads in 
drug discovery may value a model that identifies more potential candidates with low precision over one 
that safely discards all uninteresting structures while also suppressing more possible leads. 50 
 
Artificially increasing samples of the highest-priced class k-fold is another way of addressing cost (cost-
sensitive learning). Keeping in mind that minimizing error is at the heart of any learning scheme, it is easily 
seen that errors in predicting this class are also punished k-fold. 
4.2.2.5. Cross-validation 
Cross-validation (CV) is the most commonly practiced method of assessing the effectiveness of a model. 
The concept goes back to the 1950s where it was developed to evaluate the accuracy of linear regression 
models [183, 184]. CV aims to maximize the amount of information that can be extracted from a data set 
by letting instances cross over between test and training sets.  
                                                           
50 This approach to model validation does not require naming an actual financial figure for cost. 
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K-FOLD CROSS-VALIDATION 
In k-fold cross validation, a data set is partitioned into k subsets (usually k=10) [185]. Of these, k-1 are re-
combined to make up a training set which is test against the last subset. This process is repeated k times 
until all instances have served as training and test data, thereby making sure that no classes are left out. 
Underrepresentation of a class in skewed data can be handled by stratified sampling. 
PARTITIONING (HOLD-OUT CROSS-VALIDATION) 
While technically not cross-validation because instances will not actually cross over, partitioning is often 
grouped with these methods and is also known as cross-validation. Here, random or stratified samples are 
taken from the data to form either test or training data. Test sets are usually 10-25% the size of the original 
data. 
LEAVE-ONE-OUT CROSS-VALIDATION (LOO) 
Leave-one-out cross-validation (LOO) is a special case of k-fold cross-validation [186, 187] where, in an 
original set of n instances, k equals n. The leave-one-out estimate is calculated by learning n models from 
the data, while each time removing one of the instances and testing the model against it. The ratio of failed 
tests is the estimate. 
4.2.3. K-nearest Neighbors (kNN) 
Among the plainest forms of learning is pure memorization of instances. If a ‘new’ instance is to be 
classified, it can be looked up in the table of seen instances and the once observed class is returned. Of 
course, as the number of available features grows and their type shifts from nominal values to continuous 
numerical variables, the chance of finding an exact match becomes very small. 
 
K-nearest neighbor (kNN) algorithms address this problem by assessing the similarity of the instance to be 
predicted with the knowledge base 51 and the majority vote (i.e. the most frequent class) is the predicted 
result. The definition of neighborhood may be a fixed number of peers (Figure 26) or a geometric measure 
of distance where a variable number of peers are selected based on the actual distance in feature space. 
Usually, the number of neighbors is between five and ten. It would seem sensible to choose an odd 
number to prevent tied votes (and so it is often done). However, provided that the data can be robustly 
separated, tied votes should prove no problem, as instances would cluster and as class margins would be 
sufficiently far apart so that instances at the fringes would still lie in the vicinity of a homogeneous field. 
                                                           
51 This follows the rationale that instances of the same class lie close to each other in feature space, much 
in the same way that certain neighborhoods are home to people of similar socio-economic status. 
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Figure 26 – Classification of an instance X using a k-nearest neighbor (kNN) approach with k=3 and 
k=5 nearest neighbors. 
kNN algorithms are lazy learning methods: apart from storage, no processing of the data takes place. This 
makes training very easy and computationally inexpensive, which is an advantage compared to eager 
learning (such as decision tree inference (see below), where generalizations are made during training and 
applied later, during runtime, at low expense). A further advantage is the possibility to continually add 
unseen instances, thereby increasing the knowledge base and potentially performance as the model gains 
experience. Other models require the entire training cycle to be repeated. However, lazy learning is 
generally less robust and therefore more sensitive to noisy data.  
4.2.4. Decision Tree Inference (DTI) 
Complex problems can sometimes be tackled by recursively breaking them down into smaller sub-
problems that are easily solved. This important paradigm in computer science is known as a ‘divide and 
conquer’ algorithm. In Decision Tree Inference (DTI), this type of approach is used to learn patterns, 
visualize data and relationships, and predict new and unknown instances. 
 
 
 
Figure 27 – Decision tree to model the XOR problem. 
Trees are human readable and can therefore be used to visually convey a decision making process, quite 
similar to flow charts, although expert knowledge is still required to properly interpret them. Similarly, they 
help in uncovering patterns in new data sets. At the same time, trees are easily translated into rules by 
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reading the path off each leaf and translating them into programming or database query languages such 
as SQL (Structured Query Language, the most widely used standard). Its applicability to real-world 
questions is further underlined by its ability to solve linearly inseparable problems such as the XOR 
problem (Figure 27). 
 
To find the optimal model for a given dataset, one would need to enumerate every possible configuration, 
which, considering that the complexity of the search space rises exponentially with the number of 
attributes and instances included, is not feasible. Instead, decision tree algorithms offer a heuristic analysis 
using a divide-and-conquer approach 52 in the hopes of achieving a good global model by solving simple 
local problems. 
4.2.4.1. General description 
DTI mimics the human learning and classification process by splitting a training data set into smaller and 
smaller subsets, with each level having higher purity than the one above. In analogy to real trees, decision 
trees also have nodes (or inner nodes), branches, and leaves (or leaf nodes, Figure 28). Nodes are where 
a given attribute is compared to a constant value and the tree branches accordingly. Nodes where no 
decision is made, i.e. where the path reaches a dead end, are called leaves and give a classification. In 
their simplest form, nodes will split two ways (binary trees), 53 although different methods exist that 
produce n-ary trees. 54 The depth (sometimes referred to as ‘height’) of a tree is the length of the path from 
the root node to deepest node.  
 
A DTI algorithm will start off with the complete training set, evaluate all available attributes, and choose the 
one which best separates it. It then recursively proceeds to split the resulting subsets until  
 
a) there a no more attributes,  
b) the tree reaches a certain complexity, or 
c) no improvements can be made by continuing to split.  
 
When one of these break conditions is met, the node is declared a leaf that gives the class that most 
frequently occurs in the subset. 55 
                                                           
52 Divide-and-conquer algorithms are an important design pattern in computer science. Problems are 
recursively broken down into ever smaller problems of the same type until they become solvable. 
53 Any n-ary tree with n>2 can be transformed into a binary tree. The nodes of a complete binary tree have 
two or no children, a perfect binary tree has all of its leaves at the same level. 
54 A typical trinary split would be “within a range”, “below the range”, and “above the range”.  
55 In case of equal probabilities, the class is selected at random. 
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Figure 28 – Example of a decision tree with a depth of 3. Boxes are inner nodes, circles are leaves, 
and the root node is the only element at the top level (adapted from [188]). 
4.2.4.2. Splitting Criteria 
An ideal DTI algorithm creates leaves that are homogenous, i.e. they contain only instances of a single 
class, hence giving predictions with absolute certainty. 
INFORMATION GAIN 
The commonly used measure of homogeneity (or purity) was introduced in 1948 by Claude Shannon [189] 
as information entropy. Entropy is maximal when all classes have the same probability and minimal when 
a subset is made up only of members of a single class. Algorithms will therefore use entropy as an error 
function which they seek to minimize. 
 
The Shannon equation is the prototypical way of calculating information entropy for a discrete random 
variable X which can take on values between x1 and xn (b is chosen arbitrarily and 0 log (0) is taken as 0): 
 
€ 
H(X) = − p(xi)
i=1
n
∑ logb p(xi)  
 
The unit of information is the bit and is not to be confused with the binary digit as it can take on fractional 
values. Information entropy is calculated by finding the probabilities for every class and multiplying it by 
their logarithms. Choice of the logarithm’s base is arbitrary but is usually equal to the number of classes so 
the equation returns values between 0 for perfect purity and 1 for equal probabilities. 
 
 
The coin toss illustrates the character of information entropy (Figure 29). In a series of tosses with a fair 
coin, i.e. one that is equally likely to come up with either face, the entropy amounts to 1 bit. As the coin is 
increasingly poised towards heads or tails, entropy converges to 0 bit. 
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Figure 29 – Information entropy of the coin toss and the probability p(X=1) of a given face coming 
up. 
The information entropy in the parent node is pitted against those of its children to produce the information 
gain. The simplest way of doing this is by subtraction. 
GINI COEFFICIENT 
The Gini coefficient was developed by the Italian statistician Corrado Gini [190] and is a measure of 
dispersion. It is most prominent in economics where it denotes the dispersion of wealth in a population, 
usually on a national level, and has only recently made its way into machine learning. 
 
In decision analysis, the Gini coefficient describes the degree of slope in a Receiver Operating 
Characteristic (ROC) curve, a cumulative graph where the x-axis corresponds to a test or split variable and 
the y-axis to the percentage of instances of the same class in a data set. As the split variable progresses 
from its minimum to the right, more and more instances are covered until they plateau at their maximum of 
100%. A variable that does not aid in discriminating between classes would run across the diagonal of the 
graph (line of perfect equality) and have the same discriminating power as a fair coin toss (Figure 30a). 
Consequently, one can gain an impression of the usefulness of the split variable by inspecting the curve 
and judging the slope it has. The farther it deviates to one corner, the better (Figure 30b and c). ROC 
curves also allow one to find the value at which no more instances of the class in question are caught, i.e. 
where sensitivity does not increase anymore. Setting the threshold in Figure 30b to 0.2 will include most 
instances and is probably preferable to a threshold of 0.4, where all instances are caught but also some of 
other classes.  
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Figure 30 – Sample ROC curves 
 
 
Figure 31 – Calculating the Gini coefficient. The area under the Lorenz curve (B) is divided by the 
area under the gray line of indifference (A+B). 
The Gini coefficient formalizes the selection of the best curve. If A is the area between the line of perfect 
equality and the ROC curve and B is the area under the ROC curve (Figure 31), the Gini coefficient G is 
 
 
 
or, taking into account that A and B cover the entire area under the line of perfect equality and therefore 
equals 0.5: 
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This equation works well for curves with a configuration as the one in Figure 30c but when G gives values 
> 1 for the mirror image Figure 30b. To remove this bias, the equation is modified to 
 
 
 
4.2.4.3. DTI algorithms 
In order to find the optimal tree for a training set, one would have to create all possible trees and then 
select the best one. However, as the search space in real-world problems quickly becomes too large to do 
this, only heuristic algorithms exist. 
ITERATIVE DICHOTOMISER 3 (ID3) 
Initially described by Ross Quinlan in the 1980s in a seminal paper [191], the Iterative Dichotomiser 3 (ID3) 
is one of the best known DTI algorithms. ID3 is based on Occam’s razor, i.e. it prefers the simpler model 
over the more complex (smaller trees over large ones). The algorithm builds trees by inspecting all 
available attributes and split points and then calculating the information gain these splits would give. The 
split with the highest gain is chosen and the procedure is repeated on the subsets. 
C4.5 AND C5.0/SEE5 
Quinlan improved ID3 to handle both continuous and discrete values, missing data, and risk/cost [192]. 
Furthermore, C4.5 also supports pruning (see below). While this implementation is freely available from his 
website (though no longer supported), Quinlan commercialized a closed-source version (C5.0 for UNIX, 
See5 for Microsoft ® Windows ™) that produces smaller trees at a higher speed and also added support 
for boosting, weighting and winnowing. 
CLASSIFICATION AND REGRESSION TREES (CART) 
First introduced by Breiman in 1984 [193], CART produces classification or regression trees depending on 
whether the dependent variable is categorical or numerical. The split criterion used is the Gini coefficient. 
CART produces trees by monitoring the error on the test data during growth and choosing the one with 
minimal error. 
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Figure 32 – Comparison of error on training set and test set (example). Training error declines 
steadily with tree complexity while the error on the test set reaches a minimum soon and then 
starts to increase again (overfitting). 
CHI-SQUARE AUTOMATIC INTERACTION DETECTOR (CHAID) 
The Chi-square Automatic Interaction Detector (CHAID) is the oldest of the DTI algorithms in use today 
and was described in 1964 [194]. Attributes are chosen with the Chi-square test and trees are subject to 
forward pruning.  
4.2.4.4. Additional techniques in DTI 
PRUNING 
When presented with two models that explain the same data with the same accuracy (or error rate), one 
would choose the simpler one in accordance with Occam’s razor. In DTI, the process of simplifying a 
decision tree is known as pruning. Apart from producing models that are easier to interpret, pruning also 
helps to avoid overfitting because the amount of information extracted from the training set is minimized. 
This makes the model more general and improves applicability to other (test) sets. 
 
There are two ways of pruning a tree: forward and backward. Forward pruning is done by setting criteria 
that stop growth such as maximum depth, maximum number of nodes, number of instances in child nodes, 
and so on. Backward pruning involves predicting a test set from a maximal tree and then successively 
cutting branches, i.e. removing subtrees, while keeping the error rate about the same. The success of a 
pruning operation is measured by an improvement on the error on the test set.  
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A special case of backward pruning is subtree raising. The most popular subtrees, i.e. the ones with the 
most instances, are identified and their subtree is raised a level to replace its parent node. Any other 
children of the removed node are reclassified in the new tree. This procedure is resource hungry and only 
the most popular subtrees are examined. 56 There is no universal agreement on the usefulness of this 
method but it is used in some of the major DTI algorithms (C4.5, CHAID).  
 
Pruning can also help in a post-mortem (post-hoc) attempt to decrease overfitting [195]. For this, 
performance on test set data is assessed and, as the tree is being pruned, constantly re-assessed in the 
hopes of seeing improvement on the unseen instances (at the expense of decreased performance on 
training data). 
 
 
Figure 33 – Subtree raising. In the original tree (a), node B is removed (b), replaced by node C, and 
the instances in leaf 2 reclassified to fall into leaves 3 and 4 (c). 
BOOTSTRAP AGGREGATING (BAGGING) 
This procedure was proposed by Leo Breiman [196] as a method to artificially improve the accuracy 57 of 
regression and classification models. Given a training set of size n, a bagging algorithm creates i subsets 
of size n’ < n by sampling the training set with replacement. All of the subsets are learned individually and 
the models are combined by voting (for classification models) or averaging (in regression). In linear models 
such as linear regression, bagging cannot be used because attributes are averaged [185, 197]. 
4.2.4.5. Evaluating DTI models 
As with other statistical models, the quality of a tree depends on its error rate on training data and its ability 
to generalize, i.e. the error on test data and the tree’s complexity. A DTI algorithm extracts as many 
features as necessary to minimize the error rate on training data. This, however, does not guarantee good 
performance on new data because the model was built specifically for this data set and training error rates 
                                                           
56 It is important to note that subtree raising is a local modification that does not allow changes in structure 
to move up the tree. Considering the example in Figure 33, raising subtree C might affect the decision 
made on attribute A. 
57 The name refers to the analogy of pulling oneself up by one’s bootstraps.  
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are therefore an overly optimistic estimation of future performance. 58 Furthermore, in practical settings, 
data are limited and test sets again make up only a fraction of the available instances. While test sets are 
usually a random sampling, it is likely that it is not entirely representative of the training set. Therefore, 
some of the predictors extracted from the data may not be present in the test set and result in higher error 
rates. Of course, this means that the test set contains additional information that could also be modeled if 
samples are chosen more adequately. 
 
The performance and features of a DTI model must be evaluated in view of its purpose. If the tree model is 
intended to discover hitherto unknown patterns in data, a simpler model is certainly preferable over a 
complex one with lower error rates. On the other hand, if the cost associated with incorrect predictions is 
high, the reverse situation is preferred. 
 
4.2.4.6. Geometrical interpretation 
Decisions in DTI are – at the node level – simple comparisons of an instance’s attribute to a threshold 
constant. Repetitions of this split the feature space into homogeneous clusters. In the case of a two-level 
binary tree, this corresponds to decision lines (Figure 34).  
 
 
Figure 34 – Geometric interpretation of decision tree inference in a two-class problem for the 
classes X and O. 
LEAF ERRORS 
When predicting an instance with a decision tree, it is passed down the branches until it reaches a leaf. 
The class the leaf votes on is the most popular one during learning. In the case of a leaf that was reached 
during learning by 15 instances of class A and only 5 of class B, it would vote on class A. When it comes 
to the certainty of the prediction, one might give the overall error of the model for a given class. A more 
                                                           
58 This is referred to as resubstitution error because data are re-entered into the model and predicted. The 
model has previous knowledge of the data set and will perform much better than on unseen instances. 
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precise way of doing so is to store leaf purity along with the tree structure and return this as the accuracy 
(that is 15/(15+5) = 75% in the previous example). 
4.2.5. Random Forests 
Taking the tree paradigm a step further, Breiman introduced Random Forests (RF) in 2001 [198]. It creates 
a pre-set number of unpruned decision trees (originally using Breiman’s own CART algorithm, but others 
are just as valid) with a small number of different features randomly selected during learning for each tree. 
Classification is according to majority vote of all trees. How many trees are created in the model depends 
on the number of features and instances, but around ten is what is usually chosen in most studies. Of 
course, to avoid tied votes, an odd number is preferable. However, if class separability is high enough, tied 
votes occur so rarely that this constraint seems superfluous. 
4.2.6. Artificial Neural Networks (ANNs) 
The concept of artificial neural networks (ANN) was first proposed in 1943 by McCulloch and Pitts [199]. 
The idea is fundamental to bionics, the modeling of artificial systems based on biological design, and 
mimics the way the brain processes information. Many variations of the classic ANN model (the 
perceptron) exist and its applications are just as varied, ranging from pattern recognition to the control of 
autonomous vehicles.  
 
 
Figure 35 – Single-layer perceptron with an input layer, a weight matrix wi, and an output layer with 
a transfer (y) and an activation (Σ) function. 
4.2.6.1. The Perceptron 
The perceptron as described by Rosenblatt [200] is a direct mathematical model of the neuron and the 
simplest incarnation of an ANN: a feed-forward linear classifier. In analogy to the neuron, the perceptron 
has any number of inputs (dendrites) and only one output (axon). Information is collected in the input layer 
(Figure 35), modified by weights, and then directed to the output layer where the information is summed up 
and passed to an activation function. 
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Mathematically, the single layer perceptron is similar to linear regression in that it multiplies individual 
variables by a constant weight and then adds them up in the transfer function: 
 
 
 
While linear regression stops here, the perceptron passes the value to an activation function f(y) that 
decides whether and to which degree the neuron fires. Figure 36a illustrates the simplest activation 
function (linear). Closer to biological template is sigmoid activation (Figure 36b) or the more extreme step 
function that models the all-or-nothing principle of the action potential in neurons. The sigmoid function in 
Figure 36b is given by the following equation 
 
 
 
where Θ is the inflection point and T regulates the slope. In the step function, also known as Heaviside 
step function or Theta function, Θ is the threshold of activation: 
 
 
 
 
Figure 36 – Examples of activation functions: linear (a), sigmoid (b), and step function (c) 
4.2.6.2. Perceptron learning 
Choosing the weights wi in a perceptron is a supervised learning process. Because of the similarities 
between linear regression and single-layer perceptrons, one could simply perform a least-squares analysis 
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of the data and substitute the calculated factors as weights. This would, in fact, yield more accurate results 
than the heuristic algorithms of ANN learning but would not be applicable to other network architectures. 
 
The learning methods for ANNs are again in close analogy to the biological model. The central rule behind 
them is known as Hebb’s Rule and states that the connection between a neuron i and a neuron j will be 
reinforced (that is, the weight wij is increased) when it is activated repeatedly. During learning, this weight 
adjustment would then follow the equation 
 
€ 
Δwij =ηxix j  
 
where η is an arbitrarily chosen learning rate. This process is repeated over the training set until a 
maximum number of iterations is reached or the overall error of the net reaches a minimum. A common 
modification of this for single-layer perceptrons is the delta rule, where η is the learning rate, tj is the target 
value, vj the actual net output, and xi the ith input: 
 
€ 
Δwij =η(t j − v j )xi  
 
Using the example topology given in Figure 35, one can formulate pseudo-code of the learning rule (Figure 
37). 
 
repeat for each instance i 
iterations = iterations + 1 
 instance_error = calculate_net(i) – expected_value(i) 
 net_error = net_error + instance_error 
 for each weight w 
  w = (instance_error – expected_value(i)) * learning_rate 
 end for 
until net error converges or iterations == maximum 
Figure 37 – Pseudo-code of a single-layer perceptron learning rule (delta rule) 
It is important to avoid biasing descriptors that are on larger scales than others. Range-scaling, a 
modification of auto-scaling (see 4.2.2.3) with σ in the denominator replaced by the spread r (the 
difference between maximum and minimum values), yields values of a range [-0.5, 0.5]. Adding 0.5 to 
results shifts the range to [0, 1] and thereby all variables to comparable ranges: 
 
 
4.2.6.3. The multi-layer Perceptron 
Adding additional layers of neurons between the input and output layers of a single-layer perceptron, 
known as hidden layers (Figure 38), yields a network architecture called the multi-layer perceptron (MLP). 
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Figure 38 – Multi-layer perceptron (MLP) with one hidden layer, a weight matrix wi, and an output 
layer with a transfer (y) and an activation (Σ) function. 
MLPs have been proven to be universal function approximators [201], that is to say they are capable of 
approximating any multivariate function with any desired degree of accuracy, given that the weights and 
network topology are chosen properly. This is particularly noteworthy because unlike single-layer 
perceptrons, MLPs can model linearly inseparable data (Figure 39). 
 
 
 
Figure 39 – XOR problem modeled in a multi-layer perceptron. The numbers along the edges are 
the weights assigned to the connections. 
4.2.6.4. Other ANN topologies 
The topologies discussed so far were feed-forward design. Recurrent variants also exist and are used in 
practice. Here, the output of certain neurons is fed back into the net (backwards propagation) in what is a 
directed cycle in graph theory. A variety of different architectures exist. One of the more common ones is 
the Hopfield network, where connections are symmetrical (Figure 40). 
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Figure 40 – Topology of a Hopfield net with 3 nodes. 
4.2.6.5. Interpreting ANNs 
Even though ANNs are a direct abstraction of how knowledge is represented in organisms, the rules 
learned cannot be read off their graphs. This is especially true of topologies with hidden layers. In single-
layer perceptrons, one can judge the relative importance of inputs by comparing their weights if the training 
data was normalized prior to learning. 
 
The models produced by ANNs are decision hyperplanes. In the linear case, these are planar and defined 
by the weights assigned to the attributes during learning. It can be stated as  
 
€ 
g(x) = wT x + w0  
 
where wT is the vector transpose of the weights learned (determining the orientation of the hyperplane) 
and w0 is a constant. Because weights are randomized in the beginning and learning is the re-orientation 
of the hyperplane until all classes are separated to a satisfying degree, ANNs return only one of an infinite 
number of solutions.  
 
More complex architectures such as the multilayer perceptron are analogous. However, because 
additional layers introduce additional weights, they operate in higher dimensionalities than the original 
feature space.  The decision boundaries therefore appear irregular (non-linear) in feature space. 
4.2.7. Support Vector Machines 
While ANNs are very expressive and capable of capturing non-linear relationships, computational 
complexity and their sensitivity to local extremes are some of their major drawbacks [29]. Support Vector 
Machines (SVM) remedy this situation. 59 SVMs aim to find a hyperplane through the problem space that 
                                                           
59 Vladimir Vapnik presented original work on SVM learning theory in 1963 [202] and continued developing 
the methodology at AT&T Laboratories. This industrial setting is echoed in the orientation towards and 
applicability of SVMs for real-world problems [203]. 
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not only separates all available classes but does so also with as large a margin as possible (increasing 
robustness). 
4.2.7.1. Classification in the linear case 
The geometrical solution of the simplest case (a linearly separable two-class problem) is illustrated in 
Figure 41. First, the outer perimeter of each class is determined, 60 similar to placing a rubber band over 
the instances. When released, the rubber band will snap into a position that coincides with the outer 
perimeter. This is a first reduction in complexity, as only the points on this polygon need to be evaluated. 
Next, for each edge or vertex of the outer perimeter, a plane can be found which runs parallel to the most 
proximal edge or vertex of the second class (the margin planes). For every pair of margin planes, a 
potential solution plane can be constructed which lies at an equal distance between them. These 
constraints limit the number of possible solution planes considerably (compared to an infinite number in 
ANN). The solution hyperplane finally chosen will be the one whose distance is maximal to the most 
proximal instances of each class. 
 
 
Figure 41 – Constructing a hyperplane in a two class case (example). Support vectors give the 
positions of the most proximal instances. Two possible solutions are given. 
This geometrical solution can be formalized in computer accessible terms. Here, the algorithm is 
presented with training data whose instances n are points xi in a hyper-dimensional space of magnitude m 
(where m is the number of attributes) with labels ci ∈ { -1, 1 } designating class membership. The decision 
hyperplane is defined by a normal vector w and a translational constant b for the offset from the origin as 
                                                           
60 Unless the instances are collinear (i.e. on a straight line), the outer perimeter is a convex hull, equivalent 
to a closed polygon. In graph theory, this is the shortest cyclical path containing all instances of the class, 
either as vertices or enclosed within the path. This shape also appears when all instances are maximally 
connected.  
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€ 
w⋅ x − b = 0 
 
As was seen before, the margin hyperplanes are parallel to each other, i.e. they share the same normal 
vector w. Their equations can be written as  
 
 
 
for all points that lie on the margin hyperplanes themselves, the support vectors. All members of a class 
therefore satisfy one of the inequalities 
 
 
 
These can be combined using the class label as 
 
€ 
ci(w⋅ xi − b) ≥1 
 
for all instances xi with their assigned labels ci. The distance of the margin hyperplanes is  
 
 
 
The goal of an SVM learning algorithm is thus to find a vector w, a set of support vectors, and a constant b 
that satisfy the above mentioned conditions. This optimization problem can be stated as: 
 
 Minimize in  for any  subject to 
€ 
ci(w⋅ xi − b) ≥1. 
 
If the term ||w|| is replaced with ½ ||w||2 in order to avoid the difficulties of working with square roots, 61 this 
problem can be tackled with quadratic programming, an extension of linear programming [29].  
 
The problem can be stated in its dual form as having to find those ai such that the expression  
 
€ 
ai −
1
2 aia jcic j (xi ⋅ x j )i, j
∑
i
∑  
 
                                                           
61 The norm of w is 
€ 
w = (x12 + x22 + ...+ xn2) . 
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is maximized subject to the constraints 
 
€ 
ai ≥ 0 ; aici = 0
i
∑  
 
SVM classification can therefore model large data sets using few instances (the support vectors of the 
margin hyperplanes). Models are very stable and rarely subject to overfitting because only the instances at 
the fringe are considered and from these only very few are selected to define the margin hyperplanes, 
which, in turn are separated by the largest possible margins. 
 
 
 
Figure 42 – Relationship of the margin hyperplanes (grey) to the decision boundary hyperplane 
(black) in SVM learning. 
4.2.7.2. Non-linear case and the Kernel Trick 
Hyperplanes are mere extensions of the decision lines encountered before. As such, they are rigid and not 
capable of solving tasks like the XOR problem (See Section 4.2.1.3). However, it can be shown that any 
problem can be solved by linear methods if only the feature space is sufficiently high-dimensional [29]. The 
linear decision boundaries in such high-dimensional spaces appear crooked or wiggly when transformed 
back. Unfortunately, as the number of dimensions d approaches the number of instances n, not only does 
computational effort increase to an unmanageable magnitude, but also the danger of overfitting. 
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Figure 43 – Graphical representation of the kernel trick. Classification tasks that are non-linear in 
low dimensionality (a) may become solvable for linear algorithms when transformed to higher 
dimensions (b). 
For SVMs, the situation is different. As was seen before, models are seldom overfitted because only a very 
few instances are needed to represent class boundaries and margins are maximized. Decision boundaries 
are therefore not very flexible. The computational cost is also not a problem. The dot product in the 
equations discussed in Section 4.2.7.1 can be replaced by other (kernel) functions that are far less tedious 
to compute. In fact, the equations can be solved before the transformation to higher dimensionality takes 
place. This is known as the Kernel Trick. 62 An overview of commonly used kernel functions is given in 
Table 10. 
  
Kernel function Description 
€ 
k(x,x ') = (x⋅ x ')d  homogeneous polynomial 
€ 
k(x,x ') = (x⋅ x '+1)d  heterogeneous polynomial 
€ 
k(x,x ') = exp(−γ x − x ' 2)  radial basis function (RBF) 
Table 10 – Commonly used kernel functions. 
4.2.7.3. Parameter optimization 
Several meta-parameters define the learning properties of SVMs and their proper settings have great 
influence on the predictive accuracy of the final model. Unfortunately, there are no practical standard 
settings or guidelines, and only experimentation can hint at good settings. A common approach to estimate 
                                                           
62 A year after Vapnik’s paper on SVM learning, Aizerman proposed kernel transformations [204]. It was 
not until the 1990s that the two approaches were successfully combined to tackle real-world problems with 
SVMs. 
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these parameters is a grid search over a log2 space with uniform resolution. An initial screening with the 
commonly used kernel function RBF (Table 10) can be performed by taking 20 samples for C and γ (a 
parameter of the kernel function) so that log2C = { -5, …, 15} and log2γ =  {-15, … 3}. Contour plots of C, γ, 
and a measure of success (such as the CCR, see 4.2.2.1) can help identify maxima which may then be 
magnified by contracting the range around the regions of interest and increasing resolution. Section 7.1.3 
of the appendix gives the listing of an application to perform grid searches. 
 
SVM learning itself is time-consuming and even more so when performed repeatedly, especially using k-
fold cross-validation. If computational expense during learning is an issue, one can consider a pattern 
searching approach. Here, a combination of parameter values is chosen randomly and searches are 
performed with hill-climbing algorithms that continue to move in a direction with upward slope (i.e. higher 
success rate). Even with backtracking, hill-climbing is prone to be stuck in local maxima, confusing the 
next best hill with the big mountain possibly just a valley away.  
 
 
Figure 44 – Coarse grid search in a log2 space with uniform resolution for the learning parameter 
cost (C, vertical axis) and the radial basis function parameter γ (gamma, horizontal axis). 
Combinations are evaluated by their corrected classification rate (CCR) and the most successful 
pair is highlighted. 
4.2.8. Feature Selection 
It is immediately apparent that models can be learned best with a set of features relevant to the problem, 
e.g. when a human expert selects them manually, based on knowledge and understanding of the domain. 
While most ML methods assign some form of weight to attributes during training (kNN being an exception), 
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others completely discard features as they are being trained (e.g. DTI). Often it is not possible, even for a 
human expert, to identify the important characteristics of a problem, and the subsequently overly large set 
of instances causes several problems. 
 
Firstly, some algorithms are more sensitive to noise than others (e.g. kNN vs. SVM). Here, irrelevant 
attributes cause performance to deteriorate significantly. 63 Secondly, spurious features unnecessarily 
complicate a problem’s feature space, leading to a potentially catastrophic increase in computational 
complexity. The phenomenon of problem space growing as an exponential function of dimensionality is 
known, somewhat informally, as the Curse of Dimensionality (coined by Richard Bellman in 1961). Not 
only does this give a computational penalty. The danger of overfitting also increases as sample size is 
outnumbered by dimensionality. For these reasons, ML is often preceded by feature selection – the 
process of reducing the number of attributes. Two different approaches exist: filter methods vs. wrapper 
methods. 
 
Wrapper methods employ an ML algorithm (possibly even the same as is to be used during learning itself) 
to select a subset of features. For example, DTI can be used with the entire feature set, removing the 
attribute in the root node and repeating the process until no attributes are left. This yields a ranked list 
ordered by performance. A ranking can also be made according to the magnitude of weights learned in 
numerical methods such as ANNs on normalized data. Filter methods, on the other hand, examine the 
general characteristics of the data. Numerical (and normalized) data can be ranked by variance and 
subsets selected via a threshold (0.05 is a common measure). Correlation coefficients (see 4.2.2.3) may 
be used to select features with high correlation with the class but low inter-correlation. 
 
Regardless of the method chosen, subsets can be built in basically two different ways: either by starting 
out with an empty set and adding to it (forward selection) or with the entire set and removing from it 
(backward elimination) until a specified stopping criterion is met (subset size, inter-correlation, etc.). This 
can be visualized as a graph traversal (Figure 45). Generally, backward elimination yields slightly better 
results while forward selection produces smaller subsets [177]. 
 
Of course, the optimal balance between subset quality and size can be found by evaluating every node. 
However, the Curse of Complexity being what it is, calculating this quickly becomes impractical (even 
merely enumerating the graph can be too expensive, let alone storing the visited nodes for backtracking). 
Luckily, the field of computer science has many sophisticated algorithms to offer. Beam search, where the 
                                                           
63 Studies with random variables (maximal irrelevance) introduced in standard datasets have shown a 
decrease by 5-10 % in C4.5 [177]. Note that this is an algorithm with ‘built-in’ feature selection. At a 
sufficiently deep node of the tree, only a small set of instances will be left to build a decision on and even 
random variables can start to appear superior to ‘relevant’ attributes. 
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subset size is limited, or best-first search, where only ‘promising’ nodes (as evaluated by a heuristic 
function) 64 are expanded, are just two examples. 
 
 
Figure 45 – Forward selection, starting with an empty set, and backward elimination, starting with 
the complete set, for four attributes (A, B, C, and D) represented as a bi-directional graph.  
                                                           
64 In search algorithms, heuristic functions rank alternatives based on information available at a given time. 
Heuristic functions that are admissible (i.e. ones that never overestimate) can be shown to always find 
optimal solutions, given enough time. These form the class of A* algorithms, of which best-first search is 
an example [29, 188]. 
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5. Projects 
5.1. Prediction of drug transport and metabolism 
5.1.1. Development of decision tree models for substrates, inhibitors, and inducers of 
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Abstract 
In silico classification of new compounds for certain properties is a useful tool to guide further experiments 
or compound selection. Interaction of new compounds with the efflux pump P-glycoprotein (P-gp) is an 
important drug property determining tissue distribution and the potential for drug-drug interactions.  We 
present three datasets on substrate, inhibitor, and inducer activities for P-gp (n = 471) obtained from a 
literature search which we compared to an existing evaluation of the Prestwick Chemical Library with the 
calcein-AM assay (retrieved from PubMed). Additionally, we present decision tree models of these 
activities with predictive accuracies of 77.7 % (substrates), 86.9 % (inhibitors), and 90.3 % (inducers) using 
three commonly used algorithms (CHAID, CART, and C4.5). We also present decision tree models of the 
calcein-AM assay (79.9 %). Apart from a comprehensive dataset of P-gp interacting compounds, our study 
provides evidence of the efficacy of logD descriptors and of two algorithms not commonly used in 
pharmacological QSAR studies (CART and CHAID). 
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P-glycoprotein, MDR1, Multidrug resistance, Calcein AM assay, QSAR, decision trees  
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Introduction 
See Section 3.3.1.3. 
 
Materials and Methods 
Quantitative Structure Activity Relationships (QSAR) 
See Section 3.1.2.3. 
 
Data set 
We based our dataset on a mass screening based on the calcein-acetoxymethyl (calcein-AM) assay of the 
Prestwick Chemical Library retrieved from PubMed [205]. Structures were cross-checked in a search of 
PubMed, yielding a total of 471 compounds. For these structures, we give activities in the three classes 
‘inducer’, ‘inhibitor’, and ‘substrate’, depending on whether publications exist that document activity 
(‘ACTIVE’) or inactivity (‘INACTIVE’) (Table 11). When the search was inconclusive, compounds were 
tagged with ‘UNKNOWN’. Activity in this context means having a given property, regardless of the 
underlying molecular mechanism. The datasets we used in numerical analysis consist of the subsets of 
compounds with known activity or inactivity (i.e. instances labeled ‘UNKNOWN’ were excluded) and 
complete set of descriptors (i.e. no missing values were allowed). 
 
 Active Inactive Total 
Inducer 49 21 70 
Inhibitor 217 123 340 
Substrate 163 95 258 
Total 429 239 668 
Table 11 – Results of a literature search of compounds with P-glycoprotein activity 
Descriptors 
See Section 4.1.7. 
 
Assessment of chemical diversity 
See Section 4.1.6. 
 
Calcein-AM assay 
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We chose data generated with the calcein-AM assay as in vitro control data for our models that was 
developed to assess the interaction of a compound with P-gp in vitro [205]. Calcein is a fluorescent dye, 
which enters living cells when substituted with an acetomethoxy group (calcein-AM) by diffusion. The 
functional group is then removed by intracellular esterases, allowing free calcein to chelate with calcium. 
The highly negatively charged green fluorescent calcein is rather polar, preventing it to leave cells by 
simple diffusion. P-gp is able to extrude calcein [206], making calcein expulsion a widely used measure of 
P-gp mediated multidrug resistance [207]. 
 
The results of a mass screening based on the calcein-AM assay and the Prestwick Chemical Library are 
available from PubChem. The data set consists of 778 molecular structures in SMILES format, along with 
changes in fluorescence in the assay, and preliminary classification into active (n=353), inactive (n=239), 
and inconclusive (n=186) compounds based on pre-determined thresholds [208]. 
 
Decision Tree Inference 
See Section 4.2.4. 
 
Data preparation 
Prior to analysis, we prepared tables for each endpoint (substrate, inducer, and inhibitor activities 
extracted from the literature, as well as activity in the calcein-AM assay) along with descriptor values 
computed previously. Compounds with an incomplete array of descriptors were excluded from analysis, 
that is, no missing values were accepted. 
 
Model validation 
Throughout this paper, 10-fold cross validation was used. See Section 4.2.2.5. 
 
Corrected Classification Rate (CCR) 
See Section 4.2.2.1. 
 
Kappa statistic 
See Section 4.2.2.2. 
 
Software 
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ChemAxon Marvin (Marvin 5.0.4, 2008, http://www.chemaxon.com) was used for characterizing chemical 
structures, substructures, and ChemAxon Calculator Plugins were used for structure property calculation. 
Additional descriptors were calculated with the open-source cheminformatics package Chemical 
Development Kit [209] (version 1.0.4, 2008, http://sourceforge.net/projects/cdk). 
 
Decision trees grown with the CHAID and CART algorithms were done in SPSS 15.0 for Microsoft 
Windows. For the C4.5 algorithm, the original software (release 8, http://www.rulequest.com/Personal) was 
used. 
Results and Discussion 
Chemical diversity 
We calculated the Tanimoto coefficient for the result of our literature search and arrived at an overall value 
of 0.34. This is an indication that these sets are reasonably diverse. 
 
Comparison of Calcein-AM assay and literature 
Of the compounds given in the original assay, we found 101 in literature. A cross-tabulation analysis 
revealed an agreement of 75 %, which is moderate in analysis with kappa statistics (κ: 0.043). This shows 
the calcein-AM assay to be prone to false negative predictions. Due to a large spread between active and 
inactive compounds, changing the thresholds to broaden the number of inclusive outcomes (thereby 
decreasing the number of active and inactive components) does not improve performance. 
 
Performance of Decision Tree Models 
A summary of CCRs for the decision tree models created is given in Table 12. 
 CHAID CART C4.5 
Substrate 77.7 % 77.0 % 70.3 % 
Inhibitor 83.0 % 86.9 % 67.3 % 
Inducer 90.3 % 85.0 % 63.0 % 
Calcein-AM 73.3 % 79.9 % 60.8 % 
Table 12 – Corrected Classification Rate (CCR) of decision tree models (performance on the test 
datasets generated during cross-validation) built with three different methods (maximum depth: 10, 
minimum parent node size: 10, minimum child node size: 5) for a literature search of compounds 
with P-glycoprotein activity along with models for a mass screening using the calcein-AM assay. 
Models with highest performance are shown in boldface. 
Calcein-AM assay 
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A tree grown with the CART algorithm (Figure 46) had a CCR of 79.9 % with a depth of 6, 12 inner nodes, 
and 17 leaves. Discerning descriptors were the polar surface area, the number of hetero and aromatic 
rings, the resonant count, partitioning coefficients at pH 3.0 and 10.0, the smallest ring size, as well as the 
connectivity indices (Wiener, Randic, Kier kappa shape). 
 
Figure 46 – Decision tree model of 434 compounds with P-glycoprotein activity determined using 
the calcein-AM assay. The corrected classification rate amounts to 79.9 %. 
Results from the literature search 
During our screening of literature, we have chosen to differentiate between the three classes of substrates, 
inhibitors, and inducers. Membership of these classes, however, is not exclusive, i.e. a compound may 
belong to more than one class (consider verapamil, which is known to be both an inhibitor [210] as well as 
a substrate [211] of P-gp) Our goal was to provide separate models with higher predictivity so that they 
may find application in different areas of drug discovery. Combining endpoints would have introduced 
unnecessary bias. 
SUBSTRATES 
With a CCR of 77.7 %, the tree grown with the CHAID algorithm (Figure 47), depth: 5 levels, inner nodes: 
7, leaves: 9) performed best and included the first and third Kier kappa shape descriptor, Wiener 
polarizability, the number of hydrogen acceptors, the number of aromatic and fused aliphatic rings, and 
bond count. 
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Figure 47 – Decision tree model of 229 P-glycoprotein substrates with a corrected classification 
rate of 77.7 %. 
INHIBITORS 
The CART algorithm performed best with a CCR of 86.9 %, yielding a tree with a depth of 8, 16 inner 
nodes, and 17 leaves (Figure 48). Discriminant descriptors include the partitioning coefficients (pH 2.0, 
8.0, 10.0, and 13.0), XlogP, the counts of aromatic bonds, total bonds, ring atoms, ring bonds, and carbo 
and hetero rings, pi energy, Dreiding energy, and the third Kier kappa shape index. 
 
 
Figure 48 – Decision tree model of 298 P-glycoprotein inhibitors with a corrected classification rate 
of 86.9 %. 
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INDUCERS 
A tree grown with the CHAID algorithm (Figure 49) and a CCR of 90.3 % showed the best results (depth of 
3, with 3 inner nodes, and 6 leaves). The third Kier kappa shape index, ring count, and the partition 
coefficient at pH 4.0 appeared in the model. 
 
 
Figure 49 – Decision tree model of 61 P-glycoprotein inducers with a corrected classification rate 
of 90.3 %. 
Discussion 
In this work, we present a structurally diverse set of compounds with known P-gp interaction status 
(inhibitors, inducers, substrates). We show that DTI models perform well in the prediction of activities, with 
CCRs ≥ 0.7 for the best models. They rely on different sets of easily accessible descriptors, and are 
potentially useful in early drug discovery and the identification of structure-activity relationships. As has 
been pointed out before, combinatorial approaches to P-gp modeling currently appear superior to 
pharmacophore-based discovery, especially as the latter is used mostly after chemical synthesis and in 
vitro assays have already been performed [212, 213]. 
 
Evaluation of the calcein-AM assay 
With 75% agreement with our literature search, we consider the calcein-AM assay only a moderately 
useful estimator of P-gp activity. This is most likely because of its inability to distinguish between 
substrates and inhibitors. We also suspect the discrepancy to arise from a greater accuracy of literature 
searches compared to mass screenings. There is debate over the validity of literature searches and 
comparability of results. For instance, Polli and colleagues [214] have shown differences in classification 
between in vitro assays of P-gp. We also feel that no single in vitro assay properly assesses P-gp activity. 
Pooling results should remedy this by allowing a wide variety of assays to enter the picture and allowing 
for the proper assay to be used for given compounds. The DTI model we present here is accurate enough 
(CCR = 79.9 %) to find application as a virtual pre-screening tool that reduces the number of test 
candidates in a mass screening.  
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Model interpretations 
In our models for P-gp substrates, low bond counts, a small number of aromatic rings, many hydrogen 
bond acceptors, and low connectivity predominate. This suggests that small molecules with a relatively 
high capacity for polar interactions are good substrates. This finding is in accordance with other studies of 
P-gp substrates [215, 216] 
 
The complex biology of P-gp inhibition (direct, via disturbance of ATP binding or hydrolysis, or through 
perturbance of the cellular membrane resulting in poor drug-transporter binding and accessibility [217]) is 
echoed in our second model. Descriptors of lipophilicity predominate, as do indicators of molecular rigidity 
(DREIDING energy, energy of π orbitals). Lipophilicity as a rate-limiting step in P-gp interaction has long 
been proposed by Seelig and Landwojtowicz [218] and is of great importance for mechanisms of 
interaction as outlined above.  
 
The model for P-gp inducers is much less complex, since only a few compounds were available and, as a 
consequence, fewer structural requirements could be extracted. P-gp substrates can act as inducers, and 
structures of inducers are hence equally diverse as for substrates, ranging for St. John’s Wort [219] and 
other psychoactive drugs [220] to HIV protease inhibitors [221]. This cross-selectivity leads to the 
appearance of similar descriptors in both models (Kier connectivity, logD, and ring count). 
 
In the literature, concerns were raised as to the stability of DTI and the need for careful sampling of 
instances for training and test sets [222].  However, these concerns only apply in situations where small 
perturbations in the selection of instances greatly influences the models learned. During our work on the 
data presented here, we found no indication for this and used random sampling during cross-validation. 
 
Conclusions 
Machine learning techniques have become popular in QSAR studies of P-gp interaction. Support vector 
machines, k-nearest neighbor models, Bayesian and neural networks have shown promising results, 
sometimes outperforming DTI [212, 223, 224]. Poorer results in DTI could stem from the wide-spread use 
of the C4.5 algorithm, which consistently trails behind CART and CHAID in this study (Table 12). As with 
all machine learning techniques, no single one is right for every job, and this holds true for DTI algorithms 
as well. The application of other modeling techniques to our dataset would make an interesting subject of 
further studies. 
 
The importance of lipophilicity is apparent in our models. Strikingly, however, traditional logP (XlogP) 
appears only in the inhibition model (in the second to last level), and logD, the measure of lipophilicity in 
ionizing environments, is featured prominently in all models. While it is debatable whether ionization is 
important for P-gp active compounds once they contact their target, it is clear that protein binding, 
membrane passage, and solubility and stability in compartments with differing pH affect a compound’s 
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ability to reach the target in the first place. Our results indicate that logD is a highly suitable descriptor 
which could be attractive for QSAR studies of other biological systems. 
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5.1.2. Classification of Cytochrome P450 activities using machine learning methods 
 
 
Felix Hammann 1, Heike Gutmann 1§, Ulli Baumann 1, Andreas Maunz 2, Christoph Helma 2, Juergen 
Drewe 1*. 
 
1 :  Department of Gastroenterology & Hepatology, University Hospital Basel, University of Basel, 
Switzerland 
2 :  Freiburg Center for Data Analysis and Modelling, Albert-Ludwigs-University Freiburg, Germany 
§ :  present address: Novartis Institutes for Biomedical Research, Drug Metabolism and 
Pharmacokinetics, Basel, Switzerland 
 
. 
 
 
Corresponding Author (*): 
Prof. Dr. Juergen Drewe 
Department of Gastroenterology & Hepatology 
University Hospital of Basel 
Petersgraben 4 
CH-4031 Basel Switzerland 
Email: juergen.drewe@unibas.ch 
Phone: +41-61-265 3848 
Fax:  +41-61-265 8581 
 
 
 
Molecular Pharmaceutics 2009;6(6);1920-1926 
  
  
 Projects 
 
 
 – 86 – 
   
Abstract 
The cytochrome P450 (CYP) system plays an integral part in the metabolism of drugs and other 
xenobiotics. Knowledge of the structural features required for interaction with any of the different isoforms 
of the CYP system is therefore immensely valuable in early drug discovery. In this paper, we focus on 
three major isoforms (CYP 1A2, CYP 2D6, and CYP 3A4) and present a dataset of 335 structurally diverse 
drug compounds classified for their interaction (as substrate, inhibitor, or any interaction) with these 
isoforms. We also present machine learning models using a variety of commonly used methods (k-nearest 
neighbors, decision tree induction using the CHAID and CRT algorithms, random forests, artificial neural 
networks, and support vector machines using the radial basis function (RBF) and homogeneous 
polynomials as kernel functions). We discuss the physico-chemical features relevant for each endpoint and 
compare it to similar studies. Many of these models perform exceptionally well, even with 10-fold cross-
validation, yielding corrected classification rates of 81.7 to 91.9 % for CYP 1A2, 89.2 to 92.9 % for CYP 
2D6, and 87.4 to 89.9 % for CYP3A4. Our models help in understanding the structural requirements for 
CYP interactions and can serve as sensitive tools in virtual screenings and lead optimization for 
toxicological profiles in drug discovery. 
 
Introduction 
The Cytochrome P450 system 
See Section 3.2. 
 
Quantitative Structure Activity Relationships (QSAR) 
See Section 3.1.2.3. 
 
Materials and Methods 
Dataset 
Our dataset is based on a list of FDA approved small molecule drugs (n = 1436, date of access: 1st of 
January 2008) from the University of Alberta’s DrugBank database [225]. We used the DRUGDEX ® 
system (Thomson Reuters, http://www.micromedex.com, date of last access: 1st of May 2008) to check for 
interactions (as substrate, inducer, and/or inhibitor) with CYP 1A2, 2D6, and 3A4. A summary is given in 
Table 13. Compounds where interaction was documented were labeled ‘ACTIVE’ whereas all other ones 
where labeled ‘INACTIVE’ when the interaction status was either unknown or known to be inactive. 
Compounds with at least one activity or documented absence of activity were included in the final data set. 
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CYP substrates inhibitors inducers total active 
1A2 66 
(18.7 %) 
33 
(9.3 %) 
7 
(2.0 %) 
88 
(24.9 %) 
2D6 99 
(28.0 %) 
77 
(21.8 %) 
0 
(0 %) 
130 
(36.8 %) 
3A4 242 
(68.6 %) 
78 
(22.1 %) 
27 
(7.6 %) 
264 
(74.8 %) 
 
Table 13 – Number of compounds (percent of total (n=353)) with given activity for each of the 
cytochrome P450 (CYP) isoforms studied. The final column contains the number of compounds 
with any of these activities. 
Assessment of chemical diversity 
See Section 4.1.6. 
 
Machine Learning (ML) Methods 
k nearest neighbor (kNN) algorithm 
See Section 4.2.3. 
 
Decision Tree Induction (DTI) 
See Section 4.2.4. 
 
Random Forests (RF) 
See Section 4.2.5. 
 
Artificial Neural Networks (ANN) 
See Section 4.2.6. 
 
Support Vector Machines (SVM) 
See Section 4.2.7. 
Corrected Classification Rate (CCR) 
See Section 4.2.2.1. 
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Model Validation 
See Section 4.2.2.5. 
 
Descriptors 
See Section 4.1.7. 
 
Data Preparation 
We calculated a total of 118 descriptors (Table 14) based on the structures deposited at the DrugBank 
server. Compounds for which some descriptors could not be computed were removed (i.e. no missing 
values were allowed). Some of the algorithms are susceptible to over-estimating the effects of features 
which are on a higher numerical scale than others (e.g. number of hydrogen bond acceptors vs. molecular 
mass) [226]. To avoid this bias, we normalized the entire data set to a range of [0, 1]. Furthermore, feature 
selection was performed for all algorithms except DTI and RF (which implicitly do so themselves), since 
they produce better results when extraneous or irrelevant information is removed a priori [227]. We 
therefore reduced the feature space to a set of 19 features with the least correlation between them using 
best first forward search (a greedy hill-climbing algorithm) with backtracking [177]. Lastly, classes were re-
coded to +1.0 for active compounds and -1.0 for inactive compounds in SVM models and 0.0 for inactive 
compounds in ANN models, respectively. 
 
Class ChemAxon Chemistry Development Kit 
charge analysis Hydrogen bond acceptor and donor counts 
and sites (acceptorCounts, 
acceptorSiteCount, donorCount, 
donorSiteCount), DREIDING energy, 
partitioning coefficients for pH 0-14 
(logD_0, logD_1, logD_2, logD_3, logD_4, 
logD_5, logD_6, logD_7, logD_74, logD_8, 
logD_9, logD_10, logD_11, logD_12, 
logD_13, logD_14), molecular polarizability 
(molPol), topological surface are 
(topologicalSurfaceArea), van-der-Waals 
surface area (vdwsa) 
Charged Partial Surface Descriptors 
(PPSA-1, PPSA-2, PPSA-3, PNSA-1, 
PNSA-2, PNSA-3, DPSA-1, DPSA-2, 
DPSA-3, FPSA-1, FNSA-1, FPSA-2, 
FNSA-2, FPSA-3, FNSA-3, WPSA-1, 
WNSA-1, WPSA-2, WNSA-2, WPSA-3, 
WNSA-3, RPCG, RNCG, RPCS, 
RNCS) [144], partitioning coefficient 
(XlogP) 
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constitutional Counts of atoms, rings, and bonds 
(aliphaticAtomCount, aliphaticBondCount, 
aromaticAtomCount, aromaticBondCount, 
aromaticRingCount, 
asymmetricAtomCount, atomCount, 
bondCount, carboaromaticRingCount, 
carboRingCount, chainAtomCount, 
chainBondCount, chiralCenterCount, 
fusedAliphaticRingCount, 
fusedAromaticRingCount, 
heteroaromaticRingCount, 
heteroRingCount, largestRingSize, 
ringAtomCount, ringBondCount, ringCount, 
rotatableBondCount, smallesRingSize), 
molecular refractivity (refractivity), 
molecular weight (molWeight), resonant 
count (resonantCount) 
Gravitational indices (GRAV-1, GRAV-
2, GRAV-3, GRAV-4, GRAV-5, GRAV-
6, GRAVH-1, GRAVH-2, GRAVH-3) 
[228], Moment of Inertia along the 
principal axes X, Y, and Z, along with 
ratios and radius of gyration (MOMIX, 
MOMIY, MOMIZ, MOMIXY, MOMIXZ, 
MOMIYZ, MOMIR) 
topological Balaban index (balabanIndex), weighted 
Burden matrix (BCUTw1l, BCUTw1h, 
BCUTc1l, BCUTc1h, BCUTp1l, BCUTp1h) 
[229], Harary index (hararyIndex), hyper 
Wiener index (hyperWienerIndex), Platt 
index (plattIndex), Randic index 
(randicIndex), Szeged index (szegedIndex) 
Kier-Hall kappa shape indices (Kier1, 
Kier2, Kier3), Petitjean number 
(PetitjeanNumber) and Petitjean 
indices (topoShape, geomShape), 
Wiener path number and polarity 
(WPATH, WPOL), Zagreb index 
(Zagreb) 
Table 14 - Overview of descriptors (n=118) used in this study by origin (ChemAxon: n=58, CDK: 
n=61) and class. 
 
Software used 
ChemAxon Marvin (Marvin 5.0.4, 2008, http://www.chemaxon.com) was used for characterizing chemical 
structures, substructures, and ChemAxon Calculator Plugins were used for structure property calculation. 
Additional descriptors were calculated with the open-source cheminformatics package Chemical 
Development Kit [209] (version 1.0.4, 2008, http://sourceforge.net/projects/cdk). For the calculation of 
certain descriptors (e.g. the set of charged partial surface area (CPSA) descriptors) 3D structures are 
required. These structures were generated from SMILES representations of the molecules as given in 
DrugBank using the Ghemical force field (http://www.uku.fi/~thassine/projects/ghemical/). With this force 
field, a search for lowest energy conformers was performed using the OpenBabel toolkit (Version 2.2.1, 
available at http://www.openbabel.org). We used SPSS (version 15.0 for Windows) for DTI and Weka 
(version 3.4; Waikato Environment for Knowledge Analysis, University of Waikato, Hamilton, NZ, 
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http://www.cs.waikato.ac.nz/~ml/Weka/) [177] for kNN, ANN, and RF. SVM models were calculated using 
LIBSVM (version 2.89; http://www.csie.ntu.edu.tw/~cjlin/libsvm). Calculation of chemical diversity and grid 
screening for SVM meta-parameters was performed with in-house software. 
 
Results and Discussion 
Chemical diversity 
We calculated the Tanimoto coefficient for the entire data set and arrived at an overall dissimilarity value 
D(M) of 0.70. This is a high value and confirms the great structural diversity of the compounds studied. 
Based on this, it is fair to assume a general applicability of our models for the domain of drug-like 
compounds. 
 
Feature selection 
We performed feature reduction for ANN, kNN, and SVM models as described. The 19 descriptors that 
made the final set were: asymmetricAtomCount, carboRingCount, dreidingEnergy, 
fusedAliphaticRingCount, largestRingSize, logD_7, logD_9, rotatableBondCount, BCUTp1h,              
PNSA1, RPCG, RPCS, THSA, TPSA, Kier3, MOMIZ, MOMIR, WPOL, and Zagreb. This selection seems 
sensible, as it covers a broad spectrum of chemical features, ranging from simple counts of substructures 
(e.g. carboRingCount) and measures of lipophilicity (e.g. logD descriptors at physiological pH and TPSA) 
to complex topological indices (e.g. Kier3 and the radius of gyration, MOMIR). 
 
Performance for different endpoints 
We did not prepare models for inducers for any of the CYP isoforms because of gross underrepresentation 
of active compounds (Table 13). Instead, we limited ourselves to substrate and inhibitor activities and a 
combined endpoint (‘global’), for which a compound is labeled as active when it shows any sort of 
interaction (as substrate, inhibitor, and / or inducer). If no interaction was documented, it was labeled 
inactive. A summary of CCRs for every endpoint is given in Table 15. 
 
Cytochrome 1A2 
Substrates of CYP 1A2 have been noted to be planar, aromatic, and lipophilic compounds with neutral or 
basic characteristics such as benzopyrene, caffeine, and propanolol [230]. Additionally, Lewis pointed out 
the relevance of logD partitioning coefficients at physiological pH and hydrogen bond characteristics for 
substances with ionizable substructures [231]. We see this reflected in the independent variables present 
in the most effective model (CHAID, CCR: 90.9%): acceptorSiteCount, asymmetricAtomCount, 
aromaticRingCount, resonantCount, FNSA3, PetitjeanNumber, dreidingEnergy, fusedRingCount, 
BCUTp1l, geomShape, rotatableBondCount, logD_5, logD_8, logD_9, logD_13, PSA, aromaticAtomCount, 
MOMIX, MOMIZ, MOMIXZ, and MOMIR.  
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Similarly, the global model for any type of CYP 1A2 interaction (CHAID, CCR: 91.5%), emphasizes polar 
features and geometric properties:  vdwsa, GRAV1, fusedAromaticRingCount, RPCS, FPSA2, logD_9, 
WNSA3, acceptorCount, carboaromaticRingCount, WPATH, logD_13, WPSA1, logD_7, WPSA2, 
balabanIndex, DPSA2, logD_0, RHSA, plattIndex, geomShape, DPSA1, BCUTw1h, MOMIZ, molPol, and 
donorCount.  More specifically, five or more hydrogen bond acceptors and at least one hydrogen bond 
donor appears as a pre-requisite along with the presence of fused aromatic rings. 
 
The best model for inhibition (CHAID, CCR: 81.7%) is markedly less successful. Included were the 
descriptors aromaticAtomCount, resonantCount, asymmetricAtomCount, BCUTp1h, logD_74, MOMIYZ, 
MOMIZ, PetitjeanNumber, topoShape, WNSA1, WPSA2, FPSA1, FPSA3, balabanIndex, and WPOL. The 
number of active compounds is also lower (half as many as in the substrate class), which suggests that a 
significant number of structures is classified as false negative.  
 
Cytochrome 2D6 
We achieved best results with the DTI algorithms CHAID and CRT and saw similar performance in SVM 
models. More than in the other endpoints, CYP 2D6 substrate activity seems to rely on ionizability and 
lipophilicity in the best model (CHAID, CCR: 92.2 %). Descriptors included were logD_2, logD_3, logD_5, 
logD_10, logD_14, XLogP, acceptorSiteCount, donorCount, smallestRingSize, heteroRingCount, 
heteroaromaticRingCount, geomShape, topoShape, PetitjeanNumber, RPCG, and FPSA3. The 
partitioning coefficients at extreme ends of the pH range (logD_2, logD_3, and logD_14) are those 
descriptors which best reflect a compound’s acid-base characteristics in the set of features we used. More 
weight is hence placed on this quality compared to, for example, the CYP 1A2 models presented above. 
This is in accordance with the common understanding that CYP 2D6 metabolizes its substrates via an ion-
pair interaction between basic nitrogen of the substrate and aspartic acid residues at the active site [232]. 
 
Performance for the global endpoint is slightly worse, with the CHAID model performing best with a CCR 
of 89.2%. Relevant descriptors were acceptorSiteCount, donorSiteCount, aromaticRingCount, 
asymmetricAtomCount, carboaromaticRingCount, smallestRingSize, logD_1, logD_5, logD_14, PPSA3, 
and PNSA-1. Generally, basic compounds with aromatic rings interact with CYP2D6 while hydrogen 
bonding behavior is of lesser importance. 
 
The CRT model for inhibitors of CYP 2D6 had the best performance of any model in this study, relying on 
the following descriptors: RHSA, WNSA-1, logD_4, logD_5, logD_11, logD_12, logD_15, FPSA3, 
dreidingEnergy, donorCount, DPSA1, topoShape, PNSA2, BCUTc1l, and MOMIXY. Again, acid-base 
characteristics and lipophilicity appear, but shape constraints are of importance as well. 
 
Cytochrome 3A4 
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The base for CYP 3A4’s broad substrate specificity is thought to lie in its large active site where weak 
hydrophobic interactions determine binding [230, 233]. Yap and Chen [227] reported on good models 
using descriptors of shape and connectivity, electronegativity, hydrophobicity, and polarizability. These 
were not only present in the features selected for SVM and ANN learning but also in the more successful 
DTI models. 
 
For the global endpoint, we saw best results with the CRT algorithm (CCR: 87.4 %) using  hararyIndex, 
XlogP, logD_6, logD_11, logD_12, balabanIndex, BCUTp1h, BCUTw1l, RNCG, RPCG, geomShape, 
WPOL, resonantCount, THSA, aliphaticBondCount, and MOMIX. This was also the case for substrates 
(CCR: 89.8 %) with MOMIR, XlogP, logD_0, logD_3, logD_6, logD_74, logD_8, logD_9 GRAV4, 
MolWeight, WPOL, RPCS, PPSA, refractivity, dreidingEnergy, geomShape, DPSA3, and 
aromaticAtomCount. Although these CCRs are quite good, they trail behind the values achieved for 
CYP1A2 and CYP2D6, whose specificity is narrower and hence more easily modeled.  
 
For inhibitors, the CHAID algorithm produced by far the most accurate model (CCR: 87.6 %), using the 
descriptors: molPol, GRAV1, PPSA3, WNSA3, GRAVH1, MOMIXZ, WNSA1, logD_0, logD_1, logD_12, 
logD_13, plattIndex, PSA, acceptorSiteCount, BCUTw1l, PNSA2, resonantCount, carboRingCount, 
PPSA1, and rotatableBondCount.  
 
Comparison of ML methods 
In all endpoints, we achieved the best results with DTI. At first glance, this seems to contradict studies 
such as Vasanthanathan et al. [226], whose modeling of CYP 1A2 inhibitor activity for approximately 7400 
substances using a similar portfolio of methods showed highest accuracy with SVM. DTI, however, often 
outperforms numerical methods (e.g. SVM or ANN) for smaller data sets, even with prior feature selection 
[29]. Other groups have reported accuracies of well over 90 % correctly predicted instances for SVM 
models [226, 234], but only when applied to training sets. The same models achieve significantly lower 
predictive power in 5-fold CV (around 75 to 80 %). 
 
Conclusions 
We present a dataset of 353 compounds and their interaction status with CYP isoforms 1A2, 2D6, and 
3A4. Additionally, we give cross-validated QSAR models for these activities using a set of common ML 
methods. Of these methods, DTI consistently outperforms its competitors. This is most probably due to the 
usefulness of DTI algorithms for smaller datasets. 
 
In our survey of over 1’400 FDA approved compounds in DrugBank, the most frequent interactions were 
with CYP 3A4. In literature, this enzyme is implicated in the metabolism of more than 50% of drug 
compounds [235], so the high proportion of CYP 3A4 active compounds (n=264, 74.8%) can be expected. 
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However, these account for only about 18% of the compounds in DrugBank. We therefore assume that 
additional screening of these could uncover many other drugs with CYP 3A4 interaction potential. 
Arguably, these interactions could be of lesser clinical importance, either because the offending drug is not 
as widely used or the interaction potential is less poignant. 
 
Furthermore, comparing our combined activity endpoints (any sort of interaction as substrate, inhibitor, and 
/ or inducer) with the isolated activities substrate and inhibitor for each isoform, we would have expected to 
see significantly better CCRs in the latter, especially when the number of active compounds approaches 
those of the combined endpoint. This was seldom the case but is easily explained by the parallel 
membership of many compounds in different classes. For example, the anti-hypertensive agent metoprolol 
and the first generation histamine receptor antagonist promethazine both act as CYP 2D6 substrates and 
inhibitors, while the calcium channel blockers verapamil and amlodipine have both activities in CYP 3A4. 
There is significant overlap in substances and therefore in characteristics relevant for activity. In the case 
of CYP 1A2, models for inhibitory compounds performed markedly worse than for the combined endpoint, 
although the decrease in active substances is the same range as for the other isoforms. Most probably this 
is due to a large number of false negative instances in the dataset. 
 
With CCRs of 81.7 to 92.9 %, our models are well suited to guide compound selection in drug discovery 
and also to differentiate between interactions between the different isoforms studied rather than CYP 
interactions in general. This is echoed in the differences between descriptors selected by the DTI 
algorithms for the respective endpoints. Models do share certain general features of drug likeness (such 
as lipophilicity and ionizing behavior) but rarely make use of very general descriptors such as molecular 
weight or measures of connectivity (e.g. the Kier and Hall kappa shape indices). The latter is often the 
case in QSAR studies of mass screenings of large chemical libraries, where algorithms must establish 
drug likeness in addition to the actual pharmacological or toxicological endpoint itself. 
 
Our analysis focuses on easily calculatable descriptors and freely available modeling tools. While 
predictive accuracies are very high, further improvements could be expected from more sophisticated 
methods. Highly resolved crystal structures have been published for many CYP P450 isoforms which have 
special relevance to drug metabolism [236], allowing the use of target-based approaches. Other groups 
have used methods similar to ours. In particular, Yap et al. have presented work on CYP P450 interactions 
with statistical learning methods [227, 237] as have Leong et al. [238, 239]. Their studies show a slightly 
higher predictive accuracy for SVM approaches, esp. when augmented with pharmacophore information. 
DTI models of CYP 3A4 inhibitors [237] were of lesser accuracy than the ones we present. However, most 
studies make use of the C4.5 algorithm [192] which is often outperformed by algorithms like the ones we 
employed. [240] This illustrates two important facets of QSAR modeling. Firstly, no single method gives 
the best results for every dataset. Secondly, the success of a given method is dependent on subtleties of 
application (setting of learning parameters, preferences of algorithms employed, etc.). 
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 CYP 1A2 CYP 2D6 CYP 3A4 
 global	
   substrates	
   inhibitors	
   global	
   substrates	
   inhibitors	
   global	
   substrates	
   inhibitors	
  
RF	
   66.7	
   57.3	
   61.9	
   78.1	
   76.3	
   72.3	
   67.5	
   73.0	
   65.8	
  
kNN	
   69.7	
   56.6	
   64.3	
   79.0	
   77.2	
   76.1	
   62.3	
   72.4	
   64.2	
  
ANN	
   67.4	
   63.2	
   57.3	
   79.6	
   70.9	
   75.4	
   61.9	
   67.4	
   62.8	
  
CHAID	
   91.5	
   90.9	
   81.7	
   89.2	
   92.2	
   91.6	
   81.4	
   88.6	
   87.6	
  
CRT	
   78.2	
   78.6	
   70.9	
   87.0	
   89.4	
   92.9	
   87.4	
   89.8	
   84.7	
  
SVM	
  RBF	
   71.2	
   66.0	
   66.6	
   83.1	
   76.5	
   77.4	
   67.2	
   66.0	
   66.4	
  
SVM	
  
polynomial	
  
68.8	
   63.3	
   63.0	
   82.6	
   75.8	
   74.4	
   66.0	
   65.1	
   62.9	
  
Table 15 – Corrected classification rates of 10-fold crossvalidated QSAR models of cytochrome 
1A2, 2D6, and 3A4 interaction. RF: Random Forest, kNN: k-nearest neighbors, ANN: artificial neural 
networks, CHAID: Chi-squared interaction detector, CRT: classification and regression trees, SVM 
RBF: support vector machines using the radial basis function kernel, SVM poly: support vector 
machine using the homogeneous polynomial kernel. Best values are in bold-face. 
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Abstract 
Drug safety is of great importance to public health. Detrimental effects of drugs not only limit their 
application, but also cause suffering in individual patients and distrust of pharmacotherapy. To identify 
suspicious drugs, we present a structure-activity relationship analysis of adverse drug reactions (ADRs) in 
the central nervous system (CNS), liver, kidney, and for allergic reactions for a broad variety of drugs 
(n=507) from the Swiss drug registry. Using decision tree induction, a machine learning method, we 
determined predisposing chemical, physical, and structural requirements. The models had high predictive 
accuracies of 78.9% to 90.2% for allergic, renal, CNS, and hepatic ADRs. 
 
We show the feasibility of predicting complex end-organ effects using simple and computationally 
inexpensive models, which can be used 1. in compound selection in drug discovery, 2. to understand how 
drugs interact with the target organ systems, and 3. for the generation of alerts in post-marketing drug 
surveillance and pharmacovigilance. 
 
Keywords: QSAR, drug safety, toxicology, central nervous system, kidney, liver, allergies, adverse drug 
reactions, ADR 
 
Introduction 
No drug has only beneficial effects for the patient. Adverse drug reactions (ADRs) are undesirable effects 
that occur when a drug is administered at the proper dose in the correct manner for an appropriate 
indication, i.e. the drug was used correctly and in good faith. ADRs are part of the larger group of adverse 
drug events (ADEs) which encompass any noxious effects related to drug therapy. ADEs therefore also 
include drug overdose, drug-drug-interactions, and other medication and prescription errors. Strategies to 
reduce ADEs due to (human) error are more easily devised than for ADRs. Here, the burden lies mostly 
with the pharmaceutical industry to develop safe compounds and test them thoroughly. Pharmacovigilance 
increases the knowledge of ADRs in daily practice, especially for less frequent adverse events. This 
requires a larger population to be medicated before effects can be observed. While ADRs may not be 
preventable they may be anticipated. 
 
The avoidance and proper management of ADRs are of great importance to public health, and the public 
at large shows high interest in drug safety. Unrecognized or underreported ADRs not only cause 
preventable human suffering and costs to the health care system, but can also unnecessarily undermine 
the public’s faith in (and compliance with) drug therapy. This issue was addressed by the 110th United 
States Congress which passed an act in 2007 to increase post-marketing surveillance of regulated drugs. 
The FDA has since started the implementation of the so-called Sentinel Initiative, integrating data from 
health-care providers, post-market surveillance agencies, and other sources.  
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The technical pre-requisites of monitoring ADRs and timely generation of alerts are essentially those of 
data mining (finding and extracting patterns from potentially huge sources of data using mathematical and 
statistical methods). It is important to have analytical tools that are simple and robust, yet specific. For drug 
safety assessments, an optimal system would receive structural information of the drug and produce 
notifications that either rule out any noxious potential or point specifically to ADRs that could be expected 
to arise. Ideally, such a system would arrive at its notifications in a straight-forward way, rather than 
breaking the problem down into different smaller tests (e.g. detailed physiological modeling of all 
processes from drug ingestion to the target structures). 
 
Data sources for the prediction of clinical effects 
Many in vitro and animal models exist to screen for toxicological effects, but these often do not translate 
well into clinical practice. Although in vitro assays allow activity and ligand optimization, the environments 
within which they are performed rarely conform to conditions in human organisms. Also, solubility and 
permeability can differ greatly between animals and humans because of different acidity and transit time in 
animal gastrointestinal tracts [160]. Lastly, ADRs which develop only under chronic use or which impair 
specific human functions (such as higher cognitive functions) are not readily evaluated by these models. 
For these reasons, human in vivo data are preferable. 
 
Such extensive safety data are not easily obtained. A great and largely untapped source, however, lies in 
the information collected by regulatory offices and pharmacovigilance sites in the form of ADR reports. For 
this study, we aim to create a comprehensive survey of ADR reports for a broad variety of drugs in clinical 
use and develop computational models for understanding and predicting such reactions. Basis for 
predictions are numerical features easily calculated from nothing but the chemical structure.  
 
Classification of ADRs 
A drug must first reach an organ to exert an effect, be it beneficial or not. For central nervous system 
(CNS) effects, a common paradigm therefore holds that drugs must be able to cross the blood-brain 
barrier (BBB). This is certainly true for substances that act directly on target structures in the CNS, but 
ADRs such as encephalopathy or delirious states can just as well be caused indirectly, for example, by 
hepatotoxic or nephrotoxic compounds which induce liver or kidney failure. Most neurological ADRs can 
be strictly assigned to the CNS. With psychiatric reactions, this is not as easy. Dependency and addiction, 
for example, can be caused by modulation of central receptors (in the case of opioid addiction). However, 
they may also be of psychological nature or due to peripheral effects (e.g. dependency on vasoconstrictor 
nasal sprays). For this study, we have therefore chosen to label an ADR as CNS-related only if its origin is 
at least predominantly within the CNS.  
 
Drug-induced liver injury is another major complicating factor in drug therapy and an important reason for 
withdrawals from the market, especially in the case of idiosyncratic reactions [241]. Risk factors for 
hepatotoxic ADRs (diabetes, obesity, old age) [242] are common and will gain in importance as the 
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average lifespan continues to increase. Compromised liver function results in decreased clearance of 
hepatically metabolized substances and toxic compounds which eventually accumulate. Ultimately, hepatic 
encephalopathy may develop, owing to the accumulation of ammonia and mercaptans. In this way, 
hepatotoxic ADRs can have CNS effects by proxy and should be taken into consideration in the evaluation 
of a drug’s CNS safety. 
 
The same holds true for renal ADRs. The kidney is central to the elimination of water-soluble metabolites 
and xenobiotics. Renal failure can lead to accumulation of primarily nitrogenous compounds (uremia) with 
devastating effects on the CNS. Nephrotoxic ADRs are seen in cardiovascular drugs (esp. ACE inhibitors), 
aminoglycosides and NSAIDs (direct tubular damage and interstitial nephritis), and a broad range of other 
drugs. 
 
Lastly, we consider allergic ADRs. These form a group of commonly reported problems, ranging from 
laboratory finding (e.g. eosinophilia) to local irritations or skin manifestations over to very serious 
complications such as first manifestations or exacerbation of allergic asthma. Allergic ADRs are therefore 
also dependent on a patient’s medical history and individual susceptibility. Events attributable to 
medication errors (esp. those which are document only for overdose) were not included. 
 
Quantitative Structure-Activity Relationships (QSAR) 
See Section 3.1.2. 
 
For this study, we restricted ourselves to decision tree induction analysis. Such models not only perform as 
prediction tools but also lend themselves to visual interpretation and provide insight into the mechanisms 
behind the endpoints.  
 
Materials and Methods 
Data acquisition 
We based our analysis on a list of FDA approved small molecule drugs (n = 1436, date of access: January 
1st, 2008) from the University of Alberta’s DrugBank database [225]. Currently, DrugBank contains over 
1’300 FDA approved small molecule drugs along with chemical, pharmaceutical and biochemical 
information. Using the official Swiss drug registry, we retrieved a list of every ADR (n = 776) known for the 
subset of 507 compounds in DrugBank which are also marketed in Switzerland. Every individual ADR was 
labeled with one or more of the following tags: CNS related, hepatotoxicity related, nephrotoxicity related, 
allergy related, and miscellaneous. ADRs which could only be classified as ‘miscellaneous’ were not 
considered. 
 
Unspecific ADRs such as fatigue, nausea, headache, and feelings of dizziness were removed from the 
final dataset because these reactions are almost regularly seen in clinical trials as a stress reaction to the 
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unfamiliar setting and rarely verified by an external examiner. We also removed dependency, anorexia (as 
a consequence of nausea), and very rare or insufficiently characterized ADRs such as fever (unless 
explicitly stated as drug fever; n = 35), symptoms of abstinence (n = 26), and death (n = 9). Based on the 
class labels, we computed the sums of ADRs for every class and every compound.  
 
For every ADR class, compounds at a low and a high risk were defined to have ADR counts equal to or 
lower than a preset lower threshold or equal to or higher than a preset upper threshold, respectively. 
Compounds with ADR counts between the two thresholds were excluded from the analysis for that class. 
The concept of using these experimentally determined thresholds allowed to obtain sharper distinctions 
between low-risk and high-risk groups of compounds. A summary of thresholds used is given in Table 16. 
A table of structures and activities in each class can be found as supplemental material. 
 
class lower 
threshold 
upper 
threshold 
active 
compounds 
inactive 
compounds 
compounds of 
undetermined 
activity 
CNS 1 20 97 67 343 
hepatotoxicity 0 4 109 177 221 
nephrotoxicity 0 3 126 208 173 
allergies 0 2 99 239 169 
Table 16 – Description of the dataset used (n = 507). Adverse drug reactions (ADRs) are grouped 
into one or more of the given classes. Compounds with an ADR count ≤ lower threshold were 
classified as inactive in the respective class, those with an ADR count ≥ upper threshold were 
classified as active. All others were classified as undetermined. 
Assessment of chemical diversity 
See Section 4.1.6.2. 
 
Decision Tree Induction (DTI) 
See Section 4.2.4. 
 
Corrected Classification Rate (CCR) 
See Section 4.2.2.1. 
 
Model Validation 
See Section 4.2.2.5. 
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Descriptors 
See Section 4.1.7. 
 
Software used 
ChemAxon Marvin (Marvin 5.0.4, 2008, http://www.chemaxon.com) was used for characterizing chemical 
structures, substructures, and ChemAxon Calculator Plugins were used for structure property calculation. 
Additional descriptors were calculated with the open-source cheminformatics package Chemical 
Development Kit [209] (version 1.0.4, 2008, http://sourceforge.net/projects/cdk). Decision trees grown with 
the CHAID and CART algorithms were done in SPSS 15.0 for Microsoft Windows. 
 
Results and Discussion 
We calculated the dissimilarity for all compounds in the data set with the Tanimoto coefficient and arrived 
at a value of 0.85. This rather high value is evidence of our data’s great structural diversity. 
 
Overall, we found very few substances without any CNS ADRs. However, when ADRs have a psychiatric 
or psychosomatic character, they become both very subjective and harder to evaluate for non-specialists. 
Furthermore, a great deal of ADR data is acquired in the form of adverse events during phase I – III clinical 
trials. Under these artificial conditions, volunteers and patients are confined to trial units and/or constantly 
monitored. This induces significant stress and oftentimes finds expression in ‘soft’ ADRs. Although these 
may very well be attributable to the study drug, the relationship is seldom clear. 
 
The safest substances in our set judging by the total number of ADRs were the vasodilator and anti-
alopecia agent minoxidil (cardiovascular and pulmonary ADRs are known) and lactulose (gastro-intestinal 
but not hepatotoxic ADRs). The highest ADR potential was achieved by the HIV-protease inhibitor 
ritonavir, the diabenzazepine carbamazepine, and the calcineurin inhibitor tacrolimus. 
 
Performance for different endpoints 
A summary of CCRs for every endpoint and DTI algorithm is given in Table 17. 
 
 CNS Liver Kidney Allergies 
CHAID 89.74 % 87.15 % 84.71 % 78.46 % 
CRT 88.01 % 90.22 % 88.69 % 78.94 % 
Table 17 – Corrected classification rates for the different classes of adverse drug reactions by 
decision tree induction algorithm used. Best values are in boldface. 
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CNS class ADRs 
A decision tree generated with the CHAID algorithm performed very well at 89.7 % accuracy (Figure 50). 
Specifically, compounds with less than 10 chain atoms, no carboxyl groups, one or no amine groups, 
absence of azoles, a partial polar surface area (PPSA-1) less than 293.7 Å2, and logP below 3.1 show the 
least CNS ADRs. Except for the low lipophilicity requirement, these are all characteristics of drugs with 
good BBB permeability. This implies that these compounds are not safe merely because they do not 
primarily cross the BBB. A possible explanation is that compounds are extruded by efflux mechanisms. 
Although activation of efflux pumps can give rise to drug-drug interactions (and, by consequence, be the 
source of medication errors and ADEs), drug efflux effectively prevents brain penetration and potentially 
toxic concentrations. One of the major efflux pumps of the BBB, P-glycoprotein (P-gp, MDR1, ABCB1), 
was the subject of a recent study conducted in our laboratory [243]. We therefore cross-checked the 
compounds in both databases and found 49 matches. Only 12 of 25 compounds with CNS ADRs (48 %) 
and 4 of 8 compounds without these ADRs (50 %) are reported to be P-gp substrates, indicating that 
clearance from the CNS is no sufficient explanation for safety. Rather, it seems that the model reflects the 
important goals of good permeability and low number of ADRs in drug discovery. This view is further 
supported by the requirement for moderate to low lipophilicity, which places a limit on accumulation in the 
fatty matrix and membranes of the CNS. The CNS concentrations of such compounds are easier to 
manage and predict, especially in chronic use. Minoxidil was one of the few compounds without any CNS 
ADRs in our dataset and is a good example in this regard.  
 
 
 
Figure 50 - CHAID decision tree model for central nervous system class adverse drug reactions for 
97 active and 67 inactive compounds (n = 164) with a corrected classification rate of 89.74 %. 
  
  
 Projects 
 
 
 – 102 – 
   
Hepatotoxic class ADRs 
Best performance was seen with a CART decision tree model (CCR: 90.2 %, Figure 51). The model is 
quite complex, spanning 39 nodes with a total depth of 5. Most prominently featured are descriptors of 
charge and lipophilicity. Important characteristics of safe compounds were a small partial negative surface 
area (PNSA-1 < 167.72 Å2), small atom-weighted partial positive surface area (PPSA-3 < 35.16), small 
polar surface area (PSA < 94.88 Å2), low nitrogen count (less than 3). Interestingly, the counts of important 
substructures such as azoles or nitro groups were not deemed relevant in the model. The CHAID decision 
tree model (CCR: 87.15 %) showed similar descriptors, but in addition found low sulfur atom and carboxyl 
and amine group counts, as well as a hydrogen bond donor site count of less than four, and places 
importance on low lipophilic partitioning. Small molecules such as pyridoxine, a form of vitamin B6 given to 
lessen the toxic effects of the isoniazide, and the histamine H1 receptor antagonist meclizine used in 
treatment of motion sickness, vertigo, and nausea during pregnancy, are examples of substances with 
small hepatic ADR potential. 
 
This is in line with the common understanding that hepatotoxicity is achieved mostly by lipophilic 
compounds, which not only have higher permeability but also accumulate more easily. The substructure 
motifs identified by the CHAID algorithm are the basis of toxic metabolites. It seems wise to avoid 
compounds which can be subject to metabolic activation and thus be the source of noxious electrophilic 
species [244]. Ritonavir, for example, is rich in nitrogen, has a large PSA and PNSA-1, as is atazanavir. 
Both are lipophilic and noted for their detrimental effects on the liver. 
 
 
 
Figure 51 - CART decision tree model for liver class adverse drug reactions for 109 active 
and 177 inactive compounds (n = 286) with a corrected classification rate of 90.22 %. 
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Nephrotoxic class ADRs 
We saw very good performance with the CHAID and CART (Figure 52) decision tree models (CCRs: 84.7 
and 88.6%). Again, low PSA (< 93.78 Å2) is an important factor for safety. Few aromatic atoms (less than 
19), a basic pKa under 10.71, van der Waals surface area (vdwsa) under 1014.5 Å2, and logP values over 
2.43 were seen in the CHAID model for safer substances. The CART model additionally points out the 
detrimental influence of amine functions, sulfur, and carboaromatic ring structures. 
 
Despite the comparatively high threshold for van der Waals surface area (vdwsa) the models associate 
lipophilic and non-polar compounds with good renal safety. Such compounds are more likely to undergo 
hepatic rather than renal elimination, and, by consequence, will not have great exposure to renal 
parenchyma. Tacrolimus appeared as one of the least safe compounds with regard to kidney and liver 
related ADRs. This is well known [245] and it has many structural features that are looked for in our 
models (high van der Waals surface area, nitrogen count, and logP). 
 
 
Figure 52 - CART decision tree model for kidney class adverse drug reactions for 126 active and 
208 inactive compounds (n = 334) with a corrected classification rate of 88.69 %. 
 
Allergy class ADRs 
Compared to the other endpoints, CCRs for this class were lower. Satisfactory models at almost equal 
CCRs were provided by the decision tree algorithms (CHAID: 78.4 %, CART: 78.9 %). A diagram of the 
CART model is given in Figure 53. Both also place emphasis on topological complexity over the mostly 
permeability and substructure oriented models above. Of note are descriptors such as the third Kier kappa 
shape index (which relates structural complexity to extreme shapes of chemical graph theory), the Wiener 
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index (a measure of the degree of branching), and relative moments of inertia, i.e. MOMI-XY and MOMI-
XZ, reflecting the degree of symmetry.  
 
Still, the predictive accuracy is somewhat impressive, given the great structural diversity of compounds 
with antigenic potential. It is likely precisely this circumstance to which these models owe their 
performance. Instead of basing their predictions on known antigenic motifs (which were largely not 
determined by the descriptor set used), both models rely on abstract measures of complexity and state 
that simple, less branched compounds are safer. This is in line with common immunological 
understanding, where complex proteins are far more immunogenic than polysaccharides. Also, smaller 
and less complex molecules do not allow for the repetitiveness or structural heterogeneity that triggers an 
immunological response. The models therefore support the observation that very sophisticated drug 
molecules such as monoclonal antibodies are potential sources of allergic ADRs. 
 
 
Figure 53 - CART decision tree model for allergy class adverse drug reactions for 99 active and 239 
inactive compounds (n = 338) with a corrected classification rate of 78.94 %. 
Conclusions 
In this study, we performed QSAR analyses using DTI for compounds causing several classes of ADRs. 
ADRs may also be considered as a surrogate marker for a compound’s ability to interact with the target 
organ in vivo and in humans (data which is notoriously hard to acquire), and all models use very different 
features to arrive at their decisions. This suggests that they do not simply model general characteristics of 
drug-likeness but specifically their endpoints. Our models can therefore be directly used as screening tools 
in late drug discovery as structural guidelines, in rational drug design, and pharmacovigilance evaluations. 
However, it should be noted that these models are only valid for drug-like molecules and are not 
necessarily suitable for other areas such as environmental toxicology. 
 
CNS ADRs were reported for almost every drug in our list. This is not surprising, as the assessment of 
CNS symptoms is often subjective to a patient’s self-perception and a clinician’s evaluation of it. They are 
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also much more influenced by external factors than are the other ADR classes examined here. Despite 
this, we were able to provide a thorough estimation tool for this major complicating factor in drug therapy. 
Models for hepatic ADRs rely on lipophilicity and count substructures. Considering the metabolic role of 
the liver in bioactivation by unmasking, modifying, and conjugating certain substructures, this is not 
surprising. Given the complexities of hepatic metabolism, it may be hard to significantly improve on the 
performance of general hepatic ADR models such as the ones we present. The models for renal ADRs 
suggest that safer compounds are less permeable and might not reach sufficiently high concentration in 
the renal parenchyma. Of course, many of the compounds are at least partially eliminated by the kidney, 
but often substances need to undergo prior metabolic alteration. Better accuracy could therefore be 
achieved if this is taken into account. However, ADR data as used in this study does not permit such an 
analysis. Finally, we presented very consistent (although only satisfactorily performing) models for allergic 
ADRs, relying on abstract measures of compound complexity. The results are in line with current 
understanding of antigenicity. 
 
We would like to point out that, while our findings are practically applicable, the requirements presented 
are more of a disjoint set of rules than a final theory of ADRs. Specific features discussed are used within 
the models to arrive at a decision and neither necessarily need to be all satisfied for a given compound nor 
does one necessarily suffice. Furthermore, we have presented rather broad classes of ADRs rather than 
models for more specific effects. While this pooling was necessary to obtain robust and expressive models 
based on a sufficient number of compounds, it also reflects how ADRs appear in clinical practice. Rather 
than causing a single detrimental effect in one organ system alone, multiple related effects are the rule 
rather than the exception.  
 
The different endpoints presented here are traditionally seen as the sum of different transport, metabolism, 
and docking events. For example, for direct CNS toxicity to occur in a peripherally administered drug, a 
compound must appear in the peripheral circulation, pass through any of the blood-CNS-barriers (most 
notably, the BBB), face potential active efflux, and be able to interact with a central binding site. While it is 
mechanistically appealing to trace this path by a series of physiological models for these events, it must be 
noted that each prediction is made with a varying degree of uncertainty (which cumulates with an 
increasing number of models put in sequence). The analyses in this paper, however, prove that it is in fact 
possible to model such very complex phenomena with simplistic means.  
 
Additionally, our models require very little computational power and could easily be applied in high-
throughput virtual screenings such as required in post-market surveillance. Uncertainty is always 
associated with the use of predictive models such as the ones presented here. Although our models are 
built on data of drug effects in humans (rather than in vitro assays of very specific toxicological 
mechanisms), they are applicable only to small molecule drugs like those encountered in clinical practice. 
Our models are meant to guide the decision-making process of professionals in the pharmaceutical 
industry, clinicians involved in pharmacological therapy, and other experts.  
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Instead of developing models for individual ADRs, we chose to combine related ADRs to form the larger 
classes described above. It would certainly be desirable to have predictive tools for individual ADRs, esp. 
when it comes to serious or potentially fatal entities. However, ADRs (n = 789) outnumber available 
compounds (n = 507) considerably and modeling of every entity is therefore impractical. Also, specific 
toxicological effects may be better modeled by analysis of culprit targets (e.g. interactions with the human 
ether-à-go-go related channel (hERG) to screen for QT prolongation).  
 
Different analytical tools might also be applied to our dataset. Linear models (e.g. multiple linear 
regression), artificial neural networks, support vector machines, or any other of the currently favored tools 
may yield additional information or improved models. Our desire, however, was to give easily interpretable 
and practically applicable models (a strong point of DTI) along with a principal proof of feasibility.  
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Abstract 
Aims: The efflux pumps P-glycoprotein (P-gp, ABCB1, MDR1) and Breast Cancer Resistance Protein 
(BCRP, ABCG2) protect the luminal cells of the gastro-intestinal tract from potentially toxic substances. 
Genetic polymorphisms of these proteins have previously been associated with disease susceptibility, 
disease severity, and treatment prognosis of inflammatory bowel diseases such as Crohn’s disease (CD) 
and ulcerative colitis (UC). In this study, we investigated the prevalence in the Swiss population of frequent 
single nucleotide polymorphisms of P-gp and BCRP in healthy volunteers (n = 17) and patients newly 
diagnosed with CD (n = 34) or UC (n = 38). Methods: We isolated DNA from peripheral blood cells and 
assessed the genotype and allele frequencies of MDR1 C3435T, MDR1 G2677T, and BCRP C421A using 
allelic discrimination assays (SNP genotyping; TaqMan). Results: We saw weak associations for BCRP 
C421A (p < 0.18) and MDR1 G2677T (p < 0.27) in patients with UC compared with healthy controls and a 
trend towards the wild type allele for MDR1 C3435T (p < 0.46) in UC. In haplotype analysis, MDR1 
3435CC / BCRP 421CC (Χ2: 1.0142, p < 0.30) in UC and MDR1 2677G / BCRP 421A (Χ2: 1.5615, p < 
0.22), also in UC, showed the strongest correlations. Results for BCRP C421A in particular justify further 
study. 
 
Introduction 
Inflammatory Bowel Diseases (IBDs) are a group of high-incidence inflammatory illnesses of the intestine, 
the two most prominent of which are ulcerative colitis (UC) and Crohn’s disease (CD) [246]. Both share 
key clinical features (e.g., nausea, maldigestion and malnutrition, and associated extra-intestinal 
manifestations [247]) but also differ in their location and the type of inflammation (UC is restricted to the 
mucosa of the colon whereas CD affects the whole length of the gastrointestinal system and all three 
layers of the epithelium). 
 
There is increasing evidence that the common cause of IBDs is a malfunction of the intestinal immune 
system and screening efforts support the existence of genetical susceptibility loci [248] which also play a 
role in treatment options and prognosis [249] 
 
P-glycoprotein 
See Section 3.3.1.3. 
 
Breast Cancer Resistance Protein (BCRP) 
See Section 3.3.1.4. 
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Synergisms of P-gp and BCRP 
ABC transporters, and P-gp and BCRP in particular, play an important role in tissue defense. Both are 
highly expressed in so-called side population (SP) cells, a line of primitive cells derived from bone marrow 
stem cells. SP cells have been detected in non-hematopoietic tissue and the two efflux pumps are thought 
to contribute strongly to tissue defense and regeneration in many organs [250]. A further synergism 
between P-gp and BCRP lies in their shared substrate affinity, for example the anti-cancer agent 
doxorubicin [251], the α1-receptor antagonist alfuzosin, and the histamine H2-receptor antagonist 
cimetidine [252]. Also, recent work by Tai et al. [253] indicates that both are involved in the clearance of 
the neurotoxic amyloid beta from the brain, thereby protecting individuals from Alzheimer’s disease. It 
therefore seems wise to consider these two efflux pumps together in studies of pharmacokinetics or 
pathogenesis. 
 
Haplotype studies 
Haplotypes of MDR1 and BCRP have been reported to be associated with different IBDs. Urcelay et al., 
for example, have identified a susceptibility haplotype (2677T / G3435) for CD [254]. Fiedler et al. [255] 
found a similar association, most notably for the MDR1 2677GG / 3435TT haplotype with UC, but not for 
CD. The haplotypes investigated by Ho et al. [256] showed positive (MDR1 G2677 / 3435T) and negative 
(MDR1 2677T / C3435) correlations with UC, and confirmed the findings of Fiedler et al. Haplotypes 
including BCRP C421A have been less frequently assessed and no associations with IBD are known of to 
date [257]. 
 
Methods and Materials 
Subjects 
We recruited a total of 89 unrelated volunteers (54 female, 35 male; age: 49.9 years ± 0.2 SEM; weight: 
72.3 kg ± 0.2 SEM; height: 1.68 m ± 0.01 SEM; BMI: 25.5 kg/m2 ± 0.1 SEM) in a series of biopsies and 
blood samples taken between 2001 and 2007. Diagnosis of UC and CD were according to current clinical 
knowledge and based on radiological, endoscopic, and histopathological assessment [258]. The study was 
approved by the local ethics committee (Ethik-Kommission Beider Basel, EKBB) and informed consent 
was obtained by all volunteers. 
 
Genotyping 
Genomic DNA was isolated from peripheral EDTA-blood using the QIAamp DNA blood Kit (Quiagen, 
Hilden, Germany). We performed TaqMan analysis on a 7900HT Sequence Detection System (Applied 
Biosystems, Rotkreuz, Switzerland). 1µl of 10 ng/ µl of genomic DNA was added in a well for a multiplex 
allelic discrimination assay along with 9 µl solution consisting of Applied Biosystems TaqMan MasterMix, 
forward primer, reverse primer, probes specific for the SNP being examined (see below), and RNase-free 
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water. Samples were pipette on a 384-well PCR plate (Treff Lab®). The probe stock solutions (=100 
pmol/µl) were diluted to a concentration of 2 pmol/µl for allelic discrimination analysis. During a run, 
samples were heated to 50°C for 2 minutes, then subjected to 95° C for initial denaturation. Then, 40 
cycles of a two-step PCR were performed at 95° C for 15 s and 60° C for 60 s. 
 
Primers and probes 
The primer set for BCRP C421A was designed with Primer Express software (Version 2.0, Applied 
Biosystems) and ordered at Invitrogen (Carlsbad, CA, USA). The sequences for the probes were taken 
from work by Korenaga et al. [259] (Table 18). For MDR1 G2677T, we used a custom assay ordered from 
Applied Biosystems. We assessed the MDR1 C3435T SNP with primers and probes according to work by 
Eap et al. [260]. 
 
 sequence 
probe 1 5´-FAM-CTGCTGAGAACTGTAAGT-MGB-3´ 
probe 2 5´-VIC`-CTGCTGAGAACTTTAAGT-MGB-3´ 
forward primer 5'-TGTTGTGATGGGCACTCTGAC-3' 
reverse primer 5`-TCATAGTTGTTGCAAGCCGAA-3` 
Artificial templates 
positive control 
(C allele) 
5'-TCATAGTTGTTGCAAGCCGAACTGCT 
GAGAACTGTAAGTGTCAGAGTGCCCAT 
CACAACA-3' 
positive control 
(A allele) 
5'-TCATAGTTGTTGCAAGCCGAACTGC 
TGAGAACTTTAAGTGTCAGAGTGCCCA 
TCACAACA-3' 
Table 18 – Primers and Probes used for detection of the Breast Cancer Resistance Protein single 
nucleotide polymorphism C421A. 
Statistical analysis 
We calculated the distribution of genotypes from the allele frequencies and compared our observations 
with distributions expected from an assumed Hardy-Weinberg equilibrium using Pearson’s Χ2 test with two 
degrees of freedom (df = 2). Odds ratios (OR) and 95 % confidence intervals (CI) were calculated using 
Fisher’s test. A p value < 0.05 was considered statistically significant. All evaluations were performed using 
Gnu R (http://r-project.org, version 2.8.1) on Microsoft Windows. 
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Results and Discussion 
Determination of genotypes for BCRP C421A, MDR1 C3435T, and MDR1 G2677T 
Distributions of all genotypes were according to the Hardy-Weinberg equilibrium. We determined allele 
frequencies for the individual patient groups (CD, UC) and a combination of both patient groups (IBD). 
Odds ratios (OR) are given with a 95 % confidence interval (CI). A summary of the results is given in Table 
19. 
 
SNP Group Genotype frequencies 
Allele 
frequencies 
p value (Odds Ratio; 95% 
Confidence interval) 
 CC CA AA C A  
Controls 15 ( 0.88) 2 (0.12) 0 (0.00) 0.94 0.06  
UC 23 (0.68) 10 (0.29) 1 (0.03) 0.82 0.18 0.18 (3.51; 0.63-37.03) 
CD 31 (0.82) 7 (0.18) 0 (0.00) 0.91 0.09 0.71 (1.68; 0.27 – 18.47) 
BCRP 
C421A 
IBD 54 (0.75) 17 (0.24) 1 (0.01) 0.91 0.09 0.35 (2.48; 0.50 – 24.43) 
 CC CT TT C T  
Controls 4 (0.24) 9 (0.53) 4 (0.24) 0.50 0.50  
UC 5 (0.15) 21 (0.62) 8 (0.24) 0.46 0.54 0.46 (1.76; 0.30 – 9.78) 
CD 7 (0.17) 23 (0.61) 8 (0.21) 0.49 0.51 0.73 (1.36; 0.25 – 6.50) 
MDR1 
C3435T 
IBD 12 (0.17) 44 (0.61) 16 (0.22) 0.49 0.51 0.50 (1.53; 0.31 – 6.20) 
 GG GT TT G T  
Controls 12 (0.71) 5 (0.29) 0 (0.00) 0.85 0.15  
UC 29 (0.93) 5 (0.15) 0 (0.00) 0.93 0.07 0.27 (0.42; 0.08 – 2.20) 
CD 30 (0.79) 7 (0.18) 1 (0.03) 0.88 0.12 0.52 (0.65; 0.15 – 3.04) 
MDR1 
G2677T 
IBD 59 (0.82) 12 (0.17) 1 (0.01) 0.88 0.12 0.33 (0.53; 0.14 – 2.27) 
Table 19 – Genotype and allele frequencies of BCRP C421A, MDR1 C3435T, and MDR1 G2677T in 
UC (n=34), CD (n=38), IBD (n=72), and healthy controls (n=17). All groups are in Hardy-Weinberg 
equilibrium. 
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MDR1 C3435T polymorphism 
Wild type and mutant alleles were distributed equally in healthy controls. This finding is in accordance with 
previously published studies [261]. A slight, but statistically insignificantly increased value of 54% in the 
mutant allele T was only seen in patients with UC (OR: 1.76, CI: 0.30 – 9.78, p< 0.46). Glas et al. [262] 
and Potocnik et al. [263] have reported similar ratios. No difference was seen for CD (OR: 1.36, CI: 0.25 – 
6.50, p < 0.73) or the combined endpoint IBD (OR: 1.53, CI: 0.31 – 6.20, p < 0.5). 
 
MDR1 G2677T polymorphism 
Although this SNP is actually tri-allelic, we limited ourselves to the T mutant allele due to our relatively 
small sample size. Other groups have done the same [256, 263]. At 85%, the wild type allele was more 
prevalent than the mutant allele in healthy controls. Compared to this, we saw an association with the wild 
type allele in UC (93%, OR: 0.42, CI: 0.08 – 2.20, p < 0.27) but no difference in either CD (OR: 0.65, CI: 
0.15 – 3.04, p < 0.52) or IBD (OR: 0.53, CI: 0.14 – 2.27, p < 0.33). 
 
BCRP C421A polymorphism 
The wild type was far more abundant (94%) than the mutant allele. There is a clearly distinguishable trend 
towards the mutant allele in UC (OR: 3.51, CI: 0.63 – 37.03, p < 0.18), albeit not a significant one. Patients 
with CD (OR: 1.68, CI: 0.27 – 18.47, p < 0.71) and the combined group of IBD patients (OR: 2.48, CI: 0.50 
– 24.43, p< 0.35) showed a similar tendency towards the A allele. 
 
Haplotype analysis 
We investigated the associations of combined haplotypes of MDR1 and BCRP SNPs with special attention 
to the haplotypes previously reported on by other authors [254, 255, 260]. Most strikingly, we found no 
occurrence of the MDR 1*2 haplotype within any of the subgroups. The strongest association of a BCRP 
haplotype was for homozygous MDR1 3435CC / BCRP 421CC (Χ2: 1.0142, p < 0.30) in UC and MDR1 
2677G / BCRP 421A (Χ2: 1.5615, p < 0.22), also in UC. 
 
Conclusions 
We investigated the prevalence of the SNPs MDR1 C3435T, MDR1 G2677T, and BCRP C421A in blood 
samples from a Swiss population of healthy volunteers and patients suffering from CD or UC. Genotype 
and allele frequencies are similar to those found in other European populations. Although the effect of 
BCRP C421A on IBD is still poorly understood, the mutant allele showed the strongest correlation with UC 
of all SNPs in this article. An analysis in a larger sample of the population may reveal a statistically 
significant association. 
 
  
  
 Projects 
 
 
 – 113 – 
   
In our survey of haplotypes, we found no cases of the much discussed MDR1 2677T / G3435. However, 
our results justify further research into the prevalence of the haplotypes MDR1 3435CC / BCRP 421CC 
and MDR1 2677G / BCRP 421A, both of which were weakly associated with susceptibility to UC. Again, a 
larger sample size would be desirable. 
 
The etiology and pathogenesis of IBDs remains poorly understood. The many factors known to influence 
disease susceptibility and phenotype cannot be pinned down to any single SNP, nor is any haplotype likely 
to discriminate the many facets of these diseases. [264] 
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Abstract 
Introduction: The Crigler-Najjar (CN) syndrome is a very rare disease clinically characterized by 
unconjugated, nonhaemolytic, severe hyperbilirubinaemia from birth due to an inherited enzyme defect of 
the uridine 5'-diphospho-glucuronosyltransferase (UGT) isoenzyme 1A1. CN type II syndrome is 
essentially a cosmetic problem. Possible treatments should therefore not be harmful. However current 
long-term treatment with phenobarbital is associated with diminished mental activity, lethargy, depression, 
and teratogenicity. We therefore decided to investigate the effect of hypericum extract, a potent pregnane 
X receptor mediated enzyme inducer, in a patient with CN type II. Methods: The patient was treated with 
300  mg St. John’s wort dry extract three times daily (Jarsin ® dragées containing the hypericum 
extract LI160) for seven weeks. Blood samples were obtained between June 21, 2007 and April 24, 2008. 
To assess enzyme induction, a midazolam kinetic study was performed, before and after hypericum 
treatment. Results: The treatment with hypericum extract was well tolerated by the patient. The area 
under the plasma concentration time curve (AUC) of midazolam decreased from 4700 ng/mL*min to 2650 
ng/mL*min (-44%), indicating cytochrome P450 3A4 (CYP3A4) induction associated with the ingestion of 
hypericum extract. Mean plasma total bilirubin concentrations were 165±11 µmol/l (mean ±SD, n = 7) 
without any medication and 112± 8 µmol/l (mean ±SD, n = 6) during treatment with hypericum extract. 
Compared to the plasma concentration without any treatment, hypericum extract was associated with an 
average 32% decrease in total plasma bilirubin. The highest measured total bilirubin plasma concentration 
in the study period without treatment was 204 µmol/L, whereas the lowest concentration with hypericum 
extract treatment was 93 µmol/L. Conclusion: Treatment with hypericum extract in a CN type II patient is 
well tolerated and showed a comparable reduction of the bilirubin plasma concentration as the current, 
more toxic treatment with phenobarbital. 
 
Introduction 
Glucuronidation represents a major pathway in mammalians for elimination of lipophilic compounds [265]. 
The transfer of glucuronic acid is catalyzed by members of the uridine 5'-diphospho-
glucuronosyltransferase (UGT) family [266, 267]. Each UGT isoenzyme exhibits a profile of substrate and 
tissue specificity, which is overlapping with other UGT isoenzymes [34]. 
 
The Crigler-Najjar (CN) type II syndrome is clinically characterized by unconjugated, nonhaemolytic severe 
hyperbilirubinaemia from birth [268, 269], due to an inherited enzyme defect of the UGT isoenzyme 1A1. 
UGT1A1 is the only enzyme that contributes significantly to bilirubin glucuronidation which is necessary for 
biliary excretion [270]. CN type II patients have, compared to patients with CN type I, only a partial 
UGT1A1 deficiency with serum bilirubin levels between 60 and 340 µmol/l [271-274]. Treatment of CN 
type II patients with 5 to 10mg phenobarbital per kilogram body weight leads to a relevant reduction of 
serum bilirubin levels within two weeks after treatment start [273-278]. The expression of the UGT1A1 has 
been shown to be induced by the activation of constitutive androstane receptor (e.g. phenobarbital [274, 
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279]), peroxisome proliferator-activated receptor α (e.g. clofibrate [280]) and furthermore pregnane X 
receptor (e.g. dexamethasone [280], progesterone [281, 282]). Since CN type II syndrome is essentially a 
cosmetic disease, treatment should not be harmful. Despite the rapid tolerance to the sedative effect of 
phenobarbital within three to four days, diminished mental activity, lethargy, depression, and teratogenicity 
are limiting factors of long-term treatment with phenobarbital [283, 284]. We therefore decided to study the 
effect of hypericum in a patient with CN type II. Hypericum (St. John’s wort) is an effective and well 
tolerated medication for mild depression [285]. Hypericum extract LI160 is a potent PXR activator with a 
high hyperforin content, the main inducing component of hypericum [286-288]. 
 
Materials and Methods 
Patient 
A non smoking, 24 year old Caucasian woman with jaundice from birth was enrolled for the study. The 
clinical suspicion of a CN type II syndrome could be confirmed by the identification of point mutations in 
the nucleotide positions 211 and 1456 of the UGT1A gene. These mutations have been described in two 
patients with phenobarbital-sensitive CN type II syndrome [289, 290]. Because of dysmenorrhea and mild 
acne vulgaris, the patient was treated with ethinylestradiol 0.03 mg and dienogest 2 mg since June 2006. 
The patient ingested no other drugs and had no other diseases. 
 
Study design 
We performed a single-case, open-label, three-period enzyme induction study in this CN type II patient. 
Since CN type II is a very rare disease, we could not find other patients for inclusion into the study. The 
primary study endpoint was changes in the serum bilirubin associated with the ingestion of hypericum. 
Because of the known high intra-individual variability of bilirubin levels, we tried to avoid known influencing 
factors as well as possible. The patient was told to refrain from sunbathing, tanning bed sessions, weight 
reducing diets, sleep deprivation, vitamin and herbal supplements, as well as grapefruit products during 
the whole investigational period from May 2007 till end April 2008. A midazolam (MDZ) kinetic study was 
performed to asses enzyme induction by the hypericum extract [288, 291-293]. The study was conducted 
in conformity with the principles of the Declaration of Helsinki and approved by the Ethics Committee of the 
State of Basel, Switzerland. The patient gave written informed consent before undergoing any study-
related procedures. 
 
Blood sampling for bilirubin determinations 
A total of 19 blood samples were obtained between June 21, 2007 and April 24, 2008. Six blood samples 
were obtained under oral contraception with ethinylestradiol 0.03 mg and dienogest 2 mg between June 
21, 2007 and October 22, 2007. End of October 2007, oral contraception was interrupted. After a washout 
phase of seven days another five blood samples were obtained without any treatment between November 
6, 2007 and January 8, 2008. On February 8th, the patient started the treatment with 300mg hypericum 
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extract three times daily (Jarsin® dragées LI160, Vifor SA, Villars-sur-Glâne, Switzerland). Thereafter, 
between February 12 and March 20, 2008, six blood samples were obtained while the patient was treated 
with hypericum extract. On March 20, 2008, we stopped treatment with hypericum extract. After a washout 
phase of one month, we obtained two additional blood samples (April 17 and April 24, 2008) without any 
treatment. 
 
Midazolam pharmacokinetics 
We verified PXR activation and subsequent CYP3A4 induction by assessing the pharmacokinetics of a 
2mg intravenous of MDZ (Dormicum®, Hoffmann-LaRoche Ltd., Basel, Switzerland) immediately before 
starting treatment with hypericum extract (February 8, 2008), and after treatment with hypericum extract 
for three weeks (February 28, 2008). Venous blood samples were obtained immediately prior to and 5, 20, 
60, 120, 240, 360, 480, 600 min after MDZ injection using Monovette tubes (Sarstedt, Nürtingen, 
Germany), containing lithium heparin as an anticoagulant. Samples were put on ice and centrifuged at 
3’000 g over 5 min at 4° C within 30 minutes after collection. The resulting plasma was stored at -70°C 
until MDZ analysis. MDZ and its metabolites were analyzed by liquid chromatography–mass 
spectrometry/mass spectrometry as described previously [294]. Free concentrations of MDZ, 1-OH-
hydroxymidazolam (1′-OHMDZ), and 4-OH-hydroxymidazolam (4-OHMDZ) were determined after ultra 
filtration of the plasma samples. The metabolite 1′-OHMDZ glucuronide was measured as 1′-OHMDZ after 
deglucuronidation using the same liquid chromatography–mass spectrometry/mass spectrometry method. 
 
Pharmacokinetic analysis 
Plasma MDZ, 1′-OHMDZ, 4-OHMDZ and glucuronide data were analyzed using compartmental (MDZ) and 
non-compartmental methods (1′-OHMDZ, 4-OHMDZ) (WinNonlin, version 5.01, Pharsight Corp., Mountain 
View, CA, USA). 
 
Results 
Bilirubin plasma levels 
Altogether, 19 blood samples were obtained between June 21, 2007 and April 24, 2008. Mean plasma 
total bilirubin concentrations were 165 ±11 µmol/l (mean ±SD, n =7) without any medication, 134 ±8 µmol/l 
(mean ±SD, n=6) under treatment with ethinylestradiol/dienogest, and 112 ±8 µmol/l (mean ±SD, n =6) 
during treatment with hypericum extract (Figure 54). Compared to the plasma concentration without any 
treatment, hypericum extract was associated with an average 32% decrease and ethinyl/dienogest with an 
average 19% decrease in total plasma bilirubin. 
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Figure 54 – Bilirubin plasma levels under treatment with the oral contraceptive Valette ®, the anti-
depressant Jarsin ®, and control without medication. 
Pharmacokinetics of midazolam 
After induction with hypericum extract the area under the plasma concentration time curve (AUC) of 
midazolam decreased from 4700 ng/mL*min to 2650 ng/mL*min (-44%). AUC of 1′-OHMDZ before (597 
ng/mL*min) and after induction (566 ng/mL*min) didn’t changed relevant, whereas a marked decrease of 
the 4-OHMDZ before (121 ng/mL*min) and after induction (48 ng/mL*min) was found. Results are 
summarized in Table 20. 
 
Tolerability of hypericum extract 
The treatment with hypericum extract was well tolerated, except a feeling of slight facial skin prickling 
without visible skin changing’s for some minutes after a one hour lasting walking tour on a sunny day. 
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Midazolam bolus 2mg 
i.v 
before hypericum 
treatment 
After 21 d hypericum  
(900 mg/d) 
AUC (0,∞) (ng ml-1 min) 4700 2647 
t1/2α (min) 14 6 
t1/2β (min) 133 128 
Cmax (ng ml-1) 49 84 
   
1’-hydroxymidazolam   
AUC (0,∞) (ng ml-1 min) 597 566 
   
4’-hydroxymidazolam   
AUC (0,∞) (ng ml-1 min) 121 48 
 
Table 20 – Pharmacokinetic evaluation of midazolam in plasma before and after treatment with 
hypericum extract. 
Discussion 
MDZ is rapidly metabolized by CYP3A4 to its main metabolite 1′-OHMDZ. The induction of this step have 
been shown in our patient, the MDZ AUC dropped by 44% after induction with hypericum. The following 
glucuronidation is performed mainly by UGT2B7 and UGT2B4 (O-Glucuronidation) and to minor extend by 
UGT1A4 (N-Glucuronidation) [295, 296]. Because of induction of the glucuronidation we expected a 
relevant decrease in the 1′-OHMDZ AUC under treatment with hypericum, but AUC of 1′-OHMDZ before 
and after induction was similar. This may be caused by the additional point mutations in the nucleotide 
positions of 1456 in the codon 5 of the UGT1A gene encoding for UGT1A4, performing N-glucuronidation 
of 1'-hydroxymidazolam.  
 
Treatment with hypericum extract in a CN type II patient is well tolerated and showed a comparable 
reduction of the bilirubin plasma concentration as the current, more toxic treatment with phenobarbital. A 
case series of five Crigler Najjar type II patients compared the highest measured serum bilirubin 
concentrations before treatment with phenobarbital with the lowest measured concentrations after 
induction treatment. The highest measured serum bilirubin concentrations fell by between 33 and 77% 
compared with the lowest measured bilirubin concentration after treatment with phenobarbital [275]. If we 
compare the highest bilirubin concentrations in our patients without treatment with the lowest concentration 
with hypericum extract treatment we find a maximal reduction of the bilirubin plasma concentration of 54%.  
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After induction with hypericum, the MDZ AUC0-12h decreased by 44% compared with basal values. From 
literature we know that the extract LI 160 (Jarsin®) decreased MDZ AUC0-12h by 79.4% (95% CI 88.6; 
70.1) [35]. The increased MDZ elimination is only a surrogate marker of induction and demonstrates that 
our patient was compliant to the study medication.  
 
Although CN type II patients become tolerant to the sedative effect of phenobarbital within three to four 
days [273], diminished mental activity, lethargy, depression, and teratogenicity are limiting factors of long-
term treatment with phenobarbital [283, 284]. On the other hand, the risk of gallbladder disease, 
pancreatitis, and malignancies are adverse reactions, limiting the use of clofibrate [297, 298]. In contrast 
hypericum extract was well tolerated by our patient, as expected from patients with depressions treated 
with hypericum extract [299]. The most common adverse effects of hypericum extract are gastrointestinal 
symptoms, dizziness and tiredness. The often discussed phototoxic skin reaction were described 
especially in studies where patients were treated with pure hypericin [300-302] whereas photosensitivity is 
extremely rare in patients treated with hypericum extract [303, 304]. 
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Abstract 
Smoking is a major risk factor for many preventable diseases and presents a great threat to the public 
health. Nicotine substitution is still one of the mainstay therapies, although nicotine patches and gum do 
not give smokers the same pharmacokinetic profile as cigarette consumption and may therefore be poorly 
effective. Here, we present a computer-controlled delivery system for pulsatile transdermal administration 
of nicotine. We enrolled twelve male volunteers who consume more than 20 cigarettes/day and 
established tolerability with three increasing doses of nicotine (6.7 mg/d, 13.4 mg/d, and 26.7 mg/d). 
Furthermore, we showed the feasibility of controlled release administration of nicotine in dose linear 
manner with dose application at precise intervals and amounts which yield effective plasma peaks. After 
additional efforts have been made to further miniaturize the system, it could find use not only in nicotine 
replacement therapy, but also for other indications such as patient-controlled analgesia. 
 
Introduction 
Tobacco use is one of the major risk factors for cardiovascular and pulmonary morbidity such as coronary 
heart disease, peripheral artery disease, chronic obstructive pulmonary disease (COPD), lung cancer, and 
infections [305-308]. Smoking also increases the risk of cancer of other organs [309]. Half of the estimated 
1-2 billion smokers worldwide will die from these and other smoking-related illnesses [310] – not 
accounting for the negative effects of passive exposure to smoking. Quitting smoking at any age is 
beneficial as duration and amount of tobacco use correlates with disease progression and severity [311]. 
Effective smoking cessation strategies are therefore of paramount importance to the public health. 
 
Mechanisms of tobacco addiction 
Nicotine ((S)-3-(1-methyl-2-pyrrolidinyl) pyridine) is the main addictive agent in tobacco products. When 
smoked, nicotine is distilled and rapidly taken up into the blood from which it readily penetrates the blood-
brain barrier. This is shown by high, short concentration peaks 10-20 s after inhalation [312]. Nicotine has 
a high abuse liability, leading to physical dependence and compulsive abuse [313]. The addictive potential 
of nicotine is rated as high as that of cocaine or heroin, but without the behavioral disruption that goes 
along with other substances of abuse [314]. Development of nicotine addiction may be modulated by the 
rate of nicotine uptake, with higher invasion rates into the CNS showing a higher risk [311]. 
 
Therapeutic options 
After willingness to quit has been assessed, treatment of nicotine dependence usually involves continued 
psychological counseling and pharmacological support. First-line drug therapies are nicotine replacements 
(e.g. patches, gums, or sublingual forms) and non-nicotine agents such as the partial nicotinic receptor 
agonist varenicline [315]. Second-line agents, e.g. antidepressants or clonidine [316], help in treating 
withdrawal symptoms. The overall performance of nicotine replacement is, however, still disappointing, 
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with only about 15% of smokers seeking treatment actually giving up the habit [317], This is probably 
because available forms of nicotine replacement therapies (NRTs) do not give the patient the immediate 
high and short peaks as caused by smoking [318]. 
 
Pulsatile delivery systems 
In pulsatile delivery, an interval of no release is followed by controlled, quick, and complete release of a 
drug dose. Site-specific pulsatile release is desirable in drugs with a high first-pass effect that target distant 
parts of the intestine. Time-controlled systems, such as the one presented in this study, release at set time 
points to produce a specific chronopharmacological profile or on demand [319, 320]. 
 
Study rationale 
In this study, we evaluated the feasibility of pulsatile transdermal delivery of nicotine to mimick the nicotine 
plasma peaks in inhalative smoking with a new microprocessor controlled system that dispenses the 
substance from a drug reservoir. Furthermore, we aimed at establishing the tolerability of nicotine with 
pulsatile release kinetics in otherwise healthy male smokers. 
 
Materials and methods 
Volunteers 
Twelve male heavy smokers, aged 28.3 (20.7-47.2) years (mean (range)), were enrolled for the study. 
Weights were within normal limits (body mass index: 23.1 (20.1-25.1) kg/m2 (mean (range)) and heights 
were 178 (170-184) cm (mean (range)). Prior to participation, subjects had to give written informed 
consent. Good health was assessed with a medical history, physical examination, and laboratory controls 
of blood and urine. Tobacco use of 20 cigarettes/day or more was assessed with a urine cotinine test. 
None of the volunteers was taking medication or suffered from an allergic condition. Two additional 
volunteers were included in the study but dropped out because of personal reasons. 
 
Study design 
The study was a single-center, open-label, three-periods, dose-escalating study, and was approved by the 
local state ethics committee (Ethische Kommission beider Basel). We consecutively assigned subjects to 
three treatment groups, where the dosing device dispensed nicotine at rates of 0.67 mg/h, 1.34 mg/h, and 
2.67 mg/h in two peaks separated by 8 h. These rates correspond to total doses of 6.7 mg, 13.4 mg, and 
26.7 mg, respectively. The rationale for these doses was based on the nicotine plasma levels in regular 
smokers [321] and the release rate required was determined in a pilot experiment. 
 
Subjects arrived at 6:00 a.m. of each test day at the Clinical Research Center (CRC) of the University 
Hospital Basel, after at least 12 hours fasting and abstaining from tobacco. Vital signs of the subjects, 
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adverse events, and any new medical conditions which might have arisen were recorded. For nicotine 
administration, the dosing device was placed on the flector side of the leading lower arm and a venous 
catheter was inserted into the cubital vein on the opposite side. 
 
Vital signs were recorded and blood was drawn pre-dose and then at hourly intervals for 16 hours and 24 
h after the start of administrations. The device remained fixed on the arm for 16 hours, releasing nicotine 
at the assigned dispensing rates reported for 2 min at 1h and 8h, after which it was removed and subjects 
remained on the ward for monitoring until they were discharged in the morning. 
 
The three consecutive treatments were separated by a wash-out period of at least three days. Adverse 
events were continually recorded and subjects were admitted to the next period only if the preceding dose 
had been tolerated well. 
 
Analysis and statistical evaluation 
Whole blood was drawn and immediately centrifuged (3’000 g over 5 min at 4° C). Supernatant plasma 
was stored at -20° C. For processing, samples were thawed at room temperature and vortexed. Then, 400 
µl of plasma were added to 400 µl of 20% w/v trichloroacetic acid, and, after further vortexing, kept at -17° 
C for 30 minutes. Subsequently, the samples were centrifuged at 14’000 g for 20 minutes. The 
supernatant was collected and used directly for HPLC-MS analysis. 
 
Agilent equipment was used, consisting of a G1312A binary pump, a G1379B degasser, a G1367B high 
performance thermostated autosampler, a G1314B UV detector, and a 6130 single quadrupole MS 
detector with an atmospheric pressure electrospray ionization source. Nicotine was quantified on the MS 
signal using positive mode selected ion monitoring at m/z 163.1, a capillary voltage of 4000 V, drying gas 
flow 10 l/min, nebulizer pressure 30 psig, drying gas temperature 350°C, a fragmenter setting of 70 V and 
gain setting 3. Chromatography was performed on a 125/2 mm Nucleosil 100-5 C8 ec column (Macherey-
Nagel) with an injection volume of 100 µl. A mobile phase consisting of 7.5% methanol and 92.5% water 
and containing 1% acetic acid (96%) and 20 mM ammonium acetate was used in isocratic mode. 
Quantification was performed against a set of external standard solutions of nicotine that were prepared in 
water and treated in the same way as the plasma samples.  
 
With this method, a linear peak area response was obtained at concentrations of injected sample between 
1 and 40 ng/ml. Over this concentration range, recovery of the drug from plasma determined by spiking 
blank human plasma with nicotine was found to be between 85 and 110%. The limit of quantification was 1 
ng/ml with a variation between 5 and 10%, and the limit of detection was approximately 0.3 ng/ml. 
 
The following pharmacokinetic parameters were determined: area under the curve (AUC) was calculated 
with the linear trapezoidal rule, Cmax, and Tmax of the first (1-7 h) and second peak (8-16h) were determined 
by inspection of the plasma concentration/time data. Statistical analysis was performed in SPSS for 
Windows software (version 15.0; SPSS Inc., Chicago Ill). The level of significance was p ≤ 0.05. 
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Materials 
Chrono Therapeutics Inc. has developed a watch-sized device (ChronoDose™, seen in Figure 55) to 
deliver drugs transdermally by microprocessor controlled delivery. For this study, we used prototypes of 
the device, which consisted of a substance reservoir and a replaceable membrane of 10 cm2. The devices 
were connected to notebook computers via a parallel connection that controlled drug release and a USB 
cable for power. 
 
 
Figure 55 – Prototypes of the ChronoDose™ transdermal drug delivery device (picture courtesy of 
Chrono Therapeutics, Inc.) 
Nicotine drug substance was obtained in GMP-quality for human use from Siegfried Ltd., Zofingen, 
Switzerland. Solutions and transdermal systems were prepared at the University of Applied Sciences 
Northwestern Switzerland under the supervision of Prof. G. Imanidis 
 
Results and Discussion 
Pharmacokinetic parameters 
Even for small lipophilic compounds such as nicotine, the efficiency of transdermal delivery is influenced 
by a large number of parameters (skin thickness, sweat production, etc.). Because of the expected 
interindividual variability and lack of experience in human subjects for this device, we used an initial flow 
rate that was estimated to yield levels just above the level of quantification. This was observed indeed after 
administration of the lowest release rate. Plasma levels were only quantifiable for 7 out of 12 volunteers 
and the dose was well tolerated. The results of the nicotine plasma analysis are summarized in Table 21 
and in Figure 56. 
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Flow rate 
(mg/cm2/h) 
AUC (ng*h/ml) 
0-24 h 
Cmax (ng/ml) 
0-7h 
Tmax (h) 
0-7h 
Cmax (ng/ml) 
8-16h 
Tmax (h) 
8-16h 
n 
0.67 56.7 ± 10.0 4.9 ± 1.5 3.7 ± 0.6 5.7 ± 1.1 10.9 ± 0.9 7 
1.34 131.4 ± 19.4 7.7 ± 1.4 4.9 ± 0.5 13.0 ± 1.9 10.2 ± 0.6 11 
2.67 262.8 ± 39.7 18.2 ± 2.8 4.8 ± 0.4 24.7 ± 4.1 10.0 ± 0.4 12 
Table 21 – Pharmacokinetics of two increasing transdermal doses of nicotine in healthy male 
smokers (AUC, area under the concentration-time curve; Cmax, peak plasma concentration; Tmax, 
time of peak plasma concentration; n, number of samples. Data represented as means +/- SEM.) 
Doses (6.7 mg, 13.4 mg, and 26.7 mg) were administered at 0h and 8h after start of administration and the 
respective peaks (Tmax) were seen on average (± SEM) at 4.5 ± 0.4 h and 10.4 ± 0.4h, respectively. AUC 
increased in linear with the dose (p < 0.02, R2 = 0.998) and so did Cmax for the second peak (p < 0.04, 
R2=0.994) while we only observed borderline significance for the linear increase of Cmax of the first peak (p 
= 0.086, R2 = 0.964). 
 
Figure 56 – Plasma concentration of nicotine in response to three increasing pulsatile transdermal 
doses. 
  
  
  
 Projects 
 
 
 – 127 – 
   
Adverse events 
At the lowest dose, several volunteers expressed a craving for nicotine. Mild to moderate erythema was 
seen at the site of membrane placement in all volunteers at all doses but had disappeared completely 
within 1-2 days after removal of the patch without need for treatment. On the next study day, no signs of 
erythema were visible. 
 
Discussion 
All three doses were well tolerated except for local irritation of the skin, a common adverse effect of topical 
nicotine [322]. Within the variability commonly seen in transdermal systems, the prototypes of the 
ChronoDose™ device used in this study were capable of delivering nicotine at precise intervals and 
amounts with dose linearity. 
 
Conclusion 
In this work, we present a computer-controlled system for transdermal delivery of nicotine and show its 
tolerability and potential benefits in NRT. Apart from NRT, this system may also find application in the 
management of postoperative pain [323, 324] or, more generally, as dispenser of other substances such 
as analgetic agents (patient-controlled analgesia) or isosorbide dinitrate (ISDN) [325]. The ChronoDose™ 
device prototype we used here requires an external computer to control it, but an embedded 
microprocessor design is being developed. 
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Abstract 
A fully automated general unknown screening using liquid chromatography-mass spectrometric method 
applying data-dependent acquisition was developed to identify toxicologically relevant substances in 
serum and urine. The method was developed to get an alternative to the HPLC Remedi System from 
Biorad the support of which will be stopped at the end of 2008.  A library including more than 405 specters 
of about 365 compounds (main drugs and important metabolites) was established. An easy to use 
program was created to automate and accelerate library search. Drugs were identified based on their 
relative retention times, molecular ions and fragment ions. Limits of detection of the majority of 100 out of 
350 compounds (67%) were lower than 100 µg/l. The developed LC-MS-MS system seems to be a 
valuable alternative to other general unknown screening methods allowing fast and specific identification of 
drugs in serum and urine samples. 
 
Introduction 
A non-target screening for detection of drugs and toxic compounds is called general unknown screening 
(GUS) procedure or systematic toxicological analysis (STA). This procedure is an analytical method 
designed to detect and identify xenobiotics in biological fluids, which is necessary for confirmation of the 
diagnosis of an acute poisoning with drugs or other exogenous compounds. Rapid and comprehensive 
screening procedures are therefore necessary. 
 
For current STA procedures in clinical and forensic toxicology, automated immunoassays for the most 
common drugs of abuse in combination with chromatographic techniques coupled to specific detectors are 
often used. Gas chromatography-mass spectrometry is so far the gold standard for this purpose [326-328]. 
Big advantages of this method are the content of compounds in the library (> 7000) and the transferability 
of the library to GCMS systems of different manufacturers.   
  
Its application however is limited to non-polar, volatile and thermally stable compounds. In addition, 
derivatization is necessary for detection of polar compounds such as metabolites, which complicates the 
screening procedure, but allow to detect compounds with different pKa values to be analyzed in one GC 
run. HPLC coupled to UV diode array detection (DAD) overcomes these limitations [329-332]. However it 
shows reduced separation efficiency and the detection of compounds is not as specific and reliable as 
compared to GC-MS [326].  
 
Therefore, in the last years, the combination of mass spectrometry with liquid chromatography has been 
evaluated for screening analysis. It was shown to be very sensitive, precise, specific, universal and very 
fast if coupled to an automated extraction system [333-340]. Several authors described screening methods 
with LC-MS that apply in-source collision induced dissociation (CID), LC-MS-MS in the multiple reaction 
monitoring mode, and LC-MS-MS using data-dependent acquisition (DDA) [333-342]. 
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With single MS, the mass spectrometer operates in the scan mode and applies in-source CID. The sample 
is screened at variable orifice voltages [337, 339-341]. Reconstructed spectra can be obtained and 
compared with in-source CID spectra libraries. MS-MS data have the advantage of providing a higher 
specificity and selectivity and more structural information than single MS. This mode has been shown to be 
helpful when an unknown substance has to be identified. Although LC-MS-MS in the multiple-reaction 
monitoring mode can be applied to a high number of previously selected compounds, this number is 
limited [336]. 
 
LC-MS-MS using DDA seems to be the best procedure for simultaneous screening and identification of 
unknown compounds using a single chromatographic run. In this procedure, ions that exceed a pre-set 
threshold are fragmented by CID and the resulting fragments are measured in the product-ion scan mode 
[333-335]. This technique is highly specific and selective. Spectra results from a single ion and the origin of 
the spectra are registered. This study presents an approach of a fully automated screening procedure with 
a specially created library search program to perform compound identification. The chosen procedure 
consisted of on-line solid-phase extraction (SPE) and LC-MS-MS using DDA.  
Experimental 
Materials 
Test substances obtained from various pharmaceutical companies were of pharmaceutical purity. Organic 
solvents and reagents were of analytical grade. Acetonitrile and methanol were purchased from Merck 
(Darmstadt, Germany), ammonium formate from Aldrich (Steinheim, Germany) and formic acid from Fluka 
(Buchs, Switzerland). De-ionized water was generated with a Milli-Q water purification system from 
Millipore (Kloten, Switzerland). Drug free serum was purchased from Biorad (Reinach, Switzerland). 
Serum and urine samples for the comparison study were made anonymous after performing the analysis 
of routine requests and used without any personal information for the comparison between different 
methods (with the verbal agreement of the Ethic Commission of the two cantons of Basel-Landschaft and 
Basel-Stadt). 
 
Apparatus 
The chromatographic system consisted of a Rheos 2000 Micro HPLC pump from ThermoFinnigan 
(Allschwil, Switzerland) and a Midas Symbiosis Autosampler from Spark Holland (Emmen, Netherlands) 
using a 100 µL loop. The detector was a ThermoFinnigan LCQ Advantage MAX ion trap mass 
spectrometer equipped with an atmospheric pressure chemical ionization (APCI) device and the Xcalibur 
software. Automated solid-phase extraction was performed using a Prospekt 2TM from Spark Holland 
consisting of an automatic cartridge-exchange module, dual cartridge clamps and a solvent delivery unit. 
HySphere Resin GP cartridges were purchased from Spark Holland. 
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Methods 
Standard solutions 
Separate stock solutions were prepared in methanol-water (1:1, v/v) at a concentration of 100 mg/l. Serum 
standards were prepared by spiking with stock solutions of drug mixtures to get concentrations ranging 
from 0.005 to 4 mg/l, resulting in a set of standards with the following concentrations: 0.005, 0.010, 0.025, 
0.050, 0.100, 0.250, 0.500, 1.000, 2.000 and 4.000 mg/l. d3-Benzoylecgonine was prepared as internal 
standard (IS) at a concentration of 5 mg/l. 
 
The results of the new method were compared to analysis performed on a Remedi Systems from Biorad 
(Remedi HS and Remedi Benzodiazepine [343]), to a in house developed LC-MS-method (Finnigan 
Navigator) following the procedure described by Bogusz et al. and to a full-scan GC-MS screening method 
[344] applied in the Department of Experimental and Clinical Toxicology, Saarland University,  
Homburg/Germany. 
 
Extraction procedure 
One ml of serum or urine was acidified by addition of 20 µL concentrated formic acid (cleaving a possible 
protein binding of drugs) and 100 µL of the IS solution were pipetted into each sample. On-line SPE and 
elution were performed using the Prospekt 2 system. The HySphere Resin GP (Spark Holland) cartridge 
was conditioned with 1 ml of methanol (5 ml/min) and with 1 ml of water (5 ml/min). A 100-µl-aliquot of the 
serum was loaded on the cartridge. The sorbent was washed with 1 ml of water (2 ml/min), and eluted 
directly with the mobile phase over 15 min. In this study, cartridges were used only once in order to avoid 
possible contamination by proteins which could reduce the extraction rate and destroy the separation 
column. 
 
Evaluation of matrix effects and process efficiency 
Possible influences by matrix effects were studied with three different methods. In the first test, process 
efficiency was determined. For calculation of the process efficiency expressed in percent (PE%), the peak 
area ratio (i.e. the peak area of the drug of interest was divided by the peak area of the IS) obtained after 
the on-line extraction of a serum sample and compared to the peak area ratio obtained after direct 
injection of the same amount of an aqueous solution into the LC-MS-MS system. (The PE% of the IS 
(84%) was also considered in the calculations (PE% = (Peak area ratio of a serum sample spiked before 
extraction / peak area ratio of an aqueous solution x 100). 
 
The second procedure is based on the post-column infusion of an analyte in a chromatographic run of 
blank serum or urine (urine samples were tested when the method was in routine). The signal was 
compared to the signal obtained with post-column infusion of the parameter to be tested into the eluent of 
the corresponding blank matrix extract. In the last experiment, blank samples (serum and urine) used as 
negative controls were analyzed. 
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Liquid chromatography 
The chromatographic separation was performed on a CC Nucleodur C18 Gravity 3 µm column (4 x 125 
mm) with an integrated guard column 3 µm (4 x 8 mm) from Macherey-Nagel (Oensingen, Switzerland). 
The mobile phase was delivered at a flow rate of 400 µL/min. Each chromatographic run was performed 
with a binary, linear A/B gradient (Solvent A was 10 mmol/l ammonium formate, pH 3.0. Solvent B was 
90% acetonitrile, 10% 10 mmol/l ammonium formate, pH 3.0.). The program was as follows: 0-1 min, 6% 
B; 1-8 min, 6 to 100% B; 8-20 min 100% B; 20-23 min column equilibration with 6% B. 
 
Mass spectrometry 
The following APCI inlet conditions were applied. The heated vaporizer was kept at 465 °C. Both the 
sheath gas set at 60 relative units and the auxiliary gas set at 15 relative units were nitrogen. The capillary 
entrance to the ion trap was at an offset of 28 V in the positive mode, -4 V in the negative mode and was 
maintained at 220° C. The corona current was 5 µA. Table 22 shows the data dependent and global data 
dependent settings. 
 
Data dependent settings  
 Default charge state 1 
 Default isolation width (m/z) 4.0 
 Normalized collision energy (% pos/neg)) 40.0 resp. 35.0 
 Minimal signal required 20’000 
 
Global data dependent settings  
 Exclusion mass width (m/z) 0.5 
 Reject mass width (m/z) 1.0 
 Dynamic exclusion enabled 
 Repeat count 1 
 Repeat duration (min) 0.5 
 Exclusion list size 25 
 Exclusion duration (min) 0.5 
 Exclusion mass width (m/z) 0.5 
Table 22 – Data dependent and global data dependent settings 
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DDA was used, generating a full-scan between 80 and 750 atomic mass units in the first mode. If ions 
exceeded the preset threshold, a MS-MS spectrum of the most intense ion of the previous full-scan was 
acquired in the second mode. The maximum injection time was set to 50 ms, and three micro-scans were 
collected for each data point. Normalized collision energy was 40.0% in the positive mode and 35.0% in 
the negative mode. Dynamic exclusion was enabled meaning that a refractory period was applied to the 
last selected ion. The refractory period was thirty seconds. 
 
Evaluation of the limit of detection (LOD) 
For qualitative purposes only the LOD of each substance in the library of a GUS method is important in 
order to know the specific performance of the procedure. The LOD’s were measured for about 100 
substances out of 350 (all other LOD’s will be measured step by step together with routine analysis) by 
analyzing each substance after spiking to drug free serum with decreasing concentrations in the range of 
4.000 mg/l to 0.005 mg/l (two times the same procedure and defining the limit by the mean of the two 
results). 
 
Mass spectral library 
Standard solutions were prepared in methanol-water (1:1, v/v) at a concentration of 1-2 mg/l. Two mass 
spectral libraries were created, one for each ionization mode (positive and negative), by injecting 20 µl of 
these solutions directly without HPLC separation into the MS system. The obtained MS-MS spectra were 
added to the library. Relative retention times (RRT) were acquired by actual LC-MS (-MS) analysis running 
a mixture of each compound spiked to serum (and in a new trial in urine) with the IS (see also under 
results of reproducibility, chapter 3). The RRT’s have a 1 to 2% reproducibility. MS-MS data obtained from 
a chromatographic run were compared to the MS-MS library using the NIST Mass Spectral Program 2.0 
from Thermo Finnigan. A computer program (XcLibraryScreening) was created to automate the searching 
process and to include the RRT and the molecular ion in the identification of unknown compounds. 
 
Mass spectral library search program (XcLibraryScreening) 
To automate the search process and to combine the MS-MS library with the RRT of each substance, we 
developed a Microsoft Windows application (XcLibraryScreening). It was written in Microsoft Visual Basic 
.NET and requires the Microsoft .NET Framework as well as a running copy of the NIST Mass Spectral 
Program 2.0 from ThermoFinnigan with a correctly configured MS-MS library. RRTs are stored in a 
separate comma separated value (CSV) file which can be edited in any spreadsheet application or text 
editor. The user can configure searches with XcLibraryScreening by giving the RT of the internal standard 
(“RT IS” in the setup dialog), mass-to-charge ratios (“m/c +/-”), and the match factors (“Match Factor” and 
“reverse Match Factor”). Output is presented in a separate window (Figure 59) and can be saved to a text 
file for reference. 
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Results and discussion 
On-line SPE was chosen as an extraction technique because this procedure is universal, rapid and can be 
automated. Therefore, this method is becoming popular in bio-analytical analysis [334]. The Prospekt SPE 
can be linked to the LC-MS-MS instrument  [333].  This system couples and automates sample extraction 
and instrumental analysis. Benefits of this technology include improved precision of all extraction steps. 
The method has a time saving advantage compared to other techniques because the evaporation of the 
liquid sample extract is not necessary. In addition, the procedure presented in this study extracts acidic, 
neutral as well as basic drugs. A polymer-based sorbent was chosen. This sorbent is stable over a large 
pH range and does not have interfering secondary groups (unbounded hydroxyl silanols) compared to 
classical hydrophobic phase. 
 
The extraction is an on-line procedure and the elution solvent is the mobile phase. In addition the mobile 
phase consists of a gradient. The PE% of 10 drugs from different substance groups was determined to 
have an idea of the extraction recovery at a concentration of 1 mg/l for each substance (Table 23). Among 
the ten substances, the PE% was between 80% and 119%. Due to this high process efficiency of the ten 
tested substances it is supposed that a high extraction rate was achieved and that our method seems not 
to be considerably affected by suppression or enhancement of ionization due to sample matrix. ME = peak 
area in sample spiked after extraction / peak area of neat standard  
 
The post-column infusion of the model substances codeine and benzoylecgonine in a chromatographic run 
of blank serum and urine compared to eluent only indicated that in general no change in the ionization 
process of the two tested substances were found due to co-eluting compounds (data not shown). 
 
Drug Process efficiency  Drug Process efficiency 
Morphine 85% Torasemide 80% 
Olanzapine 119% Propranolol 95% 
Ephedrine 94% Bupivacaine 105% 
Gliclazide 91% Phenprocoumon 97% 
Citalopram 106% Phenolphtaleine 118% 
Table 23 – Process efficiency (%) of 10 substances from different substance groups. Each 
substance in a concentration of 1 mg/l in a drug free serum 
The separation of the drugs was carried out under acidic conditions (pH = 3) in order to limit secondary 
interaction on the free silanol groups of the C18 separation column. The first peak eluted at 5.9 min 
(morphine) and the last at 18.4 min (delta-8-THC). The absolute retention times (RT) as an example for 
100 out of 365 compounds are shown in Table 24 (all retention times of the 365 compounds are 
summarized in an excel table in the library together with all needed information for the search program). 
Analysis of eight different plasma samples was performed on the same day and on different days to study 
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the intra- and inter-assay precision of the IS retention times. The intra- and inter-assay precision of the IS 
were 6.92 ± 0.02 minutes and 6.91±0.03 minutes respectively. 
 
Drug Retention time (min) Drug Retention time (min) 
Morphine 5.89 Imipramine 8.40 
Amiloride 6.10 Phenobarbital 8.45 
Atenolol 6.10 Amitryptiline 8.48 
Hydromorphone 6.16 Canrenone 8.48 
Sotalol 6.25 Trimipramine 8.55 
Codeine 6.30 Brallobarbital 8.56 
Dihydrocodeine 6.42 Nelfinavir 8.57 
Norcodeine 6.42 Sertraline 8.58 
6-Acetylmorphine 6.51 Zuclopenthixol 8.58 
Acetaminophen 6.53 Saquinavir 8.61 
Olanzapine 6.53 Thioridazine 8.93 
Hydrocodone 6.55 Crimidine 8.97 
Pseudoephedrine 6.55 Furosemide 8.97 
Ephedrine 6.56 Phenolphthalein 9.08 
Nadolol 6.60 Alprazolam 9.16 
Tubocurarine 6.67 Lorazepam 9.28 
Nalbuphine 6.76 Propyphenazone 9.67 
Acetazolamide 6.81 Amprenavir 9.80 
Ritalinic acid 6.86 Tolbutamide 9.80 
Pindolol 6.89 Rhein 10.30 
Benzoylecgonine 6.90 Aloeemodine 10.34 
Mepivacaine 7.00 Acenocoumarol 10.40 
Acebutolol 7.05 Gliclazide 10.49 
Timolol 7.05 Warfarin 10.53 
Lidocaine 7.06 Glibornuride 10.57 
Metoprolol 7.19 Bisacodyl 10.59 
Cocaine 7.27 Glibenclamide 10.73 
Oxprenolol 7.32 Ritonavir 10.82 
Hydrochlorothiazide 7.43 Diazepam 10.87 
Venlafaxine 7.45 Lopinavir 10.89 
Cocaethylene 7.50 Phenprocoumon 10.91 
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Bupivacaine 7.76 Diclofenac 11.11 
Propranolol 7.76 Coumachlor 11.12 
Alprenolol 7.79 Coumatetralyl 11.17 
Chlorthalidone 7.80 Efavirenz 11.58 
Quetiapine 7.88 Emodine 11.65 
Indinavir 7.92 Mefenamic acid 12.05 
Torasemide 7.99 Bromadiolone 12.85 
Citalopram 8.02 Chlorophacinone 13.78 
Levomepromazine 8.02 Cannabidiol 14.15 
Nevirapine 8.08 Cannabinol 16.58 
Chlordiazepoxide 8.17 delta-9-THC 18.23 
Flupenthixol 8.33 delta-8-THC 18.44 
Cinchocaine 8.39   
Table 24 – Recorded LC retention times of 87 drugs out of 365 as an example. (The peaks of these 
recorded LC retention times show a possible overlay as following) 
Compared to HPLC, only a rudimentary separation of substances is necessary to detect the analytes at 
low concentrations. Ionization of mobile phase components (acetonitrile, ammonium formate) and 
endogenous compounds is the main source of background noise. Contamination of the mass spectra by 
these compounds potentially hampers the identification expected analytes at low concentrations. The 
screening and extraction of a sample can be performed for both modes (positive and negative) in less than 
one hour including the library search which is an acceptable analytical time for a GUS. 
 
Out of all tested compounds (about 365), only 13 (3.7%,amobarbital, acetylsalicylic acid, butalbital, 
carbromal, coumaphos, ibuprofen, methylphenidate, naproxen, pentobarbital, salicylic acid, secobarbital, 
spironolactone and thiopental) were not detectable with this LC-MS method.  These compounds were 
identified neither at high therapeutic concentrations nor at low toxic concentrations. Methylphenidate could 
be detected by its metabolite ritalinic acid, acetylsalicylic acid and salicylic acid by the metabolite gentisic 
acid. Most of the undetectable drugs were acidic compounds belonging to the class of analgesics or 
barbiturates. These compounds were undetectable because the ionization efficiency was very low or the 
normalized collision energy was too high for fragmentation to occur. Generally, these compounds have 
high therapeutic serum concentrations. As an alternative to this drawback of the method, these substances 
could, for example, be detected with HPLC-DAD methods described in literature [338]. 
 
APCI was preferred to electrospray ionization in order to reduce the risk of ion suppression. This 
phenomenon affects the formation of the analyte ions during the electrospray process. Sample matrix and 
co-eluting compounds can contribute to ion suppression. Although ion suppression can have effects on 
both electrospray ionization and APCI, evidence indicates that the electrospray interface is more impacted 
[343, 345, 346].  
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The method of choice in this study to detect and identify compounds was a DDA procedure. As shown in 
Table 3, compounds can elute at identical retention times. In this case, only the mass spectra of the ion 
with the highest intensity would be detected. In contrast, ions with low intensity would be lost. To overcome 
this problem a refractory period was introduced. Based on the average peak width this period was set at 
30 seconds. A refractory period longer than 30 seconds can result in a loss of identification of one or more 
of the compounds with the same molecular mass ion. With a shorter refractory period the method can fail 
to detect substances eluting with a similar retention time. 
 
Due to different chemical properties of the substances mass spectra (established with pure drugs in 
aqueous solution) were recorded in the negative as well as in the positive mode. Limit of detection (LOD) 
values differed for the distinct modes. For example, morphine was better detected in the positive mode, 
whereas bromadiolone was better detected in the negative mode. For both modes a library was created. 
At best, substances detected in both polarities could be identified in the two respective libraries. The 
normalized collision energies of 40.0% in the positive and 35.0% in the negative mode were empirically 
chosen in order to obtain fragmentation of the compounds. A decrease in the normalized collision energy 
would yield less fragmentation. Applying higher normalized collision energy would result in lower peak 
intensities of the fragments because further fragmentation occurs in most cases. 
 
The established library includes for each spectrum the name of the compound, the molecular formula and 
the molecular ion together with its relative retention time for all 350 substances (the MSMS spectra are in 
an Xcalibur library which is connected to the library search program). This mass spectral library comprises 
spectra of about 280 drugs and 85 metabolites (important metabolites for screening in urine) from a large 
diversity of substance classes. With this procedure, some acidic, neutral as well as basic drugs could be 
detected and identified.  A small application program was developed for the automated identification of 
unknown compounds with LC-MS. 
 
In order to identify unknown compounds in a serum sample a chromatographic run was performed in each 
ionization mode. In the next step the developed application program compared each recorded MS-MS 
spectrum to the reference spectra in the library from the Xcalibur software.  With the help of this 
application program the number of best hits that the unknown spectrum should be compared to could be 
specified. In the procedure described in this paper, the ten best hits were chosen. 
 
The similarity between the library spectra and the unknown spectra is characterized by the match factor 
and the reverse match factor. The match factor indicates the correlation between the unknown spectrum 
and the library spectrum (presence and relative intensities of mass-to-charge ratios). The reverse match 
factor indicates an inverse search where the presence and the relative intensity of the ions of the library 
spectrum are compared to those of the unknown spectrum. This parameter ignores the ions present in the 
unknown spectrum if absent in the reference spectrum.  
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The match factor and the inverse match factor range between 0 and 1000 with 0 indicating no similarity 
and 1000 indicating perfect similarity. About 37 compounds newly added to the existing library were tested 
on other equipments from Thermo Finnigan like a LCQ Deca and a new generation of linear iontrap the 
Thermo Finnigan LTQ, for comparability of spectra production. All spectra were identical.   In our 
procedure, the threshold was set at 400 for both factors. With this threshold, the best results were 
obtained. If the maintenance of the equipment follows the recommendations of the manufacturer, this 
threshold is not varying (experience after routine use of the method since 3 years). For security reasons, 
this threshold should be approved in each laboratory using other equipments. A higher threshold resulted 
in a higher LOD together with more specificity of results. In contrast a lower threshold resulted in a lower 
LOD but also in a higher number of false positives (which is not a big problem when metabolites are 
present, the whole ion scan including Bruch pieces is consulted, metabolites are present or but a better 
way in such cases would be to work with MS3 or MS4). The following example (Figure 57) shows a run with 
a serum sample spiked with phenolphthalein, gliclazide, bisacodyl, glibornuride and glibenclamide at a 
concentration of 1 mg/l. The run was performed in the positive mode. 
 
 
Figure 57 - Chromatogram of 5 substances and the internal standard (D3 benzoylecgonine) all 
together spiked into a drug free serum (see Material section 2.1) of a 1 mg/l IS 5 mg/l concentration. 
Each product ion mass spectrum was subjected to an automated library searching routine against the 
library spectra. Figure 58 shows the MS-MS spectrum of glibornuride from spiked serum obtained with this 
procedure compared to the MS-MS spectrum of the library. The match factor of the presented mass 
spectra was 889, the reverse match factor was 989. 
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Figure 58 - Comparison of the positive tandem mass spectrometry (MS-MS) spectrum of 
glibornuride spiked  at a concentration of 1mg/l in a serum sample using data-dependent 
acquisition (DDA) to the MS-MS spectrum of the library. 
Compound identification took into account the mass-to-charge ratio of the unknown compound selected 
before fragmentation. The mass-to-charge ratio had to be within ± 2 m/z of the reference mass-to charge 
ratio recorded in the library to be considered as a hit. This width of the mass-to-charge ratio window 
allowed the search for possible isotopes of the compounds (see Figure 60 where several possibilities are 
proposed for one substance). With a larger window the risk for false positives was increased during routine 
screening with the described method the search program proposed some false positive for substances 
arising if many compounds were in the sample. The comparison of the whole ionscan spectre resulted in 
exclusion of such mistakes. All these pitfalls are documented as addition to a SOP (standard operation 
procedure for interpretation). A smaller window resulted in false negatives because of differences in mass 
related to isotopes of the element. 
 
The pseudo-molecular ion (usually protonated in the positive mode, deprotonated in the negative mode) 
and its fragments were detected and compared to references in the library. Each MS-MS spectrum 
recorded was derived from one single mass-to-charge ratio (representing the most intense ion of the 
previous full scan). Other authors used collision-induced dissociation at different voltages to obtain the 
same information. Mass spectra were acquired by continuously switching between a low and a high orifice 
voltage throughout the run to obtain both protonated molecular ion (low-voltage scan) and mass spectral 
fragments (high voltage scan) from the CID in the ion source [7,17]. With the procedure presented in this 
study it was not necessary to switch between different orifice voltages. 
 
RRT was also considered in the identification procedure. The RRT of the unknown compound had to be 
within a range of ±5% of the reference RRT (routine experience showed a 1 to 2% variation of the RRT’s. 
This large time-window was chosen because the MS-MS spectra could be obtained within the whole peak 
width and the refractory period was set at 30 seconds. The RT of the IS was registered in the positive 
mode with a value of approximately 6.9 min. Variations in RT occur when using different lots of columns 
with the same adsorption material. 
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Only if all the parameters were within the fixed areas a hit was reported. In summary the match factor and 
the reverse match factor had to be above 400, the mass-to-charge ratio had to be ± 2 m/z and the RRT 
had to be within 5% compared to the library parameters (Figure 59). Each MS-MS spectrum, which fulfilled 
these conditions, was reported. The new program automatically releases a report, which consists of 
different hits with the substance names together with the parameters mentioned above compared to the 
ones in the library. 
 
 
Figure 59 - The library search parameters and the library can be specified. In the described method 
the threshold of the match factors were set at 400, the relative retention time (RRT) has to be within 
± 5% and the maximum deviation of the mass-to-charge was two. 
 
In the above mentioned serum sample all 5 substances (phenolphthalein, gliclazide, bisacodyl, 
glibornuride and glibenclamide) were identified at a concentration of 1 mg/l with our procedure as an 
example (concentration in a toxic level for these substances). Figure 60shows the output generated by the 
application program and the instrument software. The substances were listed in the results file. Gliclazide, 
bisacodyl, glibornuride and glibenclamide all have similar retention times. However, this was no problem 
because the refractory period applied enabled to identify the compounds even though they were not 
chromatographically separated. Importantly, in contrast to single MS CID methods the co-eluting 
substances did not affect the MS-MS spectra in the presented procedure. Therefore, the analysis of 
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unknown compounds was more rapid using MS-MS (there was no ion suppression detectable between co 
eluting substances so far). 
 
 
Figure 60 - In this result file, the different hits are presented with their substance name, match 
factor, reverse match factor, relative retention time (RRT) and mass-to-charge relation compared to 
the corresponding parameters in the library. The same substance can be found several times with 
different tandem mass spectrometry (MS-MS) spectra. 
Serum samples spiked with decreasing concentrations of the tested drugs were analyzed in order to 
determine the LOD’s. Each concentration of the drugs from 0.005 to 4 mg/l was extracted and analyzed 
two times. The LOD was defined as the lowest concentration where both runs of each substance fulfilled 
the mentioned requirements to be identified. 
 
Table 25 shows the different LODs for 87 compounds detected either in the positive and/or in the negative 
mode. With our procedure all these 87 compounds out of 365 tested for LOD could be detected at high 
therapeutic drug concentrations or at concentrations in the low toxic range. For drug confirmation 
measurements in urine all substances like opiates, amphetamines, cocaine metabolites have LOD’s 
beyond the SAMSHA cutoff for chromatographic confirmations. THC-carbonic acid PCP and LSD cannot 
be confirmed with this method. The LOD was ≤ 100 µg/l for 67% of the compounds. Most of the drugs 
were better detected in the positive mode, especially compounds with chemical structures of amines such 
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as neuroleptics, opioids and anti-depressants. In the negative mode a lower LOD was seen with molecules 
containing acidic sites like diclofenac. 
 
 LOD (µg/l)  LOD (µg/l) 
 positive negative  positive negative 
6-Acetylmorphine 100  Hydrochlorothiazide  4000 
Acebutolol 100  Hydrocodone 50  
Acenocoumarol  25 Hydromorphone 50  
Acetaminophen 500  Imipramine 500  
Acetazolamide  2000 Indinavir 25 250 
Aloeemodine  50 Levomepromazine 500  
Alprazolam 50  Lidocaine 250  
Alprenolol 250  Lopinavir 50 25 
Amiloride 100  Lorazepam 100 100 
Amitryptiline 25  Mefenamic acid 250 250 
Amprenavir 50 50 Mepivacaine 100  
Atenolol 25  Metoprolol 250  
Benzoylecgonine 50  Morphine 50  
Bisacodyl 100  Nadolol 50  
Brallobarbital  1000 Nalbuphine 50  
Bromadiolone 1000 250 Nelfinavir 25 100 
Bupivacaine 250  Nevirapine 50  
Cannabidiol 100  Norcodeine 100  
Cannabinol 250  Olanzapine 250  
Canrenone 50  Oxprenolol 250  
Chlordiazepoxide 100  Phenobarbital  2000 
Chlorophacinone  50 Phenolphthalein 50  
Chlorthalidone 1000  Phenprocoumon 500 50 
Cinchocaine 25  Pindolol 100  
Citalopram 100  Propranolol 100  
Cocaethylene 500  Propyphenazone 50  
Cocaine 100  Pseudoephedrine 100  
Codeine 100  Quetiapine 50  
Coumachlor 500 50 Rhein  50 
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Coumatetralyl 1000 100 Ritalinic acid 500  
Crimidine 250  Ritonavir 50  
Delta-8-THC 100  Saquinavir 10  
Delta-9-THC 100  Sertraline 250 25 
Diazepam 250  Sotalol 25  
Diclofenac 1000 500 Thioridazine 500  
Dihydrocodeine 25  Timolol 100  
Efavirenz  100 Tolbutamide  250 
Emodine  50 Torasemide 100  
Ephedrine 500  Trimipramine 250  
Flupenthixol 100  Tubocurarine 100  
Furosemide  100 Venlafaxine 250  
Glibenclamide 25 50 Warfarin 250 25 
Glibornuride 100 100 Zuclopenthixol 100  
Table 25 – LODs in serum determined for 87 drugs out of 365 (as an example) applying negative 
and positive ionization mode. 
The following examples illustrate the application of the DDA LC-MS-MS system to clinical investigations 
(Table 26). The results of serum and urine sample analysis using SPE-LC-MS-MS were compared to the 
results obtained with a conventional STA strategy (including a combination of immunoassays, HPLC 
(Remedi) and LC-MS). REMEDi (Biorad) is an HPLC-based broad-spectrum drug profiling system. It is 
used to detect and identify basic and neutral drugs and their metabolites in serum and urine samples of 
patients) [342]. To identify benzodiazepines an additional run has to be performed on a special Remedi 
System. This conventional STA strategy has been applied for several years in the laboratory of the 
University Hospital Basel. 
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No. Conventional STA DDA LC-MS-MS 
1 (Serum) Benzodiazepines (CEDIA) 
 
Metoclopramide (REMEDi) 
Oxazepam, Oxazepam Metabolite, 
Desmethyldiazepam 
Metoclopramide 
2 (Serum) Benzodiazepines (CEDIA) 
Ranitidine (REMEDi) 
Lidocaine, Lidocaine Metabolite (REMEDi) 
Atracurium (REMEDi) 
Dipyrone (REMEDi) 
nd 
Oxazepam, Oxazepam Glucuronide 
Ranitidine 
Lidocaine 
nl 
nl 
Metoclopramide 
3 (Serum) Antidepressants (DRI), Trimipramine Meta-bolite (REMEDi) 
Methadone (CEDIA, REMEDi) 
Benzodiazepines (CEDIA) 
Trimipramine, Desmethyltrimipramine 
 
Methadone 
Diazepam, Desmethyldiazepam 
4 (Serum) Citalopram (REMEDi) 
Clozapine, Clozapine Metabolite (REMEDi) 
 
nd 
nd 
nd 
Clozapine, N-Desmethylclozapine, Clozapine-
N-Oxide 
Amisulpiride 
Atenolol 
5 (Serum) THC-Carbonic acid (CEDIA)  
Fluoxetine, Fluoxetine Metabolite (REMEDi) 
nd 
Fluoxetine 
6 (Serum) Benzoylecgonine (EMIT, REMEDi), Cocaine (REMEDi) Benzoylecgonine 
7 (Serum) Opiates (CEDIA), Pethidine, Pethidine Meta-bolite (REMEDi) 
Benzodiazepine (CEDIA) 
Dipyrone (REMEDi) 
Pethidine 
 
Diazepam 
nl 
8 (Serum) Antidepressants (DRI), Amitryptiline (REMEDi) 
 
Zolpidem (REMEDi) 
Salicylates (EMIT) 
Amitryptiline, 10-OH-Amitryptiline, Nortryptiline 
Zolpidem 
nd 
9 (Serum) Quetiapine, Quetiapine Metabolite (REMEDi) 
nd 
Quetiapine 
Lamotrigine 
10 
(Serum) 
Benzodiazepines (CEDIA) Lorazepam 
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11 
(Serum) 
Opiates (CEDIA) 
Benzoylecgonine (CEDIA, REMEDi), Cocaine (REMEDi) 
Codeine-6-glucuronide 
Benzoylecgonine 
12 
(Serum) 
nd Mefenamic acid 
13 (Urine) Opiates (CEDIA), Morphine, Morphine Meta-bolites, Codeine Metabolites 
(all REMEDi and LC-MS), Codeine (LC-MS) 
Normorphine, Morphine, Codeine-6-
Glucuronide, Codeine, Norcodeine 
14 (Urine) Opiates (CEDIA), Morphine, Codeine Metabolite, Codeine (all REMEDi) 
Atenolol (REMEDi) 
Normorphine, Morphine-Glucuronide, 
Codeine-6-glucuronide, Codeine 
Atenolol 
15 (Urine) Benzoylecgonine (CEDIA, REMEDi), Cocaine (REMEDi) 
Mepivacaine 
Benzoylecgonine, Cocaine, Cocaethylene 
 
Mepivacaine 
16 (Urine) Citalopram 
Levomepromazine, Levomepromazine Meta-bolite 
Clozapine, Clozapine Metabolite 
Tiapride 
Citalopram 
Levomepromazine Metabolites 
 
Clozapine, Clozapine Metabolites 
Tiapride 
17 (Urine) Methadone (CEDIA), EDDP (CEDIA, REMEDi) 
Opiates (CEDIA), Dihydromorphine, Hydro-morphone (both REMEDi), 
Hydrocodone (REMEDi, LC-MS), Dihydrocodeine, Morphine Metabolite 
(LC-MS) 
Benzodiazepines (CEDIA), Desmethyl-diazepam, Temazepam (REMEDi) 
 
THC-Carbonic acid (CEDIA) 
EDDP 
Hydrocodone, Dihydrocodeine, 
Dihydrocodeine-6-Glucuronide, Norcodeine 
 
 
Desmethyldiazepam, Temazepam-
glucuronide, Oxazepam, Oxazepam-
glucurondie 
11-nor-delta-THC-COOH 
18 (Urine) Mirtazapine Metabolite (REMEDi) Mirtazapine, Desmethylmirtazapine 
19 (Urine) Venlafaxine, Venlafaxine Metabolite (REMEDi) 
Benzodiazepines (CEDIA) Oxazepam (REMEDi) 
nd 
nd 
nd 
Venlafaxine, Desmethylvenlafaxine 
Oxazepam, Oxazepamglucuronide 
 
Mirtazapine 
Zolpidem 
Metoprolol 
20 (Urine) Antidepressants (CEDIA), Amitryptiline, Nortryptiline (REMEDi) 
Benzodiazepines (CEDIA) 
Nortryptiline, Hydroxynortryptiline  
 
Bromazepam, Hydroxybromazepam 
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22 (Urine) Amphetamines (CEDIA), MDMA (REMEDi, LC-MS), Ephedrine, MDA, 
Amphetamine, Metamphetamine (all LC-MS) 
Benzoylecgonine (CEDIA, REMEDi) 
Benzodiazepines (CEDIA)  
Methadone, EDDP, (CEDIA) 
nd 
Ephedrine, MDMA 
 
 
Benzoylecgonine 
 
EDDP 
Lidocaine 
23 (Urine) Lidocaine, Lidocaine Metabolite (REMEDi) 
Mirtazapine Metabolite (REMEDi) 
Chlorprothixene Metabolite 
Opiates (CEDIA), Morphine (REMEDi) 
nd 
nl 
Lidocaine 
Mirtazapine 
Chlorprothixene 
Morphine, Codeine, Codeine Metabolite  
Paroxetine 
Furosemide 
24 (Urine) Amphetamines (CEDIA), MDMA, MDA (REMEDi) 
Cocaine, Benzoylecgonine (REMEDi) 
Benzodiazepines (CEDIA), Flurazepam Metabolites 
MDMA 
 
Benzoylecgonine 
Flurazepam, Hydroxyethylflurazepam, 
Hydroxybromazepam  
25 (Urine) Benzoylecgonine (CEDIA, LC-MS), Cocaine (LC-MS) 
Benzodiazepine (CEDIA), Temazepam, Desmethyldiazepam (REMEDi)  
Opiates (CEDIA) 
THC-Carbonic acid (CEDIA) 
Benzoylecgonine 
 
Oxazepam, Temazepam, 
Temazepamglucuronide 
nd 
nd 
26 (Urine) Olanzapine (REMEDi)  
Quetiapine Metabolite (REMEDi) 
Amphetamines (CEDIA ) MDA, MDMA (REMEDi, LC-MS), MDEA (LC-MS) 
Benzodiazepines (CEDIA), Flurazepam Metabolite (REMEDi) 
Carbamazepine (REMEDi) 
Olanzapine 
nd 
MDA, MDMA, MDEA 
 
nd 
 
Carbamazepine 
Table 26 – Comparison of DDA LC-MS-MS procedure to conventional STA Technique 
(Immunoassay, LC-MS and REMEDi) of serum and urine samples 
In addition, the different opiates, amphetamines, benzoylecgonine, cocaine, ethylcocaine, buprenorphine, 
norbuprenorphine, and additional opioides were analyzed on a validated LCMS system with methods 
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adapted for each drug class (lower LOD’s between 5 to 20ng/ml. These methods are not only used for 
confirmation but differenciation and quantification of the substances).  Twelve serum and fourteen urine 
samples of expected intoxicated individuals and drug addicts were analyzed (Table 26). With the new 
method, urine samples were treated like serum samples (automated extraction followed by 
chromatography). 
 
In addition to the drugs identified by the conventional STA, the newly developed DDA LC-MS-MS system 
also found metoclopramide (case 2), trimipramine (case 3), amisulpride, atenolol (case 4), amitryptiline 
metabolite, nortryptiline (case 8), lamotrigine (case 9) and mefenamic acid (case 12) in serum samples 
(confirmed by HPLC). In contrast, the lidocaine metabolite (MEGX), atracurium (both case 2), dipyrone 
(metamizole, case 2 and 7), fluoxetine metabolites (case 5), pethidine metabolites (case 7) and quetiapine 
metabolites (case 9) were not detected most probably because the MS data of these substances were not 
included into the library.. The LC-MS-MS procedure failed to detect citalopram (case 4), THC (THC or 
THC-carbonic acid, case 5), cocaine (case 6 and 11) and salicylates (case 8). THC and cocaine were at a 
concentration beyond their LODs. Salicylates are not detectable with this system as described above. 
 
In urine samples, a number of drugs, which were not found by the conventional STA procedure, were 
detected by the DDA approach including oxazepam (case 17), zolpidem, metoprolol (both case 19), 
lidocaine (case 22), codeine, paroxetine, furosemide (case 23), and bromazepam metabolite (case 24). On 
the other hand amitryptiline (case 20), amphetamine, metamphetamine (case 22), THC-carbonic acid 
(case 25), desmethyldiazepam (case 25), quetiapine metabolite (case 26) and flurazepam metabolite 
(case 26) were missed by the newly developed system. 7-hydroxy-quetiapine was not detected because 
its MS data was not included in the library.  
 
In general, the new system identified – with some exceptions - the same drugs as the conventional STA 
and some additional substances. With the developed LC-MS-MS procedure, basic, neutral as well as 
acidic substances can be identified within the same system. However, some of the acidic compounds 
should be analyzed with a different procedure. 
 
Importantly, with the new method, drugs were identified in two runs and hydrolysis of glucuronides was not 
necessary (except for the screening of benzodiazepines). Furthermore, time-consuming dilutions of 
samples can be avoided. The presented approach was robust and the information content was high. 
Substances from different groups (amphetamine-derived designer drugs, antidepressants, 
benzodiazepines, cocaine, opiates, antidiabetics, neuroleptics etc.) were detected and identified. 
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Figure 61 – Extracted ion chromatograms (XICs) of aqueous solutions spiked with compounds. 17 
compounds are displayed in the positive mode. 
The results of the analysis of 25 urine samples using the new method were compared to those obtained 
using an established GC-MS screening method in an external laboratory. Table 27 shows the results of 
these comparisons. Unfortunately, the sample volumes were lower than described for this GC-MS STA, so 
that a few drugs with low concentrations could not be detected. For the same reason, the screening for 
acidic compounds could not be performed. 
 
No. Urine Conventional GUS, GC-MS (Maurer, Homburg) DDA LC-MS-MS  
1  Morphine 
Papaverine 
Codeine 
Amphetamine 
Ephedrine/Norephedrine 
Morphine, Normorphine 
nd 
Codeine, Codeineglucuronide 
nd (masked by very high concentration of a different substance) 
Ephedrine, Pseudoephedrine 
2  ----- ----- 
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3  Diazepam 
Flurazepam 
Morphine 
Apomorphine 
Midazolam + metabolites 
Oxazepam, Temazepam + Glucuronide, Desmethyldiazepam 
nd 
Morphine, (Morphineglucuronides 
nd 
Midazolam, α-Hydroxymidazolam 
7-Aminoflunitrazepam 
Mefenamic Acid 
4 --- Lormetazepam 
5  Citalopram Citalopram, Desmethylcitalopram 
Naltrexone 
Temazepamglucuronide 
6  Diazepam + metabolites 
Doxepin + metabolites 
Lorazepam 
Triclosan 
Oxazepam, Temazepam, Temazepamglucuronide  
Doxepin, Desmethyldoxepin 
nd deglu 
nl 
Dibenzepine  
7  Venlafaxine + metabolites 
Mirtazapine + metabolites 
Lorazepam 
Venlafaxine, Desmethylvenlafaxine 
Desmethylmirtazapine 
nd deglu 
8  Triclosan nl 
9  Methadone 
Diazepam + metabolites 
Mirtazapine 
Methadone 
Oxazepamglucuronide, Temazepamglucuronide, 
Desmethyldiazepam 
Mirtazapine 
10  --- --- 
11  Paracetamol 
Tramadol 
Morphine 
Sertraline 
Methadone 
Diazepam + metabolites 
Fluconazole 
nd deglu 
Tramadol (traces) 
Morphine 
Masked by high concentrations of EDDP 
Methadone, EDDP 
Oxazepam, Oxazepamgluc., Temazepamgluc., 
Demethyldiazepam 
nl 
Metoclopramide 
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12  Paracetamol 
Metoclopramide 
nd deglu  
Metoclopramide 
Benzoylecgonine  
Oxazepam 
13  Lorazepam 
Ticlodipine 
Lidocaine 
Paracetamol 
Methadone + metabolites 
Diazepam + metabolites 
Metoprolol 
nd deglu  
nl 
nd  
nd deglu  
Methadone, EDDP 
Oxazepam, Temazepamglucuronide 
 
Metroprolol 
14  Morphine 
Amphetamine 
Diazepam + metabolites 
 
Methaqualone 
Morphine, Morphineglucuronides 
nd  
Oxazepam, Oxazepamglucuronide, Temazepam, Temazepam-
glucuronide . 
Methaqualone 
Carbamazepine 
Methylphenidate 
15  Paracetamol 
Diazepam + metabolites 
MDMA + metabolites 
Codeine 
Morphine + metabolites 
nd deglu 
Oxazepamglucuronide., Temazepam and Temazepamglucuronide 
MDMA, MDA 
Codeine, Codeineglucuronide 
Morphine, Normorphine 
Noscapine 
Chlordiazepoxide 
7-Aminoflunitrazepam 
16  Morphine + metabolites 
Diazepam + metabolites 
Trimipramine + metabolites 
Midazolam + metabolites 
Morphine, (6-Acetylmorphine, Diacetylmorphine, Normorphine) 
Diazepam, Desmethyldiazepam, Oxazepam 
Desmethyltrimipramine, Trimipramine, Hydroxy-Trimipramine 
4-Hydroxy- Midazolam 
7-Aminoflunitrazepam  
Apomorphine 
17  Oxazepam nd  
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18  Oxazepam 
Lidocaine 
Lorazepam 
Methadone + metabolites 
Trometamol 
Oxazepam, Oxazepamglucuronide 
nd (to low signals of the internal standard, no rerun possible) 
nd deglu 
Methadone, EDDP 
nl 
19  Paracetamol 
Morphine 
Methadone + metabolites 
Codeine 
nd deglu 
nd 
Methadone, EDDP 
nd 
Venlafaxine 
20  Paracetamol 
Mirtazapine + metabolites 
Flurazepam 
Clotiapine 
Betablocker 
nd deglu 
Mirtazapine, Desmethylmirtazapine 
N-1-OH-Ethylflurazepam 
Clotiapine 
Atenolol 
21 Morphine  
22  Morphine 
Methadone + metabolites 
Diazepam + metabolites 
 
Tramadol 
Morphine, Morphine-6-Glucuronide, Normorphine 
Methadone, EDDP 
Oxazepam + Gluc., Temazepamgluc., Diazepam, 
Desmethyldiazepam, Diazepam 
nd 
Venlafaxine, Desmethylvenlafaxine  
Olanzapine 
23  Clozapine + metabolites 
Lorazepam 
Clozapine, Desmethylclozapine 
Lorazepam  
24  Lidocaine 
Midazolam + metabolites 
Fentanyl 
Atracurium 
nd  
α-Hydroxy-Midazolam, 4-OH-Midazolam, Midazolam 
nd (in general not detected at low concentrations) 
nl 
25  Amitriptyline 
Methadone + metabolites 
Midazolam + metabolites 
nd (confirmation negative: HPLC, IA) 
Methadone, EDDP 
α-Hydroxy-Midazolam 
Benzoylecgonine (confirmed) 
Table 27 – Comparison of DDA LC-MS-MS procedure to conventional GUS Technique (GC-MS) of 
urine samples. Nicotine and caffeine are not listed. 
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In the 25 urine samples, 83 corresponding or different substances were found by the GC-MS screening 
method (urines tested negative for any substance were defined as 1 “substance” result ). 50 results (60%) 
were in agreement with the new LC-MS-MS method. In 6 cases, drugs found by GC-MS could not be 
confirmed because they were not included in the LC-MS-MS library (7.2%). Ten further findings (12.1%) 
obtained by GC-MS were not in agreement with the presented procedure because the glucuronides were 
not hydrolysed for the measurement with the LC-MS-MS method at that time. Therefore two substances 
(paracetamol and lorazepam) were missed in all these samples. The glucuronides of these two 
substances were not included in the library. 
 
Three substances (3.6%), positive by GC-MS and negative by LC-MS-MS, could not be confirmed as 
positive by additional analysis methods (immunoassays, HPLC). Three substances detected by LC-MS-
MS were negative by GC-MS (3.6%), maybe due to the too low concentrations. Two substances could not 
be found by LC-MS-MS because they were masked by other substances in high concentrations having the 
same retention time (2.4%). For example, sertraline in low concentrations was masked by EDDP in very 
high concentrations. Nine additional substances all at low concentrations (not in the toxic range) were not 
found by LC-MS-MS (10.8%).   
 
With the new LC-MS-MS method, 120 substances (xx drugs and xx metabolites) were found in the 25 
urine samples. Mefenamic acid and 7-aminoflunitrazepam in sample 3, lormetazepam in sample 4, 
naltrexone and temazepam in sample 5, dibenzepine in sample 6, metoclopramide in sample 11, 
benzoylecgonine and oxazepam in sample 12, carbamazepine  and methylphenidate in sample 14, 
noscapine, chlordiazepoxide and 7-aminoflunitrazepam in sample 15, 7-aminoflunitrazepam and 
apomorphine in sample 16, venlafaxine in sample 19 and sample 22, olanzapine and venlafaxine in 
sample 22, benzoylecgonine in sample 25 were only detected by the new LC-MS-MS method, because – 
as already mentioned - the sample volume for the GC-MS screening was too low. 
Conclusions 
In this study, it was demonstrated that the DDA LC-MS-MS screening method seems suitable for routine 
measurements of serum and urine samples. The described procedure is fully automated (from the 
extraction to the detection of a drug) and easy to handle. The method was highly specific because 
compounds were detected and identified by their retention times, the mass to charge ratio of their 
molecular ions and fragments. Rapid identification in screening experiments was achieved by the creation 
of the small application program. With the method presented here, the analysis and interpretation of serum 
or urine samples could be performed in less than one hour. The constructed library comprises more than 
400 spectra with the corresponding relative retention times of more than 350 compounds. Most of the 
compounds were detected at therapeutic concentrations. The matrix effects appeared to be negligible. 
 
However, some pitfalls appeared when substances with the same molecular weight eluted at the same 
retention time. In such a case, only the substance dominating the mass spectrum might be identified and 
the other substance with the less intensive peak might be missed. For example, clozapine in a range over 
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2 mg/l could mask citalopram at a concentration of about 0.1 mg/l. In conclusion, for routine screening, the 
combination of SPE, LC and APCI-MS seems to represent an attractive alternative for the analysis of 
samples from suspected intoxicated individuals or drug addicts, if combined with HPLC-DAD. 
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6. Conclusions and Outlook 
This thesis deals with the prediction and modulation of transport, pharmacokinetics, and the effects of 
drugs and implications in drug discovery, drug safety, and clinical practice. A large part of the work 
concerns the development and application of machine learning tools for the prediction and analysis of drug 
properties. 
 
The models presented for P-gp interaction are robust and accurate enough to find application in the real 
world. The data for which these models were built are a survey of the information available in literature. 
Not all compounds are drug-like compounds and accuracy for pharmacological purposes may be improved 
by restricting the set to such substances. More insight into the complex and as of yet poorly understood 
biology of P-gp may be gained by employing other analytical methods such as the ones described in this 
thesis. 
 
Data for the cytochrome P450 models was based on a library of FDA approved substances. This prior focus 
certainly contributed much to the high accuracy of the models. The CYP system is highly connected, 
specificities overlap greatly, and the many possible ways of interaction make it difficult to find structural 
requirements that are specific to any CYP isoform or mode of interaction. Also, activities are not only 
derived from in vivo data in humans but also from animal experiments and in vitro assay. While the CCRs 
of the models are proof to the validity of this approach, a purified data set using only one class of analysis 
may yield even better results. 
 
Analysis of structure-activity relationships for general classes of ADRs revealed distinct structural 
requirements for all four classes examined. It was shown how permeability and solubility affects the 
occurrence of ADRs in the CNS, liver, and kidney, and how structural complexity influences the allergic 
potential. While emphasis of this study is clearly on ADRs, the results may contribute to an understanding 
of how compounds reach their target organs by using ADRs as surrogate marker. Comparison with the 
data on P-gp interaction from the first study in this thesis indicated that P-gp efflux may not protect from 
CNS ADRs as much as could be expected. Refinements could certainly be made by including metabolites 
and by applying any of the other ML methods discussed above.  
 
In the study of P-gp and BCRP SNPs, we tried to predict the risk for developing IBD for subjects with P-gp 
or BCRP. In this study in healthy controls and IBD patients from the Swiss population, trends were seen 
for SNPs and haplotypes involving BCRP C421A. This in itself is of great interest for the Swiss medical 
community. However, the study suffers from a small sample size. Increasing the number of patients would 
most likely show statistically significant results for some of the genetic polymorphisms discussed. 
Furthermore, considering the physiological role of these efflux pumps, an understanding of the prevalence 
of polymorphisms with decreased activity can increase safety of drug therapy not only in IBD patients but 
also the general Swiss population. Still, it is evident that for multifactorial diseases such as IBD no single 
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genetic marker for susceptibility or disease phenotype will likely be identified, but the three SNPs and the 
haplotypes derived from them may prove useful in the prediction of such parameters in the future. 
 
In the study of St. John’s Wort in a single patient suffering from Crigler-Najjar syndrome type II, clinically 
as well as statistically significant reduction of plasma bilirubin was seen, leading to an evident decrease in 
jaundice and increase in quality of life for the patient. This supports the prediction that the constitutionally 
decreased activity of UGT 1A1 can be enhanced by translational activation (in this case, via pregnane X 
receptor activation). If other patients with CN II (or even just phenobarbital sensitive subtypes) benefit from 
this finding, remains to be seen. Given the rarity of the disease, it will be difficult to conduct larger scale 
studies. 
 
The evaluation of the prototype device for the pulsatile transdermal delivery of nicotine was successful as 
judged by the plasma levels. As of now, the device itself is cumbersome and requires an external 
computer to control it. Efforts are being made by the developing company to improve on size and handling. 
How this form of delivery compares to conventional means of nicotine substitution and what other 
compounds the device may deliver in a similarly safe manner remains to be seen in further studies. 
 
Lastly, the automated general unknown screening system developed in the final (isolated) project has 
successfully been in use for several years at the University Hospital of Basel, handling the majority of GUS 
tasks in blood and urine. Minor revisions were made to port it to the next generation LC/MS machines and 
recently it has been extended to not only report qualitative results (i.e. the presence of toxic compounds) 
but also quantitative results (estimating the absolute amounts of substances). 
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7. Appendix 
7.1. Source code 
7.1.1. Retrieval of structure information from PubChem in Ruby 
The following script program performs a query over a hypertext transfer protocol (http) connection to the 
PubChem database (http://pubchem.ncbi.nlm.nih.gov/) of the National Center for Biotechnology 
Information (Bethesda, MD, USA). It takes the Compound Identification Number (CID), which is unique for 
each compound in the database, and retrieves an extensible markup language (XML) file containing 
systematic names, fingerprints, and several descriptors (subject to change without notice) along with the 
structure represented as canonical and / or isomeric SMILES codes. The script then parses the 
information and returns it in tabular format suitable for import in any spreadsheet program or database 
system. It was written in Ruby (Version 1.8.6, http://www.ruby-lang.org/) and uses the XML conformant 
parser REXML (Version 3.1.7.3, http://www.germane-software.com/software/rexml, also part of the Ruby 
standard library). 
 
#!/usr/bin/ruby -w 
 
# fetch.rb 
# 
# retrieves compound summary from PubChem 
#  
# Date: 28-APR-2009 
# Ruby 1.8.6 
# 
# syntax: 
# ruby fetch.rb CID [-toCSV] [-headers] 
# 
# CID: PubChem Compound ID 
# -toCSV: dump result on single line with field separated by tabs (optional) 
# -headers: dump headers for CSV file with fields separated by tabs (optional) 
# 
#  
 
require 'net/http' 
require 'rexml/document' 
 
if ARGV.length == 0 then 
  puts "need at least one argument (CID)" 
  exit 
end 
 
asCSV = false 
dumpHeaders = false 
ARGV.each do |arg| 
  arg = arg.upcase 
  if arg == "-TOCSV" then 
    asCSV = true 
  end 
  if arg == "-HEADERS" then 
    dumpHeaders = true 
  end 
end 
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url = 'http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=' + ARGV[0] + 
'&disopt=SaveXML' 
xml_data = Net::HTTP.get_response(URI.parse(url)).body 
doc = REXML::Document.new(xml_data) 
titles = [] 
links = [] 
doc.elements.each('PC-Compound/PC-Compound_props/PC-InfoData/PC-InfoData_urn/PC-Urn/PC-
Urn_label') do |e| 
  titles << e.text 
end 
 
doc.elements.each('PC-Compound/PC-Compound_props/PC-InfoData/PC-InfoData_value/*') do 
|e| 
  links << e.text 
end 
 
if asCSV then 
  puts titles.join("\t") if dumpHeaders 
  puts links.join("\t") 
  else     
    titles.each_with_index do |title, idx| 
      print "#{title} => #{links[idx]}\n" 
    end 
end 
7.1.2. Calculation of chemical similarity using Tanimoto’s coefficient in Java 
This program written in Java (Java 2 Platform, Standard Edition, Version 1.4.2, http://www.sun.com/java, 
Sun Microsystems, Santa Clara, CA, USA) calculates the Tanimoto coefficient of similarity (see 4.1.6.2) 
based on a vector of numerical features for every instance. Data is supplied in the form of a comma 
separated file (CSV) using the tabulator character as a field delimiter. It returns the matrix of similarity 
coefficients for all instances and calculates the overall similarity as described previously. 
 
/** 
 * SimilarityCalculator 
 * calculates Tanimoto coefficient 
 *  
 * Date: 10-DEC-2008 
 * Java 1.4 
 */ 
 
import java.io.BufferedReader; 
import java.io.FileNotFoundException; 
import java.io.FileReader; 
import java.io.IOException; 
import java.util.StringTokenizer; 
import java.util.Vector; 
 
 
public class SimilarityCalc { 
    double[][] data;     
    char separator = '\t'; 
     
    public SimilarityCalc( String fileName, boolean skipHeaders, boolean dumpMatrix ) 
throws FileNotFoundException, IOException { 
        System.out.print( "reading " + fileName + " ... " ); 
        BufferedReader reader = new BufferedReader( new FileReader(fileName) ); 
        String line = reader.readLine(); 
        if( line!=null && skipHeaders ) // suppress headers row? 
            line = reader.readLine(); 
         
        // count cols 
        int colCount = 1; 
        for( int i=0; i<line.length(); i++ ) 
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            if( line.charAt(i) == separator ) 
                colCount++; 
         
        // because number of lines is unknown at this point, 
        // store every row of the matrix in a vector and convert later 
        Vector v = new Vector(); 
        while( line!=null ) { 
            double[] row = new double[colCount]; 
            StringTokenizer tokenizer = new StringTokenizer( line, ""+separator ); 
            for( int i=0; i<colCount; i++ ) 
                row[i] = Double.parseDouble( tokenizer.nextToken() ); 
            v.addElement(row); 
            line = reader.readLine(); 
        } 
        data = new double[v.size()][colCount]; 
        for( int i=0; i<v.size(); i++ ) 
            data[i] = (double[]) v.elementAt(i); 
         
        System.out.println( v.size() + " line(s). done." ); 
         
        double[][] matrix = tanimotoMatrix(); 
        if( dumpMatrix ) 
            dumpArray( matrix ); 
    } 
     
    // dump array to console as CSV readable data 
    private void dumpArray( double[][] array ) { 
        for( int i=0; i<array.length; i++ ){ 
            for( int j=0; j<array[i].length; j++ ) { 
                if( i==j ) // identity. 
                    System.out.print( "1.0\t" ); 
                else 
                    System.out.print( array[i][j] + "\t" ); 
            } 
            System.out.println(  ); 
        } 
    } 
     
    protected double normalizeArray( double[][] array, int count ) { 
        double result = 0.0; 
        for( int i=0; i<array.length; i++ ) 
            for( int j=0; j<array[i].length; j++ ) 
                result+=array[i][j]; 
         
        return result / count; 
    } 
     
    protected double[][] tanimotoMatrix() { 
        double[][] result = new double[data.length][data.length]; 
        int count=0; 
        for( int i=0; i<data.length; i++ ) { 
            for( int j=i+1; j<data.length; j++ ) { 
                count++; 
                double index = 0; 
                for( int k=0; k<data[i].length; k++ ) { 
                    index += tanimotoDistance( data[i][k], data[j][k] ); 
                } 
                result[i][j] = index / data[j].length; 
            } 
        } 
         
        System.out.println( "Index: " + normalizeArray(result, count) ); 
         
        return result; 
    } 
     
    protected double tanimotoDistance( double a, double b ) { 
  if( a==0.0 && b==0.0 ) return 0.0; // avoid NaN 
        return (a*b)/(a*a+b*b-a*b); 
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    } 
     
    public static void main(String[] args) { 
        if( args.length < 1 ) { 
            System.out.println( "must supply file name" ); 
            System.exit(-1); 
        } 
         
        boolean skipHeaders = false; 
        boolean dump = false; 
        for( int i=1; i<args.length; i++ ){ 
            String command = args[i].toUpperCase(); 
            if( command.equals("-SKIPHEADERS") ) 
                skipHeaders = true; 
            if( command.equals("-DUMP") ) 
                dump = true; 
        } 
         
        try { 
            new SimilarityCalc( args[0], skipHeaders, dump  ); 
        } catch( Exception e ) { 
            e.printStackTrace(); 
        } 
    }  
} 
7.1.3. Support Vector Machine grid search in Java 
This Java program implements a grid search for support vector machine learning parameters cost (C) and 
γ (gamma) as previously described (see 4.2.7.3). It uses the Weka toolkit (Version 3.6, 
http://www.cs.waikato.ac.nz/~ml/weka/, University of Waikato, Hamilton, New Zealand) for cross-validation 
(see 4.2.2.5) and feature selection (see 4.2.8) [177] and LibSVM as a faster and more versatile 
implementation of SVM learning algorithms (Version 2.89, http://www.csie.ntu.edu.tw/~cjlin/libsvm) as 
described by the authors [347]. Integration of LibSVM with the Weka toolkit was achieved with WLSVM, 
written by Yasser EL-Manzalawy and Vasant Honavar (http://www.cs.iastate.edu/~yasser/wlsvm, Iowa 
State University, Ames, IO, USA). 
 
/* 
 * SVM grid search 
 * Weka 3.4.13 
 * libsvm as wlswm 
 * 
 * last rev: 17-APR-09 
 */ 
 
package svmgridsearch; 
 
import java.io.BufferedReader; 
import java.io.FileReader; 
import java.io.IOException; 
 
import java.util.Random; 
import java.util.Vector; 
import weka.attributeSelection.BestFirst; 
import weka.attributeSelection.CfsSubsetEval; 
import weka.classifiers.Evaluation; 
import weka.classifiers.functions.SMO; 
import weka.classifiers.meta.AttributeSelectedClassifier; 
import weka.core.Instances; 
import wlsvm.WLSVM; 
 
 
  
  
 Appendix 
 
 
 – 160 – 
   
/** 
 * 
 * @author lix 
 */ 
public class SVMGrid { 
    private double[][] values; 
    private double[][] labels; 
    private double[][] results; 
    private int svm = 0; 
    private int kernel = 2; 
    private int c_count = 10; 
    private double c_start = -5; 
    private double c_step = 2.0; 
    private double gamma_start = -15; 
    private int gamma_count = 10; 
    private double gamma_step = 2.0; 
    private double variance_threshold = 0.0; 
    private boolean printVariance = false; 
 
    AttributeSelectedClassifier reducedClassifier; 
    CfsSubsetEval evaluator; 
    BestFirst search; 
 
    private double[] learnSVM( Instances data, double c, double gamma ) throws 
Exception { 
        double[] result = new double[4]; 
        Evaluation eval = new Evaluation(data); 
        SMO scheme = new SMO(); 
        String[] options = weka.core.Utils.splitOptions("-C "+c+" -E 1.0 -G "+gamma+" -
A 250007 -L 0.0010 -P 1.0E-12 -N 0 -R -V -1 -W 1"); 
        scheme.setOptions( options ); 
        eval = new Evaluation(data); 
        eval.crossValidateModel(scheme, data, 10, new Random(1)); 
        double[][] matrix = eval.confusionMatrix(); 
        for (int i = 0; i < matrix.length; i++) { 
            for (int j = 0; j < matrix[0].length; j++) { 
                result[i*2+j] = matrix[i][j]; 
            } 
        } 
 
        return result; 
    } 
 
    private double[] learnLibSVM( Instances data, double c, double gamma, int svm_type, 
int kernel ) throws Exception { 
        double[] result = new double[4]; 
        Evaluation eval = new Evaluation(data); 
        boolean selection = true; 
 
  WLSVM lib = new WLSVM(); 
        String[] ops = weka.core.Utils.splitOptions("-S "+svm_type+" -K "+kernel+" -G 
"+gamma+" -C " + c + " -M 100 -Z 1"); 
        lib.setOptions( ops ); 
 
        if( selection ) { 
            reducedClassifier.setClassifier(lib); 
            reducedClassifier.setEvaluator(evaluator); 
            reducedClassifier.setSearch(search); 
            eval = new Evaluation(data); 
            eval.crossValidateModel(reducedClassifier, data, 10, new Random(1)); 
        } else { 
            eval = new Evaluation(data); 
            eval.crossValidateModel(lib, data, 10, new Random(1)); 
        } 
        // lib.buildClassifier(data); 
        // eval.evaluateModel(lib, data); 
        double[][] matrix = eval.confusionMatrix(); 
        for (int i = 0; i < matrix.length; i++) { 
            for (int j = 0; j < matrix[0].length; j++) { 
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                result[i*2+j] = matrix[i][j]; 
            } 
        } 
 
        return result; 
    } 
 
 
    public SVMGrid() {} 
 
    public SVMGrid( String file, int svm, int kernel, 
                                 int c_count, double c_start, double c_step, 
                                 int gamma_count, double gamma_start, 
                                 double gamma_step, 
                                 double variance_threshold, boolean printVariance ) { 
        try { 
            Instances data = new Instances(new BufferedReader(new FileReader(file))); 
            data.setClassIndex( data.numAttributes() - 1); 
            System.out.println( data.toSummaryString() ); 
            System.out.println( "Class index: " + data.classIndex() ); 
            System.out.println( "read: " + data.numInstances() + " instances" ); 
 
            this.svm = svm; 
            this.kernel = kernel; 
            this.c_start = c_start; 
            this.c_count = c_count; 
            this.c_step = c_step; 
            this.gamma_start = gamma_start; 
            this.gamma_count = gamma_count; 
            this.gamma_step = gamma_step; 
            this.variance_threshold = variance_threshold; 
            this.printVariance = printVariance; 
 
            /* 
             * feature selection 
             * 
             * if variance_threshold is set, i.e. > 0.0, remove all attributes with 
             * a variance below this limit 
             */ 
            if (variance_threshold > 0) { 
                System.out.println( "Removing attributes with variance < " + 
variance_threshold ); 
                Vector lowVariance = new Vector(); // store indices of low variance 
attributes 
                for (int i = 0; i < data.numAttributes(); i++) { 
                    if (data.attribute(i).isNumeric()) { 
                        if( printVariance) 
                            System.out.println(data.attribute(i).toString() + ":\t " + 
data.variance(i)); 
                        if (data.variance(i) < variance_threshold) { 
                            lowVariance.addElement(i); 
                        } 
                    } 
                } 
 
                // remove low variance attributes 
                // because index changes upon removal, keep track of 
                // number of changes and adjust index 
                for (int i = 0; i < lowVariance.size(); i++) { 
                    int index = (Integer) lowVariance.elementAt(i); 
                    // System.out.println("Deleting index " + index + " (i=" + i + ") -
> new index: " + (index - i) + " size: " + data.numAttributes()); 
                    index = index - i; 
                    data.deleteAttributeAt(index); 
                } 
 
                System.out.println("\nNumber of attributes after removal: " + 
data.numAttributes() +"\n"); 
            } 
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            reducedClassifier = new AttributeSelectedClassifier(); 
            evaluator = new CfsSubsetEval(); 
            search = new BestFirst(); 
 
            results = new double[c_count*gamma_count][6]; 
            values = new double[c_count][gamma_count]; // plot values 
            labels = new double[c_count][gamma_count]; // label values 
 
            for( int i=0; i<c_count; i++ ) { 
                double c = Math.pow( 2, c_start+c_step*i ); 
                labels[0][i] = c; 
                for( int j=0; j<gamma_count; j++ ) { 
                    double gamma = Math.pow( 2, gamma_start+gamma_step*j ); 
                    try { 
                        double[] res = learnLibSVM( data, c, gamma, svm, kernel ); 
                        results[i*gamma_count+j][0] = c; 
                        results[i*gamma_count+j][1] = gamma; 
                        for( int k=0; k<res.length; k++ ) 
                            results[i*gamma_count+j][k+2] = res[k]; 
                        values[i][j] = ( 
(res[0]/(res[0]+res[1]))+(res[3]/(res[2]+res[3])) ) * 0.5; // CCR 
                        labels[1][j] = gamma; 
                        System.out.println( "run " + (i*gamma_count+j+1) + "/" + 
(c_count*gamma_count) + ", c: " + c + ", gamma: " + gamma + ", CCR: " + values[i][j]); 
                    } catch( Exception e ) { 
                        e.printStackTrace(); 
                    } 
 
                } 
            } 
        } catch( IOException ioe ) { 
            ioe.printStackTrace(); 
        } 
    } 
 
    public static void main(String[] args) { 
    } 
 
    /** 
     * @return the values 
     */ 
    public double[][] getValues() { 
        return values; 
    } 
 
    /** 
     * @return the labels 
     */ 
    public double[][] getLabels() { 
        return labels; 
    } 
 
    /** 
     * @return the results 
     */ 
    public double[][] getResults() { 
        return results; 
    } 
 
    /** 
     * @return the c_count 
     */ 
    public int getC_count() { 
        return c_count; 
    } 
 
    /** 
     * @param c_count the c_count to set 
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     */ 
    public void setC_count(int c_count) { 
        this.c_count = c_count; 
    } 
 
    /** 
     * @return the c_start 
     */ 
    public double getC_start() { 
        return c_start; 
    } 
 
    /** 
     * @param c_start the c_start to set 
     */ 
    public void setC_start(double c_start) { 
        this.c_start = c_start; 
    } 
 
    /** 
     * @return the c_step 
     */ 
    public double getC_step() { 
        return c_step; 
    } 
 
    /** 
     * @param c_step the c_step to set 
     */ 
    public void setC_step(double c_step) { 
        this.c_step = c_step; 
    } 
 
    /** 
     * @return the gamma_count 
     */ 
    public int getGamma_count() { 
        return gamma_count; 
    } 
 
    /** 
     * @param gamma_count the gamma_count to set 
     */ 
    public void setGamma_count(int gamma_count) { 
        this.gamma_count = gamma_count; 
    } 
 
    /** 
     * @return the gamma_start 
     */ 
    public double getGamma_start() { 
        return gamma_start; 
    } 
 
    /** 
     * @param gamma_start the gamma_start to set 
     */ 
    public void setGamma_start(double gamma_start) { 
        this.gamma_start = gamma_start; 
    } 
 
    /** 
     * @return the gamma_step 
     */ 
    public double getGamma_step() { 
        return gamma_step; 
    } 
 
    /** 
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     * @param gamma_step the gamma_step to set 
     */ 
    public void setGamma_step(double gamma_step) { 
        this.gamma_step = gamma_step; 
    } 
 
    /** 
     * @return the variance_threshold 
     */ 
    public double getVariance_threshold() { 
        return variance_threshold; 
    } 
 
    /** 
     * @param variance_threshold the variance_threshold to set 
     */ 
    public void setVariance_threshold(double variance_threshold) { 
        this.variance_threshold = variance_threshold; 
    } 
 
    /** 
     * @return the printVariance 
     */ 
    public boolean isPrintVariance() { 
        return printVariance; 
    } 
 
    /** 
     * @param printVariance the printVariance to set 
     */ 
    public void setPrintVariance(boolean printVariance) { 
        this.printVariance = printVariance; 
    } 
 
    /** 
     * @return the svm 
     */ 
    public int getSvm() { 
        return svm; 
    } 
 
    /** 
     * @param svm the svm to set 
     */ 
    public void setSvm(int svm) { 
        this.svm = svm; 
    } 
 
    /** 
     * @return the kernel 
     */ 
    public int getKernel() { 
        return kernel; 
    } 
 
    /** 
     * @param kernel the kernel to set 
     */ 
    public void setKernel(int kernel) { 
        this.kernel = kernel; 
    } 
 
} 
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